

09/29/00
JC932 U.S. PTO

10-02-00

A/Box/seq

UTILITY PATENT APPLICATION TRANSMITTAL
(only for continuation and divisional
applications under 37 CFR 1.53(b))

Docket No.: P-LJ 4377

Prior Application Info:
Examiner: M. Moran
Group/Art Unit: 1631

Address to: COMMISSIONER FOR PATENTS
Box Patent Application
Washington, D.C. 20231



23601

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER: EL690155883US

DATE OF DEPOSIT: September 29, 2000

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER
37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE, AND IS
ADDRESSED TO: COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231.

Brian Ho
(TYPED OR PRINTED NAME OR PERSON MAILING PAPER OR FEE)

Brian Ho
(SIGNATURE OF PERSON MAILING PAPER OR FEE)

JC928 U.S. PTO
09/676475
09/29/00

This is a request for filing a
___ continuation X divisional

application under 37 CFR 1.53(b), of pending prior application
serial no. **09/258,754**, filed **February 26, 1999**, (list only
immediate prior application).

Title: **METHODS OF IDENTIFYING LUNG HOMING MOLECULES USING
MEMBRANE DIPEPTIDASE**

Inventor(s) (full name of each inventor): **Daniel Rajotte
Renata Pasqualini
Erkki Ruoslahti**

No abandonment of, or termination of proceedings, has occurred in
the above-identified prior application.

1. X An application based on the prior application as filed
and containing no new matter is enclosed, consisting
of:
1 page application cover sheet
174 pages of specification (includes claims and
abstract)
11 sheets of drawing(s).
2. X 3 pages of a copy of the oath or declaration as
originally filed on **May 26, 1999**, in prior
application (37 CFR 1.63(d)), U.S. serial no.
09/258,754, filed **February 26, 1999**, is enclosed.
3. ___ A signed statement DELETING inventor(s) named in the
prior application (37 CFR 1.63(d)(2) and 1.33(b)) is
attached.

4. ☒ Nucleotide and/or Amino Acid Sequence Submission is enclosed:
☒ computer readable copy of sequence listing
☒ paper copy of sequence listing, pages 1 through 134
☒ Statement Under § 1.821(f) and (g)
☐ Request to Use Computer Readable Form of Sequence Listing From Another Application
☐ Other:
5. ☒ Incorporation by Reference: The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under item no. 2 of this form, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference herein.
6. ☐ Enter the unentered amendment previously filed on _____ under 37 CFR 1.116 in the prior application.
7. ☐ A preliminary amendment is enclosed.
8. Small entity status:
a. ☐ A small entity statement is enclosed.
b. ☒ A small entity statement was filed in prior application serial no. **09/258,754**, and such status is still proper and desired.
c. ☐ is no longer claimed.
9. ☒ Amend the specification by:
☐ inserting before the first paragraph on page 1: or
☒ deleting the paragraph on page 1 regarding related applications and inserting therefor:

This application is a divisional of application serial no. **09/258,754**, filed **February 26, 1999**.
(list entire parentage)
10. ☒ Cancel in this application original claims **1 to 4 and 31 to 40** of the prior application before calculating the filing fee. (At least one original independent claims must be retained for filing purposes.)
11. The prior application is assigned of record to **The Burnham Institute**.
12. The power of attorney in the prior application is to **Cathryn Campbell, Reg. No. 31,815**.
13. ☐ A copy of a change in power of attorney or authorization of agent as filed in the prior application (37 CFR 1.63(d)(4)) is enclosed.
14. ☒ A return receipt postcard is enclosed.
15. ☒ A Patent Application Bibliographic Data Sheet is enclosed.

09676475-092900

Inventors: Rajotte et al.
Docket No.: P-LJ 4377
Page 3

16. Also enclosed:

The filing fee is calculated below:

	NUMBER FILED		NUMBER EXTRA		RATE	FEE
TOTAL CLAIMS	26 - 20	0	6	x	\$9 \$18	\$54
INDEPENDENT CLAIMS	1 - 3	=	0	x	\$39 \$78	\$0
MULTIPLE DEPENDENT CLAIMS _____ YES _____ X _____ NO					\$130 \$260	\$0
BASIC FEE					\$345 \$690	\$345
TOTAL FEE						\$399

17. x A check in the amount of **\$399.00** is enclosed, which covers the small entity filing fee. A duplicate copy of this sheet is enclosed.
18. _____ The filing fee is not enclosed. Do not charge our deposit account.
19. x The Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 which may be required or credit any overpayment to Deposit Account No. **03-0370**. A duplicate copy of this sheet is enclosed.

Address all future communications to:

Cathryn Campbell
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive, 7th Floor
San Diego, California 92122
telephone: (858) 535-9001
facsimile: (858) 535-8949
USPTO CUSTOMER NO. 23601

Respectfully submitted,

Date: September 29, 2000

Andrea L. Gashler
Andrea L. Gashler
Registration No. 41,029
Attorney for Applicant
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122

_____ inventor(s)

x attorney or agent of record

_____ assignee of complete
interest

_____ filed under Sec. 1.34(a)

09676475-092900

INVENTOR INFORMATION

Inventor One Given Name:: Daniel
Family Name:: Rajotte
Postal Address Line One:: 517 1/2 Stratford Court
City:: Del Mar
State or Province:: California
Country:: USA
Postal or Zip Code:: 92014
City of Residence:: Del Mar
State or Province of Residence:: California
Country of Residence:: USA
Citizenship Country:: Canada
Inventor Two Given Name:: Pasqualini
Family Name:: Renata
Postal Address Line One:: 707 S. Sierra Avenue, #29
City:: Solana Beach
State or Province:: California
Country:: USA
Postal or Zip Code:: 92075
City of Residence:: Solana Beach
State or Province of Residence:: California
Country of Residence:: USA
Citizenship Country:: Brazil
Inventor Three Given Name:: Ruoslahti
Family Name:: Erkki
Postal Address Line One:: Post Office Box 1054
City:: Rancho Santa Fe
State or Province:: California
Country:: USA
Postal or Zip Code:: 92067
City of Residence:: Rancho Santa Fe
State or Province of Residence:: California
Country of Residence:: USA
Citizenship Country:: USA

CORRESPONDENCE INFORMATION

Name Line One:: CAMPBELL & FLORES LLP
Name Line Two:: 4370 La Jolla Village Drive
Address Line One:: 7th Floor
City:: San Diego
State or Province:: California
Country:: USA
Postal or Zip Code:: 92122
Telephone One:: (858) 535-9001
Fax One:: (858) 535-8949

APPLICATION INFORMATION

006260" 543450

Title Line One:: METHODS OF IDENTIFYING LUNG HOMING MOLEC
Title Line Two:: ULES USING MEMBRANE DIPEPTIDASE
Total Drawing Sheets:: 11
Formal Drawings?: Yes
Application Type:: Utility
Docket Number:: P-LJ 4377
Secrecy Order in Parent Appl.?: No

REPRESENTATIVE INFORMATION

Registration Number One:: 31815
Registration Number Two:: 34949
Registration Number Three:: 44048
Registration Number Four:: 45201
Registration Number Five:: 39200
Registration Number Six:: 41029
Registration Number Seven:: 38444
Registration Number Eight:: 37915

CONTINUITY INFORMATION

This application is a:: DIVISION OF
> Application One:: 09/258,754
Filing Date:: 02-26-1999

Source:: PrintEFS Version 1.0.1

006250" 64492350

A P P L I C A T I O N

for

UNITED STATES LETTERS PATENT

on

METHODS OF IDENTIFYING LUNG HOMING MOLECULES
USING MEMBRANE DIPEPTIDASE

by

Daniel Rajotte,
Renata Pasqualini
and
Erkki Ruoslahti

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER: EL690155883US

DATE OF DEPOSIT: September 29, 2000

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER
37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE COMMISSIONER FOR PATENTS, ATTENTION
BOX PATENT APPLICATION, WASHINGTON, D.C. 20231.

Brian H

Printed Name of Person Mailing Paper or Fee

Brian H

Signature of Person Mailing Paper or Fee

Sheets of Drawings: 11

Docket No.: P-LJ 4377

Attorneys

CAMPBELL & FLORES LLP
4370 La Jolla Village Drive, Suite 700
San Diego, California 92122

09676475 "092500

**METHODS OF IDENTIFYING LUNG HOMING MOLECULES
USING MEMBRANE DIPEPTIDASE**

This application is a continuation-in-part of
U.S. Application Serial No. 09/042,107, filed
5 March 13, 1998, the entire contents of which is
incorporated herein by reference.

This invention was made with government
support under grant numbers CA 74238 and CA 30199
awarded by the National Institutes of Health.

10

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The present invention relates generally to
the fields of molecular medicine and drug delivery and,
more specifically, to molecules that home to a specific
15 organ or tissue.

BACKGROUND INFORMATION

Although the effect of a particular pathology
often is manifest throughout the body of the afflicted
person, generally, the underlying pathology may affect
20 only a single organ or tissue. It is rare, however,
that a drug or other treatment will target only the
diseased organ or tissue. More commonly, treatment
results in undesirable side effects due, for example,
to generalized toxic effects throughout the patient's
25 body. It would be desirable to selectively target
organs or tissues, for example, for treatment of
diseases associated with the target organ or tissue.

005250" 52492360

In particular, targeting of an organ or tissue can be useful for directing the expression of a gene to a certain organ or tissue because incorporation of a foreign gene into nontargeted cells can cause unwanted side effects such as malignant transformation.

Most therapeutic substances are delivered to the target organ or tissue through the circulation. The endothelium, which lines the internal surfaces of blood vessels, is the first cell type encountered by a circulating therapeutic substance in the target organ or tissue. These cells provide a target for selectively directing therapies to an organ or tissue.

Endothelium can have distinct morphologies and biochemical markers in different tissues. The blood vessels of the lymphatic system, for example, express various adhesion proteins that serve to guide lymphocyte homing. For example, endothelial cells present in lymph nodes express a cell surface marker that is a ligand for L-selectin and endothelial cells in Peyer's patch venules express a ligand for the $\alpha_4\beta_7$ integrin. These ligands are involved in specific lymphocyte homing to their respective lymphoid organs. Thus, linking a drug to L-selectin or to the $\alpha_4\beta_7$ integrin may provide a means for targeting the drug to diseased lymph nodes or Peyer's patches, respectively, provided that these molecules do not bind to similar ligands present in a significant number of other organs or tissues.

Although the homing molecules present in the blood vessels of non-lymphoid tissues have not been clearly defined, certain observations of lymphocyte

circulation suggest that organ and tissue specific endothelial markers exist. Similarly, the homing or metastasis of particular types of tumor cells to specific organs or tissues further suggests that organ and tissue specific markers may exist. Thus, a need exists to identify molecules that can bind to such organ or tissue specific markers and, therefore, can home to the organ or tissue. The present invention satisfies this need and provides related advantages as well.

SUMMARY OF THE INVENTION

The present invention provides a method of identifying a membrane dipeptidase (MDP)-binding homing molecule, which is a molecule that selectively homes to lung endothelium. The method includes the steps of contacting MDP with one or more molecules; and determining specific binding of a molecule to the MDP, where the presence of specific binding identifies the molecule as a MDP-binding homing molecule that selectively homes to lung endothelium. In a method of the invention, the MDP can be, for example, in its natural state or substantially purified and, if desired, immobilized on a support. The membrane dipeptidase can be any mammalian MDP, for example, human MDP having SEQ ID NO: 448.

Further provided by the invention is a method of selectively directing a moiety to lung endothelium in a subject by administering to the subject a conjugate containing a moiety linked to a MDP-binding homing molecule that selectively homes to lung endothelium, whereby the moiety is selectively directed

to lung endothelium in the subject. Such a method can be useful, for example, for drug targeting to lung. In a method of the invention, the MDP-binding homing molecule is identified by contacting membrane

5 dipeptidase (MDP) with one or more molecules; and determining specific binding of a molecule to the MDP, where the presence of specific binding identifies the molecule as a MDP-binding homing molecule that selectively homes to lung endothelium. A variety of

10 moieties can be selectively directed to lung endothelium according to a method of the invention. A moiety useful in the invention can be, for example, a gene therapy vector or drug.


In one embodiment, the invention provides a

15 method for selectively directing a moiety to lung endothelium where the MDP-binding homing molecule is a peptide including the sequence X_1 -G-F-E- X_2 (SEQ ID NO: 17), where X_1 and X_2 each is 1 to 10 independently selected amino acids. Such a MDP-binding homing

20 peptide can include, for example, the sequence CGFECVRQCPERC (SEQ ID NO: 1) or CGFELETC (SEQ ID NO: 2).

In another embodiment, the invention provides a method for selectively directing a moiety to lung

25 endothelium where the MDP-binding homing molecule contains the following Structure 1:



where R^2 and R^3 are hydrocarbon radicals in the range respectively of 3-10 and 1-15 carbon atoms; in either one of these R^2 or R^3 hydrocarbon chains 1-6 hydrogens may be replaced by halogens or a nonterminal methylene may be replaced by oxygen or sulfur, including oxidized forms of the latter; additionally, a terminal hydrogen in R^3 can also be replaced by hydroxyl or thiol, which may be acylated or carbamoylated; or the hydrogen can be replaced by amino, which may be derivatized as in an acylamino, ureido, amidino, guanidino, or alkyl or substituted amino group, including quaternary nitrogen grouping; or, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, or cyano; or combinations thereof, such as a terminal amino acid grouping; and R^1 is hydrogen, or lower alkyl (C_{1-6}) or dialkylaminoalkyl, or a pharmaceutically acceptable cation. Such an MDP-binding homing molecule for reducing or preventing lung metastasis can be, for example, 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropane carboxamido)-2-heptenoic acid, also known as cilastatin.

An MDP-binding homing molecule can be, for example, a compound having Structure 1 in which R^2 is branched alkyl or cycloalkyl with a limitation that the carbon adjacent to the carbonyl cannot be tertiary.

An MDP-binding homing molecule also can be, for example, a compound having Structure 1 in which R² is branched alkyl or cycloalkyl with a limitation that the carbon adjacent to the carbonyl cannot be tertiary, and in which R³ is n-alkyl (1-9 carbons) or n-alkyl (1-9 carbons) having a terminal substituent which is a quaternary nitrogen, amine derivative or amino acid derived group.

10 An MDP-binding homing molecule can be, for example, a compound having Structure 1 in which R² is 2,2-dimethylcyclopropyl or 2,2-dichlorocyclopropyl and in which R³ is a hydrocarbon chain of 3 to 7 carbon atoms

15 without a terminal substituent or having a terminal substituent which is trimethylammonium, amidino, guanidino or 2-amino-2-carboethylthio.

Exemplary MDP-binding homing

20 molecules having Structure 1 useful in the invention include the following: Z-2-(2,2-dimethylcyclopropane carboxamido)-8-trimethylammonium hydroxide-2-octenoic acid inner salt; Z-2-(2,2-dichlorocyclo

25 propanecarboxamido)-8-trimethylammonium hydroxide-2-octenoic acid inner salt; Z-2-(2,2-dimethylcyclopropane carboxamido)-8-guanidino-2-octenoic acid; Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-

30 guanidino-2-octenoic acid; Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-ureido-2-octenoic acid; Z-8-(1-2-amino-2-carboxy ethylthio)-2-(2,2-dimethylcyclopropane

carboxamido)-2-octenoic acid; Z-2-(2,2-dimethylcyclopropane carboxamido)-2-octenoic acid (racemic and dextrorotatory forms); Z-2-(2,2-dichloro cyclopropanecarboxamido)-2-octenoic acid; 7-(L-2-amino-2-carboxyethylthio) -2-(2,2-dimethylcyclopropane carboxamido)-2-heptenoic acid; and 6-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropane carboxamido)-2-hexenoic acid.

The present invention also provides a method of reducing or preventing lung metastasis in a subject having cancer by administering to the subject a membrane dipeptidase (MDP)-binding homing molecule. In a preferred embodiment, an MDP-binding homing molecule is a lung homing peptide including the sequence X_1 -G-F-E- X_2 (SEQ ID NO: 17), where X_1 and X_2 each is 1 to 10 independently selected amino acids, such as a peptide including the sequence CGFECVRQCPERC (SEQ ID NO: 1) or CGFELETC (SEQ ID NO: 2).

In another preferred embodiment, an MDP-binding homing molecule is a molecule containing Structure 1, described hereinabove. Such an MDP-binding homing molecule can be, for example, 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropane carboxamido)-2-heptenoic acid, commonly known as cilastatin.

In one embodiment, an MDP-binding homing molecule useful in the invention is an MDP inhibitor. Such an MDP inhibitor can exhibit, for example, a K_i against MDP of 1000 nM or less. In other embodiments,

an MDP inhibitor useful in reducing or preventing lung metastasis exhibits a K_i against MDP of 100 nM or less or a K_i against MDP of 1 nM or less.

5 The present invention also provides a method of reducing or preventing lung metastasis in a subject having cancer by administering to the subject a MDP negative regulatory agent. A MDP negative regulatory agent useful in the invention can be, for example, a soluble MDP polypeptide or an antibody that selectively
10 reacts with MDP.

Further provided herein are methods of reducing or preventing cell homing to lung endothelium in a subject by administering to the subject a MDP negative regulatory agent. A MDP negative regulatory
15 agent useful for reducing or preventing cell homing to lung endothelium can be, for example, a soluble MDP polypeptide or an antibody that selectively reacts with MDP.

The present invention also provides a method
20 of identifying a molecule that reduces or prevents lung metastasis by contacting membrane dipeptidase (MDP) with one or more molecules; and determining MDP activity in the presence of the molecule as compared to a control value, where diminished MDP activity in the
25 presence of the molecule identifies the molecule as a molecule that reduces or prevents lung metastasis. The membrane dipeptidase can be, for example, substantially purified. MDP activity can be determined, for example, by release of D-Phe from Gly-D-Phe.

In one embodiment, the invention provides a method of identifying a molecule that reduces or prevents lung metastasis by contacting MDP with one or more molecules; determining MDP activity in the presence of the molecule as compared to a control value; administering the molecule to a subject having cancer; and assaying lung metastasis in the subject as compared to a control level of metastasis, where diminished MDP activity in the presence of the molecule identifies the molecule as a molecule that reduces or prevents lung metastasis.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the results of three rounds of *in vivo* panning of a CX₆C (SEQ ID NO: 26) library for identifying molecules that home to lung. Phage recovered from the lung five minutes after injection of 10¹⁰ transducing units into the tail vein of mice were amplified and reinjected in two consecutive rounds. The number of phage recovered per gram of lung, kidney or brain is indicated for each round, with bars representing standard error of the mean from triplicate platings.

Figures 2A to 2D show the selectivity of phage displaying a lung (Figures 2A and 2B), skin (Figure 2C) or pancreas (Figure 2D) homing peptides. Selected phage expressing peptides that home to lung (Figure 2A, CGFECVRQCPERC, SEQ ID NO: 1, "GFE-1"; Figure 2B, CGFELETC, SEQ ID NO: 2, "GFE-2"); skin (Figure 2C, CVALCREACGEGC, SEQ ID NO: 3) or pancreas (Figure 2D, SWCEPGWCR, SEQ ID NO: 4) were individually

amplified, injected into mice and recovered (Example I). The amount of phage displaying a selected peptide that was recovered per gram of lung, skin or pancreas or control kidney or brain was determined.

5 The amount of unselected (control) phage recovered from lung, skin, pancreas, kidney or brain also was determined. Bars indicate standard error of the mean from triplicate platings.

Figures 3A and 3B show the effect of
10 coadministration of glutathione S-transferase- (GST)-fusion proteins on the homing of phage displaying lung or skin homing peptides.

In Figure 3A, 100 µg or 500 µg of
GST-CGFECVRQCPCRC (SEQ ID NO: 1, "GFE-1") or 500 µg GST
15 was coinjected into mice with 10^9 transducing units of the individually amplified phage displaying the lung homing sequence CGFECVRQCPCRC (SEQ ID NO: 1). The recovery of phage after 5 minutes of circulation from lung and kidney was determined, with bars indicating
20 standard error of the mean from triplicate platings.

In Figure 3B, 10^9 transducing units of individually amplified phage displaying either the lung homing peptides CGFECVRQCPCRC (SEQ ID NO: 1, "GFE-1") or CGFELETC (SEQ ID NO: 2, "GFE-2") or the skin homing
25 peptide CVALCREACGEGC (SEQ ID NO: 3) were coinjected into mice with 500 µg of the cognate GST-fusion peptide. Control mice (not shown) were injected with the selected phage and 500 µg of GST. The percentage of inhibition of selected phage homing to lung or skin
30 in the presence of the cognate GST-fusion peptide compared to GST is shown.

Figure 4 shows that a 55 kDa cell surface protein from lung extracts specifically binds to a GFE-1 peptide affinity column. An *in vivo* biotinylated lung extract was fractionated on a CGFECVRQCPERC (SEQ ID NO: 1; GFE-1) peptide column or on a control peptide column (GRGESP; SEQ ID NO: 442), washed, and eluted with GFE-1 peptide. Aliquots (30 μ l) from the wash fraction ("-"), GFE-1 peptide elution, and 8M urea elution were resolved by SDS-PAGE under reducing conditions. Molecular weight markers (in kDa) are indicated on the right side of each panel.

Figure 5 shows a time course of the fluorimetric detection of D-phenylalanine (D-Phe) produced by hydrolysis of Gly-D-Phe. Samples from the wash fraction (O) and the CGFECVRQCPERC (SEQ ID NO: 1; GFE-1) peptide eluate (●) from a GFE-1 peptide affinity column were assayed for MDP activity with a Gly-D-Phe substrate. The time-dependent conversion of D-Phe into a fluorescent compound is shown.

Figure 6 shows binding of phage bearing peptide CGFECVRQCPERC (SEQ ID NO: 1; GFE-1) or CGFELETC (SEQ ID NO: 2; GFE-2) to COS-1 cells expressing membrane dipeptidase (MDP).

In Figure 6A, COS-1 cells were transfected with the MDP expression vector or vector alone. Two days after the transfection, cell extracts were prepared and analyzed for MDP activity.

In Figure 6B, COS-1 cells transfected with either the MDP expression vector or control empty vector were subjected to a binding assay in the

presence of equal amounts of either control phage (fd-tet) or phage bearing the skin-homing peptide CVALCREACGEGC (SEQ ID NO: 3; "shp-1"), CGFECVRQCPERC (SEQ ID NO: 1; GFE-1) peptide, or CGFELETC (SEQ ID NO: 2; GFE-2) peptide. In each case, the total number of phage transducing units rescued from these cells is shown. Error bars indicate standard deviation of the mean from triplicate platings.

Figure 7 shows inhibition of MDP activity by the GFE-1 peptide CGFECVRQCPERC (SEQ ID NO: 1). Extracts from MDP-expressing COS-1 cells were assayed for MDP activity in the presence of increasing concentrations of CGFECVRQCPERC (SEQ ID NO: 1; GFE-1) (●) or CARAC control peptide (SEQ ID NO: 443), shown as (○).

Figure 8 shows that GFE-1 (SEQ ID NO: 1) inhibits lung metastasis of human melanoma cells. Lung weight is shown for mice five weeks after injection with 10^5 C8161 human melanoma cells alone ("vehicle"); 10^5 C8161 cells coadministered with 250 μ g GFE-1 peptide SEQ ID NO: 1 ("GFE-1 peptide"); or 10^5 C8161 cells coadministered with 250 μ g CARAC peptide SEQ ID NO: 443 ("control peptide").

Figure 9 shows an alignment of the predicted amino acid sequences of membrane dipeptidase from five species. The amino acid sequences of the human ("HUM;" SEQ ID NO: 448); pig ("PIG;" SEQ ID NO: 449); rat ("RAT;" SEQ ID NO: 450); and mouse ("MOU;" SEQ ID NO: 451) MDPs are aligned together with the sequence of rabbit MDP ("RAB;" SEQ ID NO: 452). Asterisks indicate N-linked glycosylation sites in human MDP. The boxed

residues Glu¹²⁵ and His²¹⁹ are essential for activity (Adachi et al., Biochim. Biophys. Acta 1163:42-48 (1993); Keynan et al., FEBS Letters 349:50-54 (1994)). Underlined residues (-1 to -16) represent the signal peptide. The boxed residues at the C-terminus indicate the hydrophobic signal that is replaced by a glycosyl-phosphatidylinositol (GPI) anchor in the mature protein. The site of GPI anchor addition is indicated by an arrow.

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides organ and tissue homing molecules and methods of using these molecules to target a moiety to a selected organ or tissue. The molecules of the invention, which were identified essentially by the method of *in vivo* panning (U.S. Patent No. 5,622,699, issued April 22, 1997, which is incorporated herein by reference), include peptides that home to various normal organs or tissues, including lung, skin, pancreas, retina, prostate, ovary, lymph node, adrenal gland, liver or gut, and to organs bearing tumors, including to lung bearing lung tumors and to pancreas bearing a pancreatic tumor. For example, the invention provides lung homing peptides, including the peptides CGFECVRQCPERC (SEQ ID NO: 1) and CGFELETC (SEQ ID NO: 2), each of which contains a tripeptide GFE motif, and the peptide GIGVEVC (SEQ ID NO: 8). The invention also provides skin homing peptides such as the peptide CVALCREACGEGC (SEQ ID NO: 3); pancreas homing peptides such as the peptide SWCEPGWCR (SEQ ID NO: 4) and retina homing peptides such as the peptides CSCFRDVCC (SEQ ID NO: 5) and CRDVVSVIC (SEQ ID NO: 6), each of which contains a

006260" 5492950

tripeptide RDV motif. Examples of peptides that home to prostate, ovary, lymph node, adrenal gland, liver and gut are also provided (see Tables 2 to 11). It should be recognized that motifs common to particular organ homing peptides can be identified by simple inspection of the peptides. For example, inspection of Table 9 reveals that the peptides AGCSVTVCG (SEQ ID NO: 315) and AGCVQSQCY (SEQ ID NO: 370) share an AGC motif; the peptides LECRRWRCD (SEQ ID NO: 328) and LECVANLCT (SEQ ID NO: 337) share an LEC motif; and the peptides SECAYRACS (SEQ ID NO: 319) and SECYTGSCP (SEQ ID NO: 375) share an SEC motif. In addition, several of these peptides were isolated more than one time (see asterisks in Table 9), indicating that such motifs are relevant to the ability of the peptides to selectively home. Peptides comprising the particular motifs disclosed herein, as well as other motifs identifiable by inspection of the disclosed peptides, are considered within the claimed invention, provided that the motif is not an RGD motif.

The homing molecules of the invention are useful for targeting a moiety to a particular organ or tissue. Thus, the invention provides conjugates, comprising an organ homing molecule linked to a moiety. Such moieties can be a therapeutic agent such as a virus; a viral gene therapy vector; a drug; a detectable or imaging agent such as a radionuclide; or a tag such as biotin. As disclosed herein, such organ homing molecules of the invention, particularly conjugates of the invention, can be used to detect or visualize a selected organ or tissue or to diagnose or treat a pathology in a selected organ or tissue. An organ homing molecule of the invention also can be used

to isolate the target molecule that is expressed in the selected organ or tissue and binds the organ homing molecule. For convenience, a molecule of the invention that homes to a selected organ or tissue is referred to
5 as an "organ homing molecule."

As used herein, the term "molecule" is used broadly to mean an organic compound having at least one reactive group that can be varied by substituting one or more different groups. An organic molecule can be a
10 drug; a nucleic acid molecule, including RNA or DNA; a peptide; a variant or modified peptide or a peptide mimetic; a protein or a fragment thereof; an oligosaccharide; a lipid; a glycolipid; or a lipoprotein.

15 An organic molecule can be a naturally occurring molecule, which can be a product of nature in that the groups comprising the organic molecule and the bonds linking the groups are produced by biological processes. For example, a naturally occurring organic
20 molecule can be an RNA molecule or a fragment thereof, which can be isolated from a cell or expressed from a recombinant nucleic acid molecule. Similarly, a peptide is considered a naturally occurring organic molecule, even if it is produced by chemical synthesis,
25 since the amino acid groups and bonds linking the groups can be produced by normal biological processes and the peptide, itself, can be produced in a cell due, for example, to proteolytic degradation of a protein containing the peptide.

30 An organic molecule also can be a nonnaturally occurring molecule. Such molecules have

006747E-092900
006250" 3492950

chemical groups or bonds that are not normally produced by biological processes. For example, a nucleic acid sequence containing nonnaturally occurring nucleoside analogs or phosphorothioate bonds that link the
5 nucleotides and protect against degradation by nucleases are examples of nonnaturally occurring molecules. A ribonucleotide containing a 2-methyl group, instead of the normal hydroxyl group, bonded to the 2'-carbon atom of ribose residues, is an example of
10 a non-naturally occurring RNA molecule that is resistant to enzymatic and chemical degradation. Other examples of nonnaturally occurring organic molecules include RNA containing 2'-aminopyrimidines, such RNA being 1000x more stable in human serum and urine as
15 compared to naturally occurring RNA (see Lin et al., Nucl. Acids Res., 22:5229-5234 (1994); and Jellinek et al., Biochemistry, 34:11363-11372 (1995), each of which is incorporated herein by reference).

For convenience, the term "peptide" is used
20 broadly herein to mean peptides, polypeptides, proteins and fragments of proteins. Other molecules useful in the invention include peptoids, peptidomimetics and the like. With respect to the organ or tissue homing peptides of the invention, peptidomimetics, which
25 include chemically modified peptides, peptide-like molecules containing nonnaturally occurring amino acids, peptoids and the like, have the binding activity of an organ homing peptide upon which the peptidomimetic is derived (see, for example, "Burger's
30 Medicinal Chemistry and Drug Discovery" 5th ed., vols. 1 to 3 (ed. M.E. Wolff; Wiley Interscience 1995), which is incorporated herein by reference).
Peptidomimetics provide various advantages over a

006250"549260

peptide, including that a peptidomimetic can be stable when administered to a subject, for example, during passage through the digestive tract and, therefore, useful for oral administration.

5 Methods for identifying a peptidomimetic are well known in the art and include, for example, the screening of databases that contain libraries of potential peptidomimetics. For example, the Cambridge Structural Database contains a collection of greater
10 than 300,000 compounds that have known crystal structures (Allen et al., Acta Crystallogr. Section B, 35:2331 (1979)). This structural depository is continually updated as new crystal structures are determined and can be screened for compounds having
15 suitable shapes, for example, the same shape as an organ or tissue homing molecule, as well as potential geometrical and chemical complementarity to a target molecule bound by an organ or tissue homing peptide. Where no crystal structure of a homing peptide or a
20 target molecule, which binds an organ or tissue homing molecule, is available, a structure can be generated using, for example, the program CONCORD (Rusinko et al., J. Chem. Inf. Comput. Sci. 29:251 (1989)). Another database, the Available Chemicals Directory
25 (Molecular Design Limited, Informations Systems; San Leandro CA), contains about 100,000 compounds that are commercially available and also can be searched to identify potential peptidomimetics of an organ or tissue homing molecule.

30 The term "nucleic acid molecule" also is used broadly to mean any polymer of two or more nucleotides, which are linked by a covalent bond such as a

006250" 5249/950

phosphodiester bond, a thioester bond, or any of various other bonds known in the art as useful and effective for linking nucleotides. Such nucleic acid molecules can be linear, circular or supercoiled, and
5 can be single stranded or double stranded DNA or RNA or can be a DNA/RNA hybrid.

As used herein, the term "library" means a collection of molecules. A library can contain a few or a large number of different molecules, varying from
10 about two to about 10^{15} molecules or more. The chemical structure of the molecules of a library can be related to each other or be diverse. If desired, the molecules constituting the library can be linked to a common or unique tag, which can facilitate recovery and/or
15 identification of the molecule.

Methods for preparing libraries containing diverse populations of various types of molecules such as peptides, peptoids and peptidomimetics are well known in the art and various libraries are commercially
20 available (see, for example, Ecker and Crooke, Biotechnology 13:351-360 (1995), and Blondelle et al., Trends Anal. Chem. 14:83-92 (1995), and the references cited therein, each of which is incorporated herein by reference; see, also, Goodman and Ro, Peptidomimetics
25 for Drug Design, in "Burger's Medicinal Chemistry and Drug Discovery" Vol. 1 (ed. M.E. Wolff; John Wiley & Sons 1995), pages 803-861, and Gordon et al., J. Med. Chem. 37:1385-1401 (1994), each of which is
30 incorporated herein by reference). Where a molecule is a peptide, protein or fragment thereof, the molecule can be produced *in vitro* directly or can be expressed from a nucleic acid, which can be produced *in vitro*.

006260-52492950

Methods of synthetic peptide and nucleic acid chemistry are well known in the art.

A library of peptide molecules also can be produced, for example, by constructing a cDNA
5 expression library from mRNA collected from a cell, tissue, organ or organism of interest. Methods for producing such libraries are well known in the art (see, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory
10 Press 1989), which is incorporated herein by reference). Preferably, a peptide encoded by the cDNA is expressed on the surface of a cell or a virus containing the cDNA. For example, cDNA can be cloned into a phage vector such as fuse 5 (Example I),
15 wherein, upon expression, the encoded peptide is expressed as a fusion protein on the surface of the phage.

In addition, a library of molecules can be a library of nucleic acid molecules, which can be DNA,
20 RNA or analogs thereof. For example, a cDNA library can be constructed from mRNA collected from a cell, tissue, organ or organism of interest, or by collecting genomic DNA, which can be treated to produce appropriately sized fragments using restriction
25 endonucleases or methods that randomly fragment genomic DNA. A library comprising RNA molecules also can be constructed by collecting RNA from cells or by synthesizing the RNA molecules chemically. Diverse libraries of nucleic acid molecules can be made using
30 solid phase synthesis, which facilitates the production of randomized regions in the molecules. If desired, the randomization can be biased to produce a library of

006260" 5492650

nucleic acid molecules containing particular percentages of one or more nucleotides at a position in the molecule (U.S. Patent No.: 5,270,163, issued December 14, 1993, which is incorporated herein by reference).

If desired, the nucleic acid molecules can be nucleic acid analogs that are less susceptible to degradation by nucleases. For example, RNA molecules containing 2'-O-methylpurine substitutions on the ribose residues and short phosphorothioate caps at the 3'- and 5'-ends exhibit enhanced resistance to nucleases (Green et al., Chem. Biol., 2:683-695 (1995), which is incorporated herein by reference). Similarly, RNA containing 2'-amino- 2'-deoxypyrimidines or 2'-fluoro- 2'-deoxypyrimidines is less susceptible to nuclease activity (Pagratis et al., Nature Biotechnol., 15:68-73 (1997), which is incorporated herein by reference). Furthermore, L-RNA, which is a stereoisomer of naturally occurring D-RNA, is resistant to nuclease activity (Nolte et al., Nature Biotechnol., 14:1116-1119 (1996); Klobmann et al., Nature Biotechnol., 14:1112-1115 (1996); each of which is incorporated herein by reference). Such RNA molecules and methods of producing them are well known and routine (see Eaton and Piekern, Ann. Rev. Biochem., 64:837-863 (1995), which is incorporated herein by reference). DNA molecules containing phosphorothioate linked oligodeoxynucleotides are nuclease resistant (Reed et al., Cancer Res. 50:6565-6570 (1990), which is incorporated herein by reference). Phosphorothioate-3' hydroxypropylamine modification of the phosphodiester bond also reduces the susceptibility of a DNA molecule to nuclease degradation (see Tam et al., Nucl. Acids

Res., 22:977-986 (1994), which is incorporated herein by reference). If desired, the diversity of a DNA library can be enhanced by replacing thymidine with 5-(1-pentynyl)-2'-deoxoridine (Latham et al., Nucl. Acids Res. 22:2817-2822 (1994), which is incorporated herein by reference). Such modified nucleic acid molecules can be useful for the manufacture of a library or for the purpose of being a tag, which is described later below.

As disclosed herein, *in vivo* panning for the purpose of identifying an organ or tissue homing molecule comprises administering a library to a subject, collecting an organ or tissue sample and identifying an organ or tissue homing molecule using various methods well known in the art. Generally, the presence of an organ or tissue homing molecule in a collected organ or tissue is identified based on one or more characteristics common to the molecules present in the library, then the structure of a particular organ or tissue homing molecule can be determined.

A highly sensitive detection method such as mass spectrometry (MS), either alone or in combination with a method such as gas chromatography (GC), can be used to identify homing molecules that are closely related even when present in small amounts in a selected organ or tissue. For example, GC in combination with MS was used to identify two major and four minor lidocaine metabolites following lidocaine injection into rats and the analysis of urine (Coutts et al., J. Chromotogr. 421:267-280 (1987), which is incorporated herein by reference). Similarly, where a library comprises diverse molecules based generally on

005250" 54792950

the structure of an organic molecule such as a drug, an organ or tissue homing molecule can be identified by determining the presence of a parent peak for the particular molecule.

5 If desired, the selected organ or tissue can be processed using a method such as HPLC, which can be used to obtain an enriched fraction of molecules having a defined range of molecular weights or polarity or the like from a complex mixture. The enriched fraction of
10 molecules then can be further analyzed for the purposes of identifying organ or tissue homing molecules. For example, HPLC coupled with GC and MS were used to identify seven metabolites of a vitamin D analogue after injection of dihydrotachysterol 3 into a rat and
15 fractionation of an isolated perfused kidney (Porteous et al., Biomed. Environ. Mass Spectrum 16:87-92 (1988), which is incorporated herein by reference). Conditions for HPLC will depend on the structure of the particular molecule and can be optimized by those skilled in the
20 art based on knowledge of the molecule.

 The organ homing molecules present in a collected sample of organ or tissue can be recovered from the sample by incubation in a solution having a defined salt concentration and temperature. Selective
25 extraction also can be used to obtain different fractions of organic molecules by sequentially incubating a collected sample in one or more solutions. Such solutions can have a different salt concentration or can effect extraction of an organic homing molecule
30 at a particular temperature. The resulting eluates from the collected sample can be collected separately or can be pooled into one or more fractions and the

organ homing molecules can be detected and identified. Similarly, methods for bulk removal of potentially interfering cellular materials such as DNA, RNA, proteins, lipids or carbohydrates are well known in the art. Such methods can be used to enrich for the particular organ homing molecule from potentially contaminating materials in the collected sample and to increase the sensitivity of detecting the molecule.

Ease of identification of an organ or tissue homing molecule, particularly an untagged molecule, depends upon various factors, including the presence of potentially contaminating background cellular material. For example, where the homing molecule is an untagged peptide, a larger number must home to the organ or tissue in order to identify the specific peptides over the background of cellular protein. In contrast, a much smaller amount of an untagged homing molecule such as a drug is identifiable because such molecules normally are generally absent from or present in very small numbers in the body. In this situation, a highly sensitive method such as MS can be used to identify an organ homing molecule. The skilled artisan will recognize that the method of identifying a molecule will depend, in part, on the structure of the particular molecule.

As disclosed herein, a sufficient number of molecules selectively home to a selected organ or tissue during *in vivo* panning such that the molecules readily can be identified. For example, peptides that were identified two or more times in a particular collected organ (see Table 1). For example, of forty clones sequenced from various selected organs, the gut

homing peptide YSGKWGK (SEQ ID NO: 9) was present in 22% of the clones; the ovary homing peptides EVRSRLS (SEQ ID NO: 10) and RVGLVAR (SEQ ID NO: 11) each was present in 22% of the clones; and the liver homing peptide VKSVCRT (SEQ ID NO: 12) was present in 11% of the clones (see Table 1). Similarly, the lung homing peptides CLAKENVVC (SEQ ID NO: 13) and CGFECVRQCPERC (SEQ ID NO: 1); the skin homing peptide CVALCREACGEGC (SEQ ID NO: 3); and the retina homing peptide CGEFKVGVC (SEQ ID NO: 14) each was independently isolated several times during *in vivo* panning of the respective organs, as were other organ homing peptides (see Tables 2 to 11; peptides marked with asterisk). These results demonstrate that a substantial fraction of the identified organ homing molecules have the same structure or, in many cases, share conserved motifs.

Following various *in vivo* panning screens, hundreds of thousands to millions of phage expressing homing peptides were recovered from the respective organ or tissue. Generally, the phage collected from a round of *in vivo* panning were plated on agar, about 250 to 300 clones were selected, grown in 5 ml cultures, then pooled and readministered for a subsequent round of *in vivo* panning ("regular method"). However, in some experiments, 1000 clones were selected, grown in 2 ml cultures, then pooled and administered for a subsequent round of screening; or the entire agar plate was scraped and all of the phage were cultured together and administered for a subsequent round of screening. The peptide inserts of various isolated phage were determined such that, of the millions of phage that homed, only a small number of sequences were identified. These results indicate that specific types

of homing molecules can be present in relatively large proportions in an organ or tissue following *in vivo* homing, thereby increasing the ease with which the molecules can be identified.

5 Where an organ or tissue homing molecule is a nucleic acid molecule, various assay methods can be used to substantially isolate or identify the molecule. For example, PCR can be particularly useful for identifying the presence of the homing molecule
10 because, in principle, PCR can detect the presence of a single nucleic acid molecule (see, for example, Erlich, PCR Technology: Principles and Applications for DNA Amplification (Stockton Press (1989), which is incorporated herein by reference). PCR also has been
15 used to amplify nucleic acid molecules that bind to a predetermined target *in vitro* and, when the nucleic acids were rendered resistant to nucleases and administered to a subject, they modulated biological processes such as lymphocyte trafficking *in vivo* (see,
20 for example, Hicke et al., J. Clin. Invest. 98:2688-2692 (1996), which is incorporated herein by reference). These findings indicate that nucleic acid molecules are sufficiently stable when administered into the circulation of a subject such that *in vivo*
25 panning can be used to identify nucleic acid molecules that selectively home to an organ or tissue *in vivo*.

 The molecules of a library can be tagged, which can facilitate recovery or identification of the organ homing molecules. As used herein, the term "tag"
30 means a physical, chemical or biological moiety such as a plastic or metallic microbead, an oligonucleotide or a bacteriophage, respectively, that is linked to a

006360"5475"09500

005250" 5494960

molecule of the library. Methods for tagging a molecule are well known in the art (Hermanson, Bioconjugate Techniques, (Academic Press 1996), which is incorporated herein by reference). The link between
5 a molecule and a tag can be a covalent or a non-covalent bond and, if desired, the link can be selectively cleavable from the molecule.

As used herein, the term "shared tag" means a physical, chemical or biological moiety that is common
10 to each molecule in a library. A shared tag can be used to identify the presence of a molecule of the library in a sample or to substantially isolate the molecules from a sample following in vivo panning. For example, a library that comprises a population of
15 diverse molecules such as nucleic acids can be linked to a shared tag. If the shared tag is biotin, for example, a nucleic acid homing molecule can be substantially isolated from a selected organ or tissue by binding, for example, to a streptavidin affinity
20 column. The presence of the organ or tissue homing nucleic acid molecule also can be detected by binding with a labeled streptavidin. A peptide such as the hemagglutinin antigen also can be a shared tag, which, when linked to each molecule in a library, allows the
25 use of an antibody specific for the hemagglutinin antigen to substantially isolate homing molecules from a selected organ or tissue. Furthermore, a molecule or a support containing a molecule can be linked to a hapten such as 4-ethoxy-methylene-2-phenyl-2-oxazoline-
30 5-one (phOx), which can be bound by an anti-phOx antibody linked to a magnetic bead as a means to recover the homing molecule. Methods for purifying phOx labeled conjugates are known in the art and the

materials for performing these procedures are commercially available (Invitrogen, La Jolla CA; Promega Corp., Madison WI).

A shared tag also can be a nucleic acid sequence that can be used to identify the presence of molecules of the library in a sample or to substantially isolate molecules of a library from a sample. For example, each of the molecules of a library can be linked to the same selected nucleotide sequence, which constitutes the shared tag. An affinity column containing a nucleotide sequence that is complementary to the shared tag then can be used to isolate the homing molecules from an organ or tissue sample by hybridizing to the shared tag linked to the molecules. A nucleotide sequence complementary to a portion of the shared tag also can be used as a PCR primer such that the presence of molecules containing the shared tag can be identified in a sample by PCR.

A tag also can be a specific or a unique tag. As used herein, the term "specific tag" means a physical, chemical or biological tag that is linked to a molecule in a library and that is unique for the particular molecule. A specific tag is particularly useful if it is readily identifiable. A nucleotide sequence that is unique for a particular molecule of a library is an example of a specific tag, for example, a unique oligonucleotide tag linked to each peptide of a library or peptides (see, for example, Brenner and Lerner, Proc. Natl. Acad. Sci., USA 89:5381-5383 (1992), which is incorporated herein by reference). Upon homing to an organ or tissue, the homing peptide can be identified by determining the sequence of the

unique oligonucleotide tag using, for example, PCR (see, for example, Erlich, PCR Technology: Principles and Applications for DNA Amplification (Stockton Press 1989), which is incorporated herein by reference).

5 Similarly, the nucleic acid sequence encoding a peptide displayed on a phage is another example of a specific nucleic acid tag, since sequencing of the nucleic acid identifies the amino acid sequence of the expressed peptide (see Example I). Such unique oligonucleotide
10 sequence tags, when linked to other libraries of molecules, can be used to identify the sequence of the homing molecule linked thereto.

A shared tag and specific tag, in combination, can be particularly useful for isolating
15 and identifying an organ or tissue homing molecule when the homing molecule is present in minute quantities. For example, each molecule of a library can be linked to an oligonucleotide tag which contains two portions; an internal unique nucleotide sequence tag and shared
20 flanking 5' and 3' nucleotide tags that serve as primer binding sites for use in PCR. Each molecule, therefore, contains an oligonucleotide tag having a unique portion to identify the homing molecule and a shared portion to provide PCR primer binding sites.
25 Such a tagged molecule, upon homing to a selected organ or tissue, can be identified by performing PCR using primers that hybridize to the shared flanking 5' and 3' nucleotide tags, then performing DNA sequencing to determine the nucleotide sequence of the internal
30 unique sequence tag. The PCR product can be sequenced directly using one of the PCR primers or the PCR product can be cloned into a vector and the DNA

005260" 5494960

sequence determined by routine methods well known in the art.

Various other combinations of shared and unique tags can be used. For example, each of the
5 molecules in a library can be linked to a specific nucleotide sequence tag (see, for example, Brenner and Lerner, *supra*, 1992), which also contains a shared 3' nucleotide sequence that can be a primer binding site for use in PCR, and can be further linked to a
10 shared tag such as biotin. Upon homing to an organ or tissue, the particular homing molecule can be substantially isolated from an organ or tissue sample based on the biotin tag. The isolated molecules can then be identified, for example, by PCR based DNA
15 sequencing of the specific tag using the shared 3' nucleotide sequence of the nucleotide tag as a primer binding site.

A tag also can serve as a support. As used herein, the term "support" means a tag having a defined
20 surface to which a molecule can be attached. In general, a tag useful as a support is a shared tag. For example, a support can be a biological tag such as a virus or virus-like particle such as a bacteriophage ("phage"); a bacterium such as *E. coli*; or a eukaryotic
25 cell such as a yeast, insect or mammalian cell; or can be a physical tag such as a liposome or a microbead, which can be composed of a plastic, agarose, gelatin or other biological or artificial material. If desired, a shared tag useful as a support can have linked thereto
30 a specific tag.

As exemplified herein, a peptide suspected of being able to home to a selected normal organ or tissue such as lung, skin, pancreas, retina, prostate, ovary, lymph node, adrenal gland, liver or gut, or to an organ or tissue containing a tumor, for example, a lung containing lung tumors or a pancreas containing a pancreatic tumor, was expressed as the N-terminus of a fusion protein, wherein the C-terminus consisted of a phage coat protein (see Example I). Upon expression of the fusion protein, the C-terminal coat protein linked the fusion protein to the surface of a phage such that the N-terminal peptide was in a position to interact with a target molecule in the organ or tissue. Thus, a molecule having a shared tag was formed by the linking of a peptide to a phage, wherein the phage provided a biological support, the peptide molecule was linked as a fusion protein, the phage-encoded portion of the fusion protein acted as a spacer molecule, and the nucleic acid encoding the peptide provided a specific tag allowing identification of organ and tissue homing peptides.

Where a molecule is linked to a support, the tagged molecule comprises the molecule attached to the surface of the support, such that the part of the molecule suspected of being able to interact with a target molecule in a cell in the subject is positioned so as to be able to participate in the interaction. For example, where the homing molecule is suspected of being a ligand for a growth factor receptor, the binding portion of the molecule attached to a support is positioned so it can interact with the growth factor receptor on a cell in an organ or tissue. If desired, an appropriate spacer can be positioned between the

molecule and the support such that the ability of the potential organ or tissue homing molecule to interact with the target molecule is not hindered. A spacer molecule also can contain a reactive group, which
5 provides a convenient and efficient means of linking a molecule to a support and, if desired, can contain a tag, which can facilitate recovery or identification of the molecule (see Hermanson, *supra*, 1996).

In general, a support should have a diameter
10 less than about 10 μm to about 50 μm in its shortest dimension, such that the support can pass relatively unhindered through the capillary beds present in the subject so as to not occlude circulation. In addition, a support can be biologically inert, so that it does
15 not perturb the normal expression of cell surface molecules or normal physiology of the subject. In addition, a support can be excretable or biodegradable, particularly where the subject used for *in vivo* panning is not sacrificed to collect a sample of a selected
20 organ or tissue.

As used herein, the term "*in vivo* panning," when used in reference to the identification of an organ or tissue homing molecule, means a method of screening a library by administering the library to a
25 subject and identifying a molecule that selectively homes to an organ or tissue in the subject (U.S. Patent No. 5,622,699, *supra*, 1997). The term "administering to a subject", when used in referring to a library of molecules or a portion of such a library, is used in
30 its broadest sense to mean that the library is delivered to a selected organ or tissue in the subject, which, generally, is a vertebrate, particularly a

mammal such as a human. Libraries of molecules can be administered by any route or means of administration, such as intravenously, intramuscularly, orally, optically, ocularly, intraperitoneally, nasally, 5 vaginally, rectally, into the uterus, into a chamber of the eye, into the central or peripheral nervous system, by inhalation, by topical administration, or by injection into any normal organ or tissue or into a pathological region such as a tumor or an organ or 10 tissue involved in a pathology, particularly into the circulatory system of the organ or tissue.

A library can be administered to a subject, for example, by injecting the library into the circulation of the subject such that the molecules pass 15 through the selected organ or tissue; after an appropriate period of time, circulation is terminated, for example, by perfusion through the heart or by removing a sample of the organ or tissue (Example I; U.S. Patent No. 5,622,699, *supra*, 1997; see, also, 20 Pasqualini and Ruoslahti, Nature 380:364-366 (1996), which is incorporated herein by reference). Alternatively, a cannula can be inserted into a blood vessel in the subject, such that the library is administered by perfusion for an appropriate period of 25 time, after which the library can be removed from the circulation through the cannula or the subject can be sacrificed or anesthetized to collect an organ or tissue sample. A library also can be shunted through one or a few organs or tissues including a selected 30 organ or tissue, by cannulation of the appropriate blood vessels in the subject. It is recognized that a library also can be administered to an isolated perfused organ or tissue. Such panning in an isolated

00676475.052500

perfused organ or tissue can be useful to identify molecules that bind to the organ or tissue.

The use of *in vivo* panning to identify organ or tissue homing molecules is exemplified herein by screening a phage peptide display library in mice and identifying peptides that selectively homed to lung, pancreas, skin and others, and in rats, for peptides that homed to retina (Examples I and II). However, phage libraries that display other protein molecules, including, for example, an antibody or an antigen binding fragment of an antibody such as an Fv, Fd or Fab fragment; a hormone receptor such as a growth factor receptor; or a cell adhesion receptor such as an integrin or a selectin also can be used to practice the invention. Variants of such molecules can be constructed using well known methods such as random, site directed or codon based mutagenesis (see Huse, U.S. Patent No. 5,264,563, issued November 23, 1993, which is incorporated herein by reference) and, if desired, peptides can be chemically modified, for example, by introducing a disulfide bridge, following expression of the phage but prior to administration to the subject. Thus, many different types of phage display libraries can be screened by *in vivo* panning.

Phage display technology provides a means for expressing a diverse population of random or selectively randomized peptides. Various methods of phage display and methods for producing diverse populations of peptides are well known in the art. For example, Ladner et al. (U.S. Patent No. 5,223,409, issued June 29, 1993, which is incorporated herein by reference) describe methods for preparing diverse

populations of binding domains on the surface of a phage. In particular, Ladner et al. describe phage vectors useful for producing a phage display library, as well as methods for selecting potential binding
5 domains and producing randomly or selectively mutated binding domains.

Similarly, Smith and Scott (Meth. Enzymol. 217:228-257 (1993); see, also, Scott and Smith, Science 249: 386-390 (1990), each of which is incorporated
10 herein by reference) describe methods of producing phage peptide display libraries, including vectors and methods of diversifying the population of peptides that are expressed (see, also, Huse, WO 91/07141 and WO 91/07149, each of which is incorporated herein by
15 reference; see, also, Example I). Phage display technology can be particularly powerful when used, for example, with a codon based mutagenesis method, which can be used to produce random peptides or randomly or desirably biased peptides (Huse, U.S. Patent No.
20 5,264,563, *supra*, 1993). These or other well known methods can be used to produce a phage display library, which can be subjected to the *in vivo* panning method of the invention in order to identify a peptide that homes to a selected organ or tissue.

25 In addition to screening a phage display library, *in vivo* panning can be used to screen various other types of libraries. For example, nucleic acid molecules that bind to a cell surface receptor have been described (see O'Connell et al., Proc. Natl. Acad.
30 Sci., USA 93:5883-5887 (1996); Tuerk and Gold, Science 249:505-510 (1990); Gold et al., *supra* (1995), each of which is incorporated herein by reference). These

in vitro results indicate that a library of nucleic acid molecules also can be examined by in vivo panning to identify nucleic acid molecules that home to a selected organ or tissue. Additional libraries
5 suitable for screening include, for example, oligosaccharide libraries (York et al., Carb. Res. 285:99-128, (1996); Liang et al., Science 274:1520-1522, (1996); and Ding et al., Adv. Expt. Med. Biol. 376:261-269, (1995), each of which is
10 incorporated by reference); lipoprotein libraries (de Kruif et al., FEBS Lett. 399:232-236, (1996), which is incorporated herein by reference); glycoprotein or glycolipid libraries (Karaoglu et al., J. Cell Biol. 130:567-577 (1995), which is incorporated herein by
15 reference); or chemical libraries containing, for example, drugs or other pharmaceutical agents (Gordon et al., J. Med. Chem. 37:1385-1401 (1994); Ecker and Crook, Bio/Technology 13:351-360 (1995); each of which is incorporated by reference). Such
20 libraries, if desired, can be tagged, which can facilitate recovery of the molecule from an organ or tissue or its identification as previously described.

In vivo panning provides a method for directly identifying molecules that can selectively
25 home to an organ or tissue. As used herein, the term "home" or "selectively home" means that a particular molecule binds relatively specifically to a target molecule present in the organ or tissue, particularly in the vasculature present in the organ or tissue,
30 following administration to a subject. In general, selective homing is characterized, in part, by detecting at least a two-fold (2x) greater selective

006260" 549360

binding of the molecule to an organ or tissue as compared to a control organ or tissue.

006660" 5492960
09676475 092900

Selective homing of a molecule to a selected organ or tissue can be due to selective recognition by the molecule of a particular cell target molecule such as a cell surface protein present on a cell in the organ or tissue. Selectivity of homing is dependent on the particular target molecule being expressed on only one or a few different cell types, such that the molecule homes to only one or a few organs or tissues. In this regard, most different cell types, particularly cell types that are unique to an organ or tissue, can express unique target molecules. Thus, in organs such as liver, spleen or lymph node, where blood circulates through sinusoids formed by the cells specific for the organ, *in vivo* panning can be useful for identifying molecules that home to the particular organ or tissue.

It should be recognized that, in some instances, a molecule can localize nonspecifically to an organ or tissue. For example, *in vivo* panning of a phage display library can result in high background in organs such as liver and spleen, which contain a marked component of the reticuloendothelial system (RES). Thus, nonspecific binding of molecules due to uptake by the RES of such an organ or tissue can make identifying an organ or tissue homing molecule more difficult. However, as disclosed herein, potential nonspecific binding can be circumvented, for example, by perfusion through the heart prior to collecting the selected organ or tissue (Example I).

006660 "5492960
09676475 "092900

In addition, selective homing readily can be distinguished from nonspecific binding by detecting differences in the abilities of different individual phage to home to an organ or tissue. For example, selective homing can be identified by combining a putative homing molecule such as a peptide expressed on a phage with an excess of non-infective phage or with about a five-fold excess of phage expressing unselected peptides, injecting the mixture into a subject and collecting a sample of the organ or tissue. In the latter case, for example, provided the portion of injected phage in which an organ or tissue homing peptide is sufficiently low so as to be nonsaturating for the target molecule, a determination that greater than about 20% of the phage in the organ or tissue contain the putative homing molecule is demonstrative evidence that the peptide expressed by the phage is a selective organ or tissue homing molecule. In addition, nonspecific localization can be distinguished from selective homing by performing competition experiments using, for example, phage expressing a putative organ or tissue homing peptide in combination with an excess amount of the "free" peptide (see Example II).

25 Various methods can be used to prevent nonspecific localization of a molecule to organs or tissues, such as those containing a component of the RES. For example, as disclosed herein, perfusion of a solution through the heart shortly after initiating
30 phage circulation decreased the background binding and allowed identification of peptides that selectively home to lung and liver, both of which contain a component of the RES (see Example II). Furthermore,

coadministration of nonreplicating control phage with a phage display library reduced nonspecific phage trapping in organs such as liver and spleen, which also contain a component of the RES. This approach allowed
5 identification of molecules that selectively home to liver (Example II). Thus, a library of molecules attached to a support can be coadministered with an excess of the support to a subject to inhibit nonspecific binding in an organ or tissue.

10 Nonspecific uptake by a component of the RES also can be prevented by administering a blocking agent that inhibits uptake by the RES. For example, polystyrene latex particles or dextran sulfate can be administered to the subject prior to the administration
15 of the library (see Kalin et al., Nucl. Med. Biol. 20:171-174 (1993); Illum et al., J. Pharm. Sci. 75:16-22 (1986); Takeya et al., J. Gen. Microbiol. 100:373-379 (1977), each of which is incorporated herein by reference). Such pre-administration of
20 dextran sulfate 500 or polystyrene microspheres has been used to block nonspecific uptake of a test substance by Kupffer cells, which are the RES component of the liver (Illum et al., *supra*, 1986). Similarly, nonspecific uptake of agents by the RES has been
25 blocked using carbon particles or silica (Takeya et al., *supra*, 1977) or a gelatine colloid (Kalin et al., *supra*, 1993). Thus, many methods useful for inhibiting nonspecific uptake by the RES are known in the art and routinely used.

30 Methods of decreasing nonspecific phage trapping include using phage that display a low background binding to a particular organ or tissue.

For example, Merrill et al. (Proc. Natl. Acad. Sci., USA 93:3188-3192 (1996), which is incorporated herein by reference) selected lambda-type phage that are not taken up by the RES and, as a result, remain in the circulation for a prolonged period of time. A comparable filamentous phage variant, for example, can be selected using similar methods.

Selective homing can be demonstrated by determining if a homing molecule for a selected organ or tissue is relatively specific. For example, the amount of homing molecule in a selected organ or tissue can be compared to a control or different organ or tissue. Selective homing also can be demonstrated by showing that molecules that home to an organ or tissue, as identified by one round of *in vivo* panning, are enriched for in a subsequent round of *in vivo* panning. For example, phage expressing the peptides CGFECVRQCPERC (SEQ ID NO: 1) and CGFELETC (SEQ ID NO: 2) were enriched for in the second and third rounds of *in vivo* panning from lung and exhibited a 35-fold and 9-fold enrichment, respectively, as compared to unselected phage (see Example II.B). Furthermore, no selective homing to kidney or brain was detected.

As used herein, the term "selected organ or tissue" is used in its broadest sense to mean a normal organ or tissue or an organ or tissue having a pathology, for example, lung containing lung tumors, to which a molecule can selectively home. Thus, the term "organ or tissue" is used broadly to mean any tissue or organ including a normal or pathological cell type such as a cancer cell, in which case the selected organ or tissue can be a primary tumor or a metastatic lesion.

0066260" 5497960

In general, a selected organ or tissue contains a cell, which can be a cell of the vasculature, that expresses a particular target molecule such as a cell surface protein to which a homing molecule can bind. By performing at least two rounds of *in vivo* panning, the selectivity of homing of the molecule for the selected organ or tissue can be determined. As discussed below, however, in some cases a homing molecule can home to more than one selected organ or tissue, in which case the molecule is considered to be able to selectively home to a family of selected organs or tissues. Generally, however, molecules that home to more than one or a few different organs or tissue are not particularly useful since an advantage of the homing molecules of the invention is that they allow targeting of a particular organ or tissue.

The term "control organ or tissue" is used to mean an organ or tissue other than the selected organ or tissue. A control organ or tissue is characterized by the inability of the organ or tissue homing molecule to home to the control organ or tissue and, therefore, is useful for identifying selective binding of a molecule to a selected organ or tissue (Example II).

Where an organ or tissue homing molecule is identified based on its ability to home to a pathologic lesion in an organ or tissue, the control organ or tissue can be a corresponding portion of the selected organ or tissue that does not exhibit the pathologic lesion.

A control organ or tissue can be collected, for example, to identify nonspecific binding of the molecule or to determine the selectivity of homing of

the molecule. In addition, nonspecific binding can be identified by administering, for example, a control molecule, which is known not to home to an organ or tissue but is chemically similar to a putative homing
5 molecule. Alternatively, where the administered molecules are linked to a support, administration of the support, alone, can be used to identify nonspecific binding. For example, a phage that does not contain a peptide fusion protein can be administered to a subject
10 and the selected organ or tissue can be examined to determine the level of nonspecific binding of the phage support.

The steps of administering the library to the subject, collecting a selected organ or tissue and
15 identifying the molecules that home to the organ or tissue, comprise a single round of *in vivo* panning. Although not required, one or more additional rounds of *in vivo* panning generally are performed. Where an additional round of *in vivo* panning is performed, the
20 molecules recovered from the selected organ or tissue in the previous round are administered to a subject, which can be the same subject used in the previous round, where only a part of the organ or tissue was collected.

25 By performing a second round of *in vivo* panning, the relative binding selectivity of the molecules recovered from the first round can be determined by administering the identified molecules to a subject, collecting the selected organ or tissue, and
30 determining whether more phage displaying a particular molecule are recovered from the organ or tissue following the second round of screening as compared to

006260"52492950

those recovered following the first round. Although not required, a control organ or tissue also can be collected and the molecules recovered from the selected organ or tissue can be compared with those recovered from the control organ or tissue. Ideally, few if any molecules are recovered from a control organ or tissue following a second or subsequent round of *in vivo* panning. Generally, however, a proportion of the molecules also will be present in a control organ or tissue. In this case, the ratio of molecules in the selected organ or tissue as compared to the control organ or tissue (selected:control) can be determined. Additional rounds of *in vivo* panning can be used to determine whether a particular molecule homes only to the selected organ or tissue or can recognize a target expressed in one or more other organs or tissues that is identical or is sufficiently similar to the target in the originally selected organ or tissue.

In general, a library of molecules, which contains a diverse population of random or selectively randomized molecules of interest, is prepared, then administered to a subject. Some time after administration, the selected organ or tissue is collected and the molecules present in the selected organ or tissue are identified (see Example I). If desired, one or more control organs or tissues or a part of a control organ or tissue are sampled as well. For example, mice injected with a phage peptide display library, after about 1 to 5 minutes, were anesthetized, then snap frozen or perfused through the heart to terminate circulation of the phage. Lung, pancreas or other organs or tissues and one or more control organs were collected and the phage present in the selected

and control organs were collected. The peptides that selectively homed to the respective organs or tissues were identified (Example II and Tables 1 to 11).

As exemplified herein, experimental animals
5 were sacrificed to collect the selected or control organ or tissue. It should be recognized, however, that only a part of an organ or tissue need be collected to recover a molecule that homes to that organ or tissue. Similarly, only part of an organ or
10 tissue need be collected as a control. Thus, for example, following administration of a library of molecules to a subject, a part of the selected organ or tissue can be collected by biopsy, the homing molecules can be collected and, if desired, amplified and
15 readministered to the same subject for a second round of *in vivo* panning. Where the molecule that is to be administered a second time to the same subject is tagged or linked, for example, to a support, the tag or support should be biologically inert and biodegradable
20 or excretable, so as not to interfere with subsequent rounds of screening.

In vitro screening of phage libraries previously was used to identify peptides that bind to antibodies or to cell surface receptors (Smith and
25 Scott, *supra*, 1993). For example, *in vitro* screening of phage peptide display libraries identified novel peptides that specifically bound to integrin adhesion receptors (Koivunen et al., J. Cell Biol. 124:373-380 (1994a), which is incorporated herein by reference) and
30 to the human urokinase receptor (Goodson et al., Proc. Natl. Acad. Sci., USA 91:7129-7133 (1994), which is incorporated herein by reference). Similarly, *in vitro*

screening of nucleic acid molecules identified molecules that specifically bind to antibodies, cell surface receptors or organic molecules (Gold et al., *supra*, 1993, 1995, 1997). For example, RNA molecules that specifically bind to HIV-1 reverse transcriptase were identified using purified HIV-1 reverse transcriptase as the target molecule (Green et al., J. Mol. Biol., 247:60-68 (1995), which is incorporated herein by reference). These *in vitro* methods were performed using defined, well-characterized target molecules in an artificial system. However, such *in vitro* studies provide no insight as to whether a molecule that binds *in vitro* also can bind to the target *in vivo*. For example, endothelial cells grown in culture tend to lose their tissue-specific differences (Pauli and Lee, Lab. Invest. 58:379-387 (1988), which is incorporated herein by reference). Thus, a molecule that binds to a target on a cell *in vitro* may not bind *in vivo* because the target may not be present on the cell. Furthermore, such *in vitro* methods are limited in that they require prior knowledge of the target molecule and yield little if any information regarding *in vivo* utility. For example, Goodson et al. (*supra*, 1994) utilized cultured cells to express a recombinant urokinase receptor to obtain binding peptides. However, the urokinase receptor is expressed in cells of many different organs and tissues and, therefore, a molecule that binds to it can interact with many organs or tissues and would not be considered an organ or tissue homing molecule within the present invention.

In contrast to *in vitro* panning methods, *in vivo* panning requires no prior knowledge or the

availability of a known target molecule to identify a molecule that binds to a target molecule that is expressed *in vivo*. Also, since "nontargeted" organs or tissues are present during the screening, the probability of isolating organ or tissue homing molecules that lack selectivity of homing is greatly reduced. Furthermore, in obtaining organ or tissue homing molecules by *in vivo* panning, any molecules that may be particularly susceptible to degradation in the circulation *in vivo* due, for example, to a metabolic activity, will be selected against and will not be recovered. Thus, *in vivo* panning provides significant advantages over previous methods by identifying molecules that selectively home *in vivo* and, if desired, the target molecule present on a selected organ or tissue.

The identification of the organ homing molecules that selectively home to various normal tissues and to pathologic lesions in a particular organ or tissue, as exemplified herein, indicates that particular endothelial cell target molecules expressed the selected organ or tissue reflects the physiologic or pathologic state of the organ or tissue. Such organ homing molecules that selectively home to an organ or tissue based on a particular physiologic or pathologic condition occurring in the organ or tissue can be identified using the *in vivo* panning method and the selectivity of the homing molecules for the pathologic or physiologic condition of the organ or tissue can be confirmed by immunohistological analysis (Example III). For example, molecules that home to pancreas afflicted with pancreatitis can be identified by *in vivo* panning of a subject having pancreatitis and selectively of the

09676475-092900

homing molecule can be confirmed by using immunohistochemistry to compare homing of the molecule in normal pancreas with homing in a pancreas afflicted with pancreatitis.

5 Homing molecules selective for a normal organ
or tissue or an organ or tissue exhibiting a
pathological state can be useful for detecting the
presence or absence of the pathology. For example,
following administration of a prostate homing molecule
10 conjugated to an imaging moiety to a subject, the
prostate can be visualized. If the image is abnormal,
for example, if the size of the prostate is other than
that expected for a size and age matched subject, the
imaging result can indicate an abnormal physiologic
15 condition or pathologic condition afflicting the
prostate. For example, a conjugate comprising an
imaging agent and a prostate homing molecule that homes
to normal, but not to abnormal prostate, can be
administered to a subject. The identification, for
20 example, of a region of the prostate that does not bind
the homing molecule can indicate the occurrence of
abnormal blood flow in the prostate and can be
diagnostic of a pathologic condition such as the
presence of a prostate tumor. A conjugate comprising a
25 molecule that homes to prostate tumor tissue, but not
to normal prostate, can be used to image a prostate
tumor directly.

A homing molecule selective for an organ or tissue can be used to deliver a therapeutic agent to the organ or tissue. Such selective targeting of the agent can increase the effective amount of the agent delivered to the target organ or tissue, while reducing

the likelihood the agent will have an adverse effect on other organs or tissues. For example, a lung homing molecule can be used to deliver, to the lung of a cystic fibrosis patient, a gene encoding the cystic
5 fibrosis transmembrane receptor (CFTR), which is defective in cystic fibrosis. Thus, the organ homing molecules of the invention are particularly useful for *in vivo* gene therapy, since they provide a means to direct a gene to a desired target organ, thereby
10 increasing the likelihood that the target cells will receive the gene and decreasing the likelihood that normal, nontarget, cells will be adversely affected. A lung homing molecule also can be used to direct a therapeutic agent to the lung, thus sparing nontarget
15 organs or tissues from the toxic effects of the agent. For example, in alveolar bacterial pneumonia, a lung homing molecule can be useful for directing an antibiotic to the afflicted region of the lung, thus increasing the effective amount of the drug at the
20 desired site.

Due to the conserved nature of cellular receptors and of ligands that bind a particular receptor, the skilled artisan would recognize that an
25 organ or tissue homing molecule identified using *in vivo* panning in a mouse or rat also can bind to the corresponding target molecule in the selected organ or tissue of a human or other mammalian species. Such a homing molecule identified using an experimental animal
30 readily can be examined for the ability to bind to the corresponding organ or tissue in a human subject by demonstrating, for example, that the molecule also can bind selectively *in vitro* to a sample of the selected organ or tissue obtained from a human subject.

Alternatively, primary cells or established cell lines derived from a human organ or tissue can be used to test for the *in vitro* binding of the homing molecule. Similarly, primary cells or established cell lines that reflect a particular human organ or tissue pathology can be used to test the binding of homing molecules selective for the pathology. Animal models such as primate models of human pathologies are known and also can be used to test for the homing of the molecules using *in vivo* panning. Thus, routine methods can be used to confirm that an organ or tissue homing molecule identified using *in vivo* panning in an experimental animal also can bind an organ or tissue-specific target molecule in a human subject. Furthermore, *in vitro* contacting of a homing molecule with a sample suspected of containing a selected organ, tissue or pathology can identify the presence of the selected organ, tissue or pathology in the sample. Having identified the target molecule by *in vivo* panning, the artisan would know that it is the true target for an organ homing molecule and, therefore, would know that the target molecule could be used *in vitro* to identify additional organ homing molecules that likely would be specific for the target molecule *in vivo*. Such potential organ homing molecules then could be examined by *in vivo* panning to confirm organ homing ability.

In vivo panning was used to identify peptides expressed by phage that selectively homed to lung, skin, pancreas, retina, prostate, ovary, lymph node, adrenal gland, liver or gut, and to lung containing lung tumors or pancreas containing a pancreatic tumor (Examples II and IV; see, also, Tables 2 to 11). Due to the large size of the phage (300 nm) and the short

time the phage were allowed to circulate, it is unlikely that a substantial number of phage would have exited the circulatory system. Indeed, immunohistochemical studies of various organ and tissue homing molecules demonstrated that the molecules primarily home to and bind endothelial cell surface markers of the vasculature. Thus, the invention provides molecules such as peptides that selectively home to the vasculature of a selected organ or tissue.

Phage peptide display libraries were constructed essentially as described by Smith and Scott (*supra*, 1993; see, also, Koivunen et al., Biotechnology 13:265-270 (1995); Koivunen et al., Meth. Enzymol. 245:346-369 (1994b), each of which is incorporated herein by reference). In some libraries, at least one codon encoding cysteine also was included in each oligonucleotide so that cyclic peptides could be formed through disulfide linkages (Example I). Upon performing *in vivo* panning, peptides that selectively home to lung, pancreas, skin, retina, prostate, ovary, lymph node, adrenal gland, liver or gut or to lung containing lung tumors or to pancreas containing a pancreatic tumor were obtained. Thus, the invention provides various organ homing molecules that selectively home to particular organs or tissue.

Remarkably, some organ homing peptides independently were recovered up to four or more times during a round of the *in vivo* panning procedure (see, for example, Table 1). In addition, various peptides that homed to particular organs or tissues shared conserved amino acid sequence motifs. For example, some lung homing peptides shared a GFE motif; some

096260" 5492650

TABLE 1
SUMMARY OF IN VIVO TARGETING OF VARIOUS ORGANS

	ORGAN/MOTIF (SEQ ID NO:)	% OF MOTIF AMONG ALL CLONES	LUNG/BRAIN RATIO
5	<u>GUT</u>		
	YSGKWGK (9)	22	30
	GISALVLS (19)	11	nd
	SRRQPLS (153)	11	2
	MSPQLAT (159)	11	nd
10	MRRDEQR (172)		
	QVRRVPE (155)		
	VRRGSPQ (164)		
	GGRGSWE (167)		
	FRVRGSP (169)		
15	RVRGPER (165)		
	<u>LIVER</u>		
	VKSVCRT (12)	11	nd
	WRQNMPL (418)	6	nd
	SRRFVGG (406)	6	nd
20	ALERRSL (408)		
	ARRGWTl (405)		
	<u>PROSTATE</u>		
	SMSIARL (21)	6	34
	VSFLEYR (22)	6	17
25	RGRWLAL (279)	6	nd
	<u>ADRENAL GLAND</u>		
	LMLPRAD (27)	11	50
	LPRYLLS (28)		
	R(Y/F)LLAGG (404)		
30	RYPLAGG (389)		

006260" 5434350

	ORGAN/MOTIF (SEQ ID NO:)	% OF MOTIF AMONG ALL CLONES	LUNG/BRAIN RATIO
	<u>OVARY</u>		
	EVRSRLS (10)	22	3
	FFAAVRS (295)		
	VRARLMS (301)		
5	RVGLVAR (11)	22	5
	RVRLVNL (294)		
	<u>PANCREAS</u>		
	SWCEPGWCR (4)		20
	<u>SKIN</u>	9	
10	CVALCREACGEGC (3)	6	7
	CSSGCSKNCLEMC (181)		2
	<u>LUNG</u>		
	CTLRDRNC (15)	10	8
15	CGKRYRNC (20)	5	5
	CLRPYLNC (45)	10	6
	CGFELETC (2)	5	9
	CIGEVEVC (16)	5	6
	_____	_____	_____
20	CKWSRLHSC (65)	11	3
	CWRGDRKIC (56)	8	2
	CERVVGSSC (59)	9	4
	CLAKENVVC (13)	13	2
	_____	_____	_____
25	CTVNEAYKTRMC (75)	22	3
	CRLRSYGTLSLC (76)	5	0.4
	CRPWHNQAHTEC (82)	14	5
	_____	_____	_____
	CGFECVRQCPERC (1)	40	60

006260" 5494960

retina homing peptides shared a RDV motif; and some adrenal gland homing peptides shared a LPR motif (see Tables 2, 6 and 11, respectively). Since it is known, for example, that the tripeptide RGD motif is
5 sufficient for integrin binding (Ruoslahti, Ann. Rev. Cell Devel. Biol. 12:697 (1996); Koivunen et al., *supra*, 1995; WO 95/14714), the results disclosed herein indicate that many ligand/receptor interactions can derive their specificity from recognition motifs as
10 small as tripeptides.

None of the sequences of the disclosed organ homing peptides exhibited significant similarity with known ligands for endothelial cell receptors. While many of the organ homing peptides may be contained
15 within larger peptides or proteins, it is not known whether they are able to impart a homing function onto the larger molecule.. Based on the previous finding that RGD mediates integrin binding when present within larger peptides and proteins, one skilled in the art
20 would recognize, however, that such homing peptides and motifs could impart a homing function when located within a larger peptide or protein. However, such naturally occurring endogenous peptides and proteins are not considered to be organ or tissue homing
25 molecules within the invention.

The organ or tissue homing peptide molecules exemplified herein range in size from about 7 to 13 amino acids in length. However, based, for example, on the ability of the RGD integrin binding motif to
30 mediate integrin binding by itself or when present in a large protein, it will be recognized that the organ homing molecules of the invention also can be expected

to maintain their homing capability in the context of a significantly longer polypeptide sequence. Thus, an organ homing peptide of the invention can be at least three amino acids, generally at least six amino acids
 5 or seven amino acids or more, and can be significantly larger, for example, about 20 to 50 amino acids or 100 amino acids or more.

The invention provides lung homing peptides such as CGFECVRQCPERC (SEQ ID NO: 1) and CGFELETC (SEQ
 10 ID NO: 2), which share a GFE motif; CTLRDRNC (SEQ ID NO: 15); and CIGEEVC (SEQ ID NO: 16; see Table 1), which contains an EVE motif that is similar to the ELE motif present in CGFELETC (SEQ ID NO: 2). The exemplified lung homing peptides were identified by
 15 injection of a CX₃CX₃CX₃C, (SEQ ID NO: 25), CX₇C (SEQ ID NO: 24) or CX₆C (SEQ ID NO: 26) cyclic library into mice (Example II). The lung homing peptides CGFECVRQCPERC (SEQ ID NO: 1) and CGFELETC (SEQ ID NO: 2) exhibited a 60-fold and 9-fold enrichment,
 20 respectively, as compared to unselected phage, with few phage detected in kidney or brain (Example II; see, also, Figures 1 and 2 and Table 1). In addition, the lung homing peptides CTLRDRNC (SEQ ID NO: 15) and CIGEEVC (SEQ ID NO: 16) exhibited a 8-fold and 6-fold
 25 enrichment, respectively, over unselected phage (Table 1). Coinjection of a glutathione-S-transferase-(GST-)CGFECVRQCPERC (SEQ ID NO: 1) fusion peptide with phage expressing the cognate CGFECVRQCPERC (SEQ ID NO: 1) peptide inhibited homing by 70%, and coinjection
 30 of GST-CGFELETC (SEQ ID NO: 2) with phage expressing (SEQ ID NO: 2) inhibited lung homing by 30% (Figure 3). Immunohistochemical staining of lung following administration of phage displaying a lung homing

006250" 5494960

peptide to mice revealed staining within the alveolar capillaries. No apparent preference for homing of the phage to any particular region of the lung was observed; however, no staining was observed in
 5 bronchioles luminal walls or some larger blood vessels (Example III), or in many other tissues analyzed. These results indicate that *in vivo* panning can be used to identify and analyze endothelial cell specificities within lung, thus providing a means to differentially
 10 target lung.

The invention also provides skin homing peptides such as CVALCREACGEGC (SEQ ID NO: 3; Table 5), which were identified by injection of a CX₃CX₃CX₃C (SEQ ID NO: 25) cyclic library into mice (Example II). The
 15 skin homing peptide sequence CVALCREACGEGC (SEQ ID NO: 3) exhibited a 7-fold selectivity for skin over unselected phage and over background in brain and kidney (Figure 2; see, also, Table 1). Coinjection of GST-CVALCREACGEGC (SEQ ID NO: 3) with phage expressing
 20 CVALCREACGEGC (SEQ ID NO: 3) inhibited homing to skin by 55%, whereas coinjection with GST, alone, had no effect on homing (see Figure 3B). Immunohistochemical staining of skin following administration of phage displaying a skin homing peptide revealed that staining
 25 was localized to the hypodermis; no staining was observed in the dermis (Example III).

The invention further provides pancreas homing peptides such as SWCEPGWCR (SEQ ID NO: 4; Table 3). The exemplified pancreas homing molecules
 30 were identified by injection of a CX₇C (SEQ ID NO: 24) or X₂CX₄CX (SEQ ID NO: 23) cyclic library into mice (Example II). The pancreas homing peptide SWCEPGWCR

(SEQ ID NO: 4) exhibited a 20-fold selectivity for pancreas over unselected phage and over brain (Table 1; Figure 2). However, coinjection of GST-SWCEPGWCR (SEQ ID NO: 4) did not inhibit SWCEPGWCR (SEQ ID NO: 4) pancreas homing, presumably due to a conformational effect of GST on the pancreas homing peptide. Immunohistochemical staining of pancreas following administration of phage displaying a pancreas homing peptide revealed that staining was localized to the capillaries as well as larger blood vessels of the exocrine pancreas; no significant staining was observed in the endocrine vasculature (Example III). This result demonstrates that histologically and physiologically distinguishable regions within a particular organ can express unique target molecules, which provide a target for an organ homing molecule of the invention. Accordingly, the organ homing molecules of the invention provide a means to differentially targeted specific regions of a selected organ or tissue.

Retina homing peptides such as CSCFRDVCC (SEQ ID NO: 5) and CRDVVSVIC (SEQ ID NO: 6) also are provided (see Table 6). The exemplified retina homing molecules were identified by injection of a CX₇C (SEQ ID NO: 24) cyclic library into rats (Example II). The retina homing peptides CSCFRDVCC (SEQ ID NO: 5) and CRDVVSVIC (SEQ ID NO: 6), when injected individually with a control fdAMPLAY88 phage, exhibited a 3-fold and 2-fold enrichment, respectively, in retina (Example II). However, immunohistochemical staining revealed an absence of retina staining, presumably due to a relatively modest accumulation of the retina homing phage in the target tissue.

The invention also provides prostate homing peptides such as SMSIARL (SEQ ID NO: 21) and VSFLEYR (SEQ ID NO: 22), which were identified by injection of an X₇ (SEQ ID NO: 29) library into mice (Table 7). The
 5 peptides were isolated by the regular method. The prostate homing peptides SMSIARL (SEQ ID NO: 21) and VSFLEYR (SEQ ID NO: 22) exhibited a 34-fold and 17-fold enrichment, respectively, in homing to prostate as compared to brain (Table 1).

Also provided are ovary homing peptides such
 10 as RVGLVAR (SEQ ID NO: 11) and EVRSRLS (SEQ ID NO: 10), which were identified by injection of an X₇ (SEQ ID NO: 29) library into mice (Table 8). The peptides were isolated by the regular method. The ovary homing
 15 peptides RVGLVAR (SEQ ID NO: 11) and EVRSRLS (SEQ ID NO: 10) each comprised 22% of 40 clones sequenced and exhibited a 5-fold and a 3-fold enrichment, respectively, in ovary as compared to brain (Table 1).

The invention also provides adrenal gland
 20 homing peptides such as LMLPRAD (SEQ ID NO: 27) and LPRYLLS (SEQ ID NO: 28), which share a LPR motif (see Table 11), or the peptides R(Y/F)LLAGG (SEQ ID NO: 404) and RYPLAGG (SEQ ID NO: 389), which share the motif LAGG (SEQ ID NO: 430; see Table 10). The exemplified
 25 adrenal gland homing peptides were identified by injection of an X₇ (SEQ ID NO: 29) library into mice. The peptides were isolated by the regular method. The adrenal gland homing peptide LMLPRAD (SEQ ID NO: 27) exhibited a 50-fold enrichment in adrenal gland as
 30 compared to brain (Table 1).

Also provided are liver homing peptides. Such peptides were identified by injection of an X₇ (SEQ ID NO: 29) library into mice. The peptides were isolated by the regular method (see Example II, Table 1, and Table 11, below).

In addition, lymph node homing peptides, such as AGCSVTVCG (SEQ ID NO: 315) are provided (Table 9, below). Such peptides were identified by injection of an X₂CX₄CX (SEQ ID NO: 23) library into mice. The peptides were isolated by the regular method.

The invention also provides gut homing peptides such as YSGKWGK (SEQ ID NO: 9) and YSGKWGW (SEQ ID NO: 156), which were identified by injection of an X₇ (SEQ ID NO: 29) library into mice (Tables 1 and 4) and differ only in the last amino acid position. The peptides were isolated by the regular method. The gut homing peptide YSGKWGK (SEQ ID NO: 9) was present in 22% of 40 clones sequenced and was enriched 30-fold in gut as compared to brain (Table 1). In addition, gut homing peptides such as QVRRVPE (SEQ ID NO: 155) and VRRGSPQ (SEQ ID NO: 164), which share a VRR motif, were identified, as were the peptides VRRGSPQ (SEQ ID NO: 164), GGRGSWE (SEQ ID NO: 167) and FRVRGSP (SEQ ID NO: 169), which share an RGS motif.

The organ homing molecules of the invention are particularly useful as conjugates, which comprise the organ homing molecule linked to a moiety. Thus, a lung, skin, pancreas, retina, prostate, ovary, lymph node, adrenal gland, liver or gut homing molecule of the invention can be linked to a moiety, such

conjugates being useful for directing the moiety to the particular selected organ.

As used herein, the term "moiety" is used broadly to mean a physical, chemical, or biological material that is linked to an organ or tissue homing molecule. Generally, a moiety linked to an organ homing molecule imparts a biologically useful function to the homing molecule. A moiety can consist of any natural or nonnatural material for example, peptide or polypeptide sequences, organic or inorganic molecules or compositions, nucleic acid molecules, carbohydrates, lipids or combinations thereof.

A moiety can be a physical, chemical or biological material such as a virus, viral gene therapy vector, cell, liposome, microcapsule, micropump or other chambered microdevice, which can be used, for example, as a drug delivery system. Generally, such microdevices should be biologically inert and, if desired, biodegradable or excretable. Various moieties, including microcapsules, which can contain an agent, and methods for linking a moiety or chambered microdevice to an organic molecule of the invention are well known in the art and commercially available (see, for example, "Remington's Pharmaceutical Sciences" 18th ed. (Mack Publishing Co. 1990), chapters 89-91; Harlow and Lane, Antibodies: A laboratory manual (Cold Spring Harbor Laboratory Press 1988), each of which is incorporated herein by reference; see, also, Hermanson, *supra*, 1996). Additional examples of moieties are known to those skilled in the art and are intended to be included within the meaning of the term so long as

they possess a biologically useful function when linked to the homing molecules of the invention.

Linking of a moiety to an organ homing molecule for the purpose of directing the moiety to the selected organ or tissue was demonstrated by the linking of a brain homing peptide to a red blood cell (RBC), wherein the peptide directed homing of the RBC to the brain (U.S. Patent No. 5,622,699, *supra*, 1997). These results indicate that an organ or tissue homing molecule of the invention can be linked to another moiety in order to direct the moiety to a selected organ or tissue. For example, a liver homing molecule or a lung homing molecule can be linked to a nucleic acid encoding the CFTR gene and upon administration to a subject, expression of CFTR is targeted to the liver or to the lung, respectively. Similarly, a lung homing molecule can be linked to a protease inhibitor such that, upon administration of the conjugate comprising the lung homing molecule and the protease inhibitor to a subject, the protease inhibitor is targeted to the lung. Such a conjugate can be useful, for example, for treating a subject suffering from emphysema, which is characterized by excessive protease production in the lungs and autodigestion of the organ.

An organ and tissue homing molecule of the invention can be useful for directing to a selected organ or tissue a therapeutic agent, diagnostic agent or imaging agent, a tag or insoluble support, a liposome or a microcapsule comprising, for example, a permeable or semipermeable membrane, wherein an agent such as a drug to be delivered to a selected organ or tissue is contained within the liposome or

05676475, 092900

microcapsule. These and other moieties known in the art can be used in a conjugate of the invention, and in a method of the invention, as disclosed herein.

In one embodiment, a moiety can be a
5 detectable agent such as a radionuclide or an imaging agent, which allows detection or visualization of the selected organ or tissue. Thus, the invention provides a conjugate comprising a lung, skin, pancreas, retina, prostate, ovary, lymph node, adrenal gland, liver or
10 gut homing molecule, linked to a detectable agent. The type of detectable agent selected will depend upon the application. For example, for an *in vivo* diagnostic imaging study of the lung in a subject, a lung homing molecule can be linked to an agent that, upon
15 administration to the subject, is detectable external to the subject. For detection of such internal organs or tissues, for example, the prostate, a gamma ray emitting radionuclide such as indium-113, indium-115 or technetium-99 can be linked to a prostate homing
20 molecule and, following administration to a subject, can be visualized using a solid scintillation detector. Alternatively, for organs or tissues at or near the external surface of a subject, for example, retina, a fluorescein-labeled retina homing molecule can be used
25 such that the endothelial structure of the retina can be visualized using an ophthalmoscope and the appropriate optical system.

Molecules that selectively home to a pathological lesion in an organ or tissue similarly can
30 be linked to an appropriate detectable agent such that the size and distribution of the lesion can be visualized. For example, where an organ or tissue

homing molecule homes to a normal organ or tissue, but not to a pathological lesion in the organ or tissue, the presence of the pathological lesion can be detected by identifying an abnormal or atypical image of the organ or tissue, for example, the absence of the detectable agent in the region of the lesion.

A detectable agent also can be an agent that facilitates detection *in vitro*. For example, a conjugate comprising a homing molecule linked to an enzyme, which produces a visible signal when an appropriate substrate is present, can detect the presence of an organ or tissue to which the homing molecule is directed. Such a conjugate, which can comprise, for example, alkaline phosphatase or luciferase or the like, can be useful in a method such as immunohistochemistry. Such a conjugate also can be used to detect the presence of a target molecule, to which the organ homing molecule binds, in a sample, for example, during purification of the target molecule.

In another embodiment, a moiety can be a therapeutic agent. Thus, the invention provides a conjugate comprising a lung, skin, pancreas, retina, prostate, ovary, lymph node, adrenal gland, liver or gut homing molecule linked to a therapeutic agent.

A therapeutic agent can be any biologically useful agent that, when linked to an organ homing molecule of the invention, exerts its function at the site of the selected organ or tissue. For example, a therapeutic agent can be a small organic molecule that, upon binding to a target cell due to the linked organ homing molecule, is internalized by the cell where it

006260" 52492960

can effect its function. A therapeutic agent can be a nucleic acid molecule that encodes a protein involved in stimulating or inhibiting cell survival, cell proliferation or cell death, as desired, in the selected organ or tissue. For example, a nucleic acid molecule encoding a protein such as Bcl-2, which inhibits apoptosis, can be used to promote cell survival, whereas a nucleic acid molecule encoding a protein such as Bax, which stimulates apoptosis, can be used to promote cell death of a target cell.

A particularly useful therapeutic agent that stimulates cell death is ricin, which, when linked to an organ homing molecule of the invention, can be useful for treating a hyperproliferative disorder, for example, cancer. A conjugate comprising an organ homing molecule of the invention and an antibiotic, such as ampicillin or an antiviral agent such as ribavirin, for example, can be useful for treating a bacterial or viral infection in a selected organ or tissue.

A therapeutic agent also can inhibit or promote the production or activity of a biological molecule, the expression or deficiency of which is associated with the pathology. Thus, a protease inhibitor can be a therapeutic agent that, when linked to an organ homing molecule, can inhibit protease activity at the selected organ or tissue, for example, the pancreas. A gene or functional equivalent thereof such as a cDNA, which can replenish or restore production of a protein in a selected organ or tissue, also can be a therapeutic agent useful for ameliorating the severity of a pathology. A therapeutic agent also

can be an antisense nucleic acid molecule, the expression of which inhibits production of a deleterious protein, or can be a nucleic acid molecule encoding a dominant negative protein or a fragment thereof, which can inhibit the activity of a deleterious protein.

In another embodiment, the invention provides a conjugate comprising a lung, skin, pancreas, retina, prostate, ovary, lymph node, adrenal gland, liver or gut homing molecule linked to a tag. A tag can be, for example, an insoluble support such as a chromatography matrix, or a molecule such as biotin, hemagglutinin antigen, polyhistidine, T7 or other molecules known in the art. Such a conjugate comprising a tag can be useful to isolate a target molecule, to which the organ homing molecule binds.

When administered to a subject, a conjugate comprising an organ homing molecule and a moiety is administered as a pharmaceutical composition containing, for example, the conjugate and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil or injectable organic esters.

A pharmaceutically acceptable carrier can contain physiologically acceptable compounds that act, for example, to stabilize or to increase the absorption of the complex. Such physiologically acceptable compounds include, for example, carbohydrates, such as

glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. One skilled in the art would know that the
5 choice of a pharmaceutically acceptable carrier, including a physiologically acceptable compound, depends, for example, on the route of administration of the composition. The pharmaceutical composition also can contain an agent such as a cancer therapeutic agent
10 or other therapeutic agent as desired.

One skilled in the art would know that a pharmaceutical composition containing an organ homing molecule can be administered to a subject by various routes including, for example, orally or parenterally,
15 such as intravenously. The composition can be administered by injection or by intubation. The pharmaceutical composition also can be an organ homing molecule linked to a moiety such as a liposome or other polymer matrix, which can have incorporated therein,
20 for example, a drug-that promotes or inhibits cell death (Gregoriadis, Liposome Technology, Vol. 1 (CRC Press, Boca Raton, FL 1984), which is incorporated herein by reference). Liposomes, for
25 lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.

In performing a diagnostic or therapeutic method as disclosed herein, an effective amount of a
30 conjugate comprising an organ homing molecule must be administered to the subject. An "effective amount" is the amount of the conjugate that produces a desired

effect. An effective amount will depend, for example, on the moiety linked to the organ homing molecule and on the intended use. For example, a lesser amount of a radiolabeled homing molecule can be required for
5 imaging as compared to the amount of the radiolabeled molecule administered for therapeutic purposes, where cell killing is desired. An effective amount of a particular conjugate for a specific purpose can be determined using methods well known to those in the
10 art.

The route of administration of an organ molecule will depend, in part, on the chemical structure of the organ homing molecule. Peptides, for example, are not particularly useful when administered
15 orally because they can be degraded in the digestive tract. However, methods for chemically modifying peptides to render them less susceptible to degradation by endogenous proteases or more absorbable through the alimentary tract are well known (see, for example,
20 Blondelle et al., *supra*, 1995; Ecker and Crooke, *supra*, 1995; Goodman and Ro, *supra*, 1995). Such methods can be performed on peptides that home to a selected organ or tissue. In addition, methods for preparing libraries of peptide analogs such as peptides
25 containing D-amino acids; peptidomimetics consisting of organic molecules that mimic the structure of a peptide; or peptoids such as vinylogous peptoids, have been previously described above and can be used to identify homing molecules suitable for oral
30 administration to a subject.

The invention provides methods of identifying a selected organ or tissue by administering to a

005260" 5492960

subject a conjugate comprising a lung, skin, pancreas, retina, prostate, ovary, lymph node, adrenal gland, liver or gut and a detectable agent. A conjugate comprising an organ homing molecule of the invention
5 linked to a detectable moiety conjugate can be administered to a subject and used to identify or visualize a selected organ or tissue. The ability to visualize an organ, particularly an internal organ, provides a means diagnose a pathology of the selected
10 organ or tissue. For example, a prostate homing molecule linked to indium-113 can be administered to a subject in order to image the prostate. Such a method can be particularly valuable because methods for imaging the prostate are limited. The presence of a
15 prostate pathology can be revealed by detecting that a region of the prostate does not contain the conjugate, thus indicating an abnormality in circulation to the region, or by detecting that the prostate is abnormally enlarged or lacking its normal boundaries. For organs
20 or tissues such as retina, which can be visualized directly using an ophthalmoscope, a conjugate comprising a retina homing molecule linked to fluorescein can be administered to a subject and used to examine the vascular integrity and circulation in
25 the retina. The absence of a normal or typical pattern of retinal image can indicate the presence of a retinal pathology in the region. For example, an abnormal retinal pattern can reflect vascular changes indicative of a hyperproliferative or degenerative pathology.

30 In principle, an organ homing molecule of the invention can have an inherent biological property, such that administration of the molecule provides direct biological effect. For example, an organ homing

In addition, an organ homing molecule of the invention can have an inherent activity of binding a particular target molecule such that a corresponding ligand cannot bind the receptor. It is known, for example, that various types of cancer cells metastasize to specific organs or tissues, indicating that the cancer cells express a ligand that binds a target molecule in the organ to which it metastasizes. Thus, administration of a lung homing molecule, for example, to a subject having a tumor that metastasizes to lung, can provide a means to prevent the potentially metastatic cancer cell from becoming established in the lung. In general, however, the organ homing molecules of the invention are particularly useful for targeting a moiety to a selected organ or tissue, particularly to

In addition, an organ homing molecule of the invention can have an inherent activity of binding a particular target molecule such that a corresponding ligand cannot bind the receptor. It is known, for example, that various types of cancer cells metastasize to specific organs or tissues, indicating that the cancer cells express a ligand that binds a target molecule in the organ to which it metastasizes. Thus, administration of a lung homing molecule, for example, to a subject having a tumor that metastasizes to lung, can provide a means to prevent the potentially metastatic cancer cell from becoming established in the lung. In general, however, the organ homing molecules of the invention are particularly useful for targeting a moiety to a selected organ or tissue, particularly to

lung, skin, pancreas, retina, prostate, ovary, lymph node, adrenal gland, liver or gut. Thus, the invention provides methods of treating a pathology in a selected organ or tissue by administering to a subject having
5 the pathology a conjugate comprising an organ homing molecule of the invention linked to a therapeutic agent.

Specific disorders of the lung, for example, can be treated by administering to a subject a
10 conjugate comprising a lung homing molecule linked to a therapeutic agent. Since a lung homing molecule of the invention can localize to the capillaries and alveoli of the lung, disorders associated with these regions are especially amenable to treatment with a conjugate
15 comprising the lung homing molecule. For example, bacterial pneumonia often originates in the alveoli and capillaries of the lung (Rubin and Farber, Pathology 2nd ed., (Lippincott Co.,1994)). Thus, a lung homing molecule conjugated to a suitable antibiotic can be
20 administered to a subject to treat the pneumonia. Similarly, cystic fibrosis causes pathological lesions in the lung due to a defect in the CFTR. Thus, administration of a lung homing molecule conjugated to a nucleic acid molecule encoding the CFTR provides a
25 means for directing the nucleic acid molecule to the lung as an *in vivo* gene therapy treatment method.

The invention also provides methods of treating a pathology of the skin by administering to a subject having the pathology a conjugate comprising a
30 skin homing molecule and a therapeutic agent. For example, a burn victim can be administered a conjugate comprising a skin homing molecule linked to epithelial

growth factor or platelet derived growth factor such that the growth factor is localized to the skin where it can accelerate regeneration or repair of the epithelium and underlying dermis. Furthermore, a
5 method of the invention can be useful for treating skin pathologies caused by bacterial infections, particularly infections that spread through the hypodermis and dermis or that are localized in these regions, by administering to a subject a conjugate
10 comprising a skin homing molecule linked to an antibiotic.

The invention also provides methods of treating a pathology of the pancreas by administering to a subject having the pathology a conjugate
15 comprising a pancreas homing molecule linked to a therapeutic agent. In particular, since a pancreas homing molecule of the invention can localize to the exocrine pancreas, a pathology associated with the exocrine pancreas can be treated and, in some cases,
20 may not adversely affect the endocrine pancreas. A method of the invention can be particularly useful to treat acute pancreatitis, which is an inflammatory condition of the exocrine pancreas caused by secreted proteases damaging the organ. A conjugate comprising a
25 pancreas homing molecule linked to a protease inhibitor can be used to inhibit the protease mediated destruction of the tissue, thus reducing the severity of the pathology. Appropriate protease inhibitors useful in such a conjugate are those that inhibit
30 enzymes associated with pancreatitis, including, for example, inhibitors of trypsin, chymotrypsin, elastase, carboxypeptidase and pancreatic lipase. A method of the invention also can be used to treat a subject

00676475 052500

having a pancreatic cancer, for example, ductal adenocarcinoma, by administering to the subject a conjugate comprising a therapeutic agent linked to a molecule that homes to pancreas.

5 The methods of the invention also can be used to treat a pathology of the eye, particularly the retina, by administering to a subject having the pathology a conjugate comprising a retina homing molecule linked to a therapeutic agent. For example, proliferative retinopathy is associated with neovascularization of the retina in response to retinal ischemia due, for example, to diabetes. Thus, administration of a conjugate comprising a retina homing molecule linked to a gene that stimulates apoptosis, for example, Bax, can be used to treat the proliferative retinopathy. Similarly, methods of the invention can be used to diagnose or treat prostate, ovary, lymph node, adrenal gland, liver, or gut pathology using the appropriate organ or tissue homing molecules disclosed herein either alone, or linked to a desired moiety.

 An organ or tissue homing molecule is useful, for example, for targeting a therapeutic or detectable agent to the selected organ or tissue. In addition, an organ or tissue homing molecule can be used to identify the presence of a target molecule in a sample. As used herein, the term "sample" is used in its broadest sense to mean a cell, tissue, organ or portion thereof that is isolated from the body. A sample can be, for example, a histologic section or a specimen obtained by biopsy or cells that are placed in or adapted to tissue culture. If desired, a sample can be processed, for

example, by homogenization, which can be an initial step for isolating the target molecule to which an organ or tissue homing molecule binds.

An organ homing molecule obtained as
 5 disclosed herein can be useful for identifying the presence of a target molecule, particularly a cell surface protein, that is recognized by the homing molecule, or for substantially isolating the target molecule. Thus, the invention provides methods of
 10 identifying target molecules that selectively bind a lung homing molecule, a skin homing molecule, a pancreas homing molecule, a retina homing molecule, a prostate homing molecule, an ovary homing molecule, a lymph node homing molecule, an adrenal gland homing
 15 molecule, a liver homing molecule or a gut homing molecule. Such a method comprises contacting a sample of the selected organ or tissue, for example, prostate, with a prostate homing molecule, and detecting selective binding of a component of a sample, wherein
 20 such binding identifies the presence of a target molecule.

An organ or tissue homing molecule such as a prostate homing peptide can be linked to a tag, for example, a solid support such as a chromatography
 25 matrix. The immobilized organ homing molecule then can be used for affinity chromatography by passing an appropriately processed sample of prostate tissue over a column containing the matrix under conditions that allow specific binding of the prostate homing molecule
 30 to the particular target molecule (see, for example, Deutshcer, Meth. Enzymol., Guide to Protein Purification (Academic Press, Inc., ed. M.P. Deutscher,

1990), Vol. 182, which is incorporated herein by reference; see, for example, pages 357-379). Unbound and nonspecifically bound material can be removed and the target molecule, which forms a complex with the prostate homing molecule, can be eluted from the column and collected in a substantially isolated form. The substantially isolated prostate target molecule then can be characterized using well known methods. An organ or tissue homing molecule also can be linked to a detectable agent such as a radionuclide, a fluorescent molecule, an enzyme or a labeled biotin tag and can be used, for example, to screen a sample in order to detect the presence of the target molecule or to follow the target molecule during its isolation.

As an alternative to using an organ or tissue sample to identify a target molecule of the selected organ or tissue, extracts of cultured cells derived from the selected organ or tissue, or extracts of cultured endothelial cells can be used as the starting material. Selection of cells containing the target molecule can be determined by using binding and cell attachment assays (see Barry et al., Nature Med. 2:299-305 1996), which is incorporated herein by reference). Those cells containing the target molecule can be used to prepare extracts for the isolation and identification of a target molecule, as described above.

Upon identifying an appropriate cell line expressing the target molecule, the target molecule can be labeled by growing the cells in medium containing radiolabeled amino acids. The radiolabeled amino acids are incorporated into the target molecule, thus

facilitating its identification during purification. Labeled cells then can be extracted with octylglucoside and the extract can be fractionated by affinity chromatography using a pancreas homing molecule coupled to a matrix such as Sepharose. Extracts prepared, for example, from human umbilical vein endothelial cells can be used as a control. The purified target molecule then can be microsequenced and antibodies can be prepared. If desired, oligonucleotide probes can be prepared and used to isolate cDNA clones encoding the target receptor. Alternatively, an anti-receptor antibody can be used to isolate a cDNA clone from an expression library (see Argraves et al., J. Cell Biol. 105:1183-1190 (1987), which is incorporated herein by reference).

In addition to biochemically isolating a target molecule, a nucleic acid encoding the target molecule can be isolated by using, for example, a pancreas homing molecule as a chemical probe to screen a pancreatic cDNA expression library for clones that express the target molecule. For example, bacteria expressing a pancreatic cDNA library can be attached to a membrane, lysed, and screened with a pancreas homing molecule conjugated, for example, to an enzyme that produces a colorimetric or fluorescent signal. Bacterial clones expressing a target molecule are identified and the cDNA encoding the target molecule can be isolated. Additionally, a mammalian cell expression cloning system such as the COS cell system can be used to identify a target molecule. For example, a cDNA library can be prepared using mRNA from primary pancreas cells which can be cloned into an expression vector. Cells expressing a cDNA encoding

the target molecule then can be selected using the pancreas homing peptide as a probe, for example, by panning of cell clones against pancreas homing peptide attached to a plate. Alternatively, phage can be used
5 to display the pancreas homing peptide and can be attached to magnetic beads coated, for example, with anti-M13 antibodies (Pharmacia). Cells expressing the target molecule that bind to the pancreas homing peptide then can be recovered and the plasmids encoding
10 the receptor can be isolated. The recovered plasmid preparations can be divided into pools and examined in COS cell transfections. The procedure can be repeated until single plasmids are obtained that enable the COS cells to bind the pancreas homing peptide.

15 The present invention also provides a method of identifying a MDP-binding homing molecule that selectively homes to lung endothelium. The method includes the steps of contacting membrane dipeptidase (MDP) with one or more molecules; and determining
20 specific binding of a molecule to the MDP, where the presence of specific binding identifies the molecule as a MDP-binding homing molecule that selectively homes to lung endothelium. In a method of the invention, the membrane dipeptidase can be substantially purified and
25 can be, for example, immobilized to a support. The membrane dipeptidase can be any mammalian MDP, for example, human MDP having SEQ ID NO: 448.

As disclosed herein, the CGFECVVRQCPERC (SEQ ID NO: 1) peptide can selectively bind to mouse lung
30 vasculature after intravenous injection (Example IIA). Furthermore, as disclosed in Example IVB, a 55 kDa lung cell surface protein that selectively binds GFE-1

(CGFECVRQCPERC; SEQ ID NO: 1) was isolated from rat lung extracts using affinity chromatography. Tryptic digestion and sequencing by mass spectrometry revealed that two peptides derived from the 55 kDa protein were
 5 completely identical to portions of rat membrane dipeptidase (EC 3.4.13.19). Further experimentation demonstrated that GFE-1 (SEQ ID NO: 1) affinity purified fractions of rat lung cell extracts have membrane dipeptidase activity, as indicated by the
 10 time-dependent conversion of the specific MDP substrate Gly-D-Phe to D-Phe (Example IVC and Figure 5). Furthermore, binding of GFE-1 phage (CGFECVRQCPERC; SEQ ID NO: 1) and, to a lesser extent, GFE-2 phage (CGFELETC; SEQ ID NO: 2) to COS cells transfected with
 15 membrane dipeptidase was significantly higher than the binding of phage bearing an unrelated peptide sequence (Example IVD and Figure 6B), indicating that membrane dipeptidase is the GFE-1 (SEQ ID NO: 1) receptor.

Thus, as disclosed herein, the lung
 20 metalloprotease, membrane dipeptidase, serves as the receptor for the selective homing of molecules to lung endothelium. An exemplary class of molecules that selectively home to lung endothelium by targeting membrane dipeptidase is the class of peptides bearing a
 25 GFE motif, for example, CGFECVRQCPERC (SEQ ID NO: 1).

Membrane dipeptidase, also known as renal dipeptidase, microsomal dipeptidase, dehydropeptidase-1, or MDP and currently classified as EC 3.4.13.19 (previously EC 3.4.13.11), is a plasma
 30 membrane glycosyl phosphatidylinositol-anchored glycoprotein (Keynan et al., in Hooper (Ed.) Zinc Metalloproteases in Health and Disease Taylor and

Francis, London pages 285-309 (1996), which is incorporated herein by reference). This zinc metalloprotease, which is expressed mainly in lung and kidney brush border, is involved *in vivo* in renal
 5 metabolism of glutathione and in pulmonary metabolism of peptidyl leukotrienes. In addition, MDP is the only known example of a mammalian β -lactamase. MDP forms a disulfide-linked homodimer, with the molecular weight of the monomer ranging from about 48 to 59 kDa
 10 depending on the species of origin (Keynan et al., Biochem. 35:12511-12517 (1996), which is herein incorporated by reference; see, also, Example IVB).

Membrane dipeptidase expression has been detected in several tissues although it is expressed
 15 mainly in lung and kidney. There have been reports of low levels of MDP activity in total extracts from liver, spleen, small intestine and brain, while others have found no detectable activity in these organs. In the mouse, four distinct MDP mRNAs are present, and
 20 they are differentially expressed in several organs (Habib et al., J. Biol. Chem. 271:16273-16280 (1996)). Organ-specific differences in the nature and extent of pig MDP N-linked glycosylation also have been reported (Hooper et al., Biochem. J. 324:151-157 (1997)).

25 In the kidney, MDP expression is restricted to epithelial cells in the brush border region of the proximal tubules. In the lung, MDP expression has been detected in many cell types including endothelial cells as well as epithelial cells of the conducting airways,
 30 alveolar ducts, capillaries, and the basement membrane of alveoli and terminal bronchioles (Habib et al., *supra*, 1996); Inamura et al., Prostaglandins

Leukotrienes and Essential Fatty Acids 50:85-92

(1994)). MDP expression also has been observed on endothelial cells of submucosal microvessels in the human trachea (Yamaya et al., Resp. Physiol.

5 111:101-109 (1998)). The level of MDP activity is highest in lung (Hirota et al., Eur. J. Biochem. 160:521-525 (1986); Habib et al., Proc. Natl. Acad. Sci. USA 95:4859-4863 (1998)). This expression pattern correlates with the strong lung homing of molecules
10 such as GFE-1 (SEQ ID NO: 1).

As used herein, the term "membrane dipeptidase" is synonymous with "MDP" and refers to the enzyme currently classified as EC 3.4.13.19 (previously EC 3.4.13.11) and also known as renal or microsomal
15 dipeptidase or dehydropeptidase-1. The term membrane dipeptidase encompasses any mammalian membrane dipeptidase, for example, the human, pig, mouse, rat and rabbit homologs having the amino acid sequences shown as SEQ ID NOS: 448 to 452 in Figure 9 as well as
20 related polypeptides having substantial amino acid sequence similarity to one of these polypeptides. Such related polypeptides will exhibit greater sequence similarity to SEQ ID NO: 448, 449, 450, 451 or 452 than to other zinc metalloproteases or peptidases such as
25 dipeptidyl peptidase IV and include alternatively spliced forms of MDP and isotype variants of the amino acid sequences shown in Figure 9. Thus, the term MDP encompasses homologous polypeptides obtained from different mammalian species as well as other variants
30 and related polypeptides that generally have amino acid identities of greater than about 65%, preferably greater than about 70% and more preferably greater than about 80% or 90% with SEQ ID NO: 448, 449, 450, 451 or

09676475.099900

452. A method of the invention preferably uses human membrane dipeptidase (SEQ ID NO: 448).

The term "substantially purified," as used herein in reference to a membrane dipeptidase polypeptide, means that the polypeptide is in a form that is relatively free from contaminating lipids, nucleic acids, unrelated polypeptides and other cellular material normally associated with membrane dipeptidase in a cell.

The methods of the invention for identifying a MDP-binding homing molecule can be practiced *in vivo* or *in vitro*, and membrane dipeptidase can be obtained from a number of sources. Sources of membrane dipeptidase include whole cells or cell extracts containing endogenous or exogenous MDP. Additional sources of MDP include partially purified cell extracts; biochemically purified enzyme, for example, affinity purified MDP; recombinant polypeptides; and transfected cell lines.

Affinity chromatography can be particularly useful for purifying or partially purifying membrane dipeptidase for use in a method of the invention. For example, membrane dipeptidase can be purified from lung cell extracts by affinity chromatography using immobilized GFE-1 peptide (SEQ ID NO: 1) as described for murine and rat membrane dipeptidase in Example IVC. Similarly, membrane dipeptidase can be obtained by affinity chromatography using other immobilized ligands such as cilastatin. For example, membrane dipeptidase can be efficiently purified in two steps, through selective release of MDP by bacterial phosphatidyl

006260" 52492960

inositol-specific phospholipase C (PI-PLC) coupled with
 cilastatin-Sepharose affinity chromatography as
 described in Littlewood et al., Biochem. J. 257:361-367
 (1989); and Campbell et al., J. Biol. Chem. 259:14586-
 5 14590 (1984), each of which is incorporated herein by
 reference.

Recombinant membrane dipeptidase also can be
 useful in a method of the invention. The amino acid
 and nucleic acid sequences of a variety of MDP homologs
 10 are known in the art. Nucleic acid sequences encoding
 the membrane dipeptidase polypeptides shown in Figure 9
 can be obtained, for example, from databases such as
 GenBank or from the literature (see, for example,
 GenBank Accession Numbers D13139 and 285150; Adachi et
 15 al., J. Biol. Chem. 265:3992-3995 (1990); Rached et
 al., 1990; Keynan et al., FEBS Letts. 349:50-54 (1994);
 Satoh et al., Biochim. Biophys. Acta 1163:234-242
 (1993); Adachi et al., Biochim. Biophys. Acta 1132:311-
 314 (1992); An et al., Biochim. Biophys. Acta 1226:337-
 20 340 (1994); and Igarashi and Karniski, Biochem. J.
 280:71-78 (1991), each of which is incorporated herein
 by reference). Novel membrane dipeptidase cDNAs can be
 isolated from additional mammalian species with a
 nucleotide sequence as a probe or primer using methods
 25 well known in the art of molecular biology (Innis et
 al. (Ed.), PCR Protocols, San Diego: Academic Press,
 Inc. (1990); Erlich, *supra*, 1989; Sambrook et al.,
supra, 1989, each of which is incorporated herein by
 reference). One skilled in the art knows a variety of
 30 methods for expression of MDP encoding nucleic acids
 and subsequent isolation of recombinant MDP
 polypeptide.

006260" 52492960

In the methods of the invention for identifying a MDP-binding homing molecule that selectively homes to lung endothelium, specific binding of a molecule to MDP identifies the molecule as a MDP-binding homing molecule that selectively homes to lung endothelium. The term "specific binding," as used herein in reference to a molecule and MDP, means that the molecule has an affinity for MDP that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity, for example, a peptide of similar size that lacks a GFE motif. In this case, specific binding is indicated if the molecule has measurably higher affinity for membrane dipeptidase than the control molecule. Specificity of binding also can be determined, for example, by competition with a control molecule that is known to bind to MDP, for example, a peptide containing the GFE motif.

The term specific binding, as used herein, includes both low and high affinity specific binding. Specific binding can be exhibited, for example, by a low affinity MDP-binding homing molecule having a K_d for membrane dipeptidase of about 10^{-4} M to about 10^{-7} M. Specific binding also can be exhibited by a high affinity MDP-binding homing molecule, for example, a MDP-binding homing molecule having a K_d for membrane dipeptidase of at least about 10^{-7} M, at least about 10^{-8} M, at least about 10^{-9} M, at least about 10^{-10} M, or at least about 10^{-11} M or 10^{-12} M or greater. A MDP-binding homing peptide including the sequence

X₁-G-F-E-X₂ (SEQ ID NO: 17), where X₁ and X₂ each is 1 to 10 independently selected amino acids, can have, for example, a K_d for membrane dipeptidase of about 2 x 10⁻⁵ M to 10⁻⁷ M, for example, a K_d of about 10⁻⁶ to 10⁻⁷ M. Both low and high affinity MDP-binding homing molecules that selectively home to lung endothelium can be useful in selectively directing a moiety to lung endothelium in a subject as described further below.

A variety of art known techniques can be used to determine specific binding of a molecule to membrane dipeptidase according to a method of the invention. Conditions suitable for specific binding are described, for example, in Example IVB. Specific binding also can be determined by transfecting cells lacking MDP expression with MDP as described, for example, in Example IVD. In this case, specific binding is determined, in part, by significantly higher binding of a molecule to the MDP-transfected cells than to untransfected cells.

The present invention is directed to the surprising discovery that MDP-binding molecules home specifically to the lung vasculature in spite of MDP expression in other tissues such as kidney. As disclosed herein, injection of MDP-binding GFE-1 (SEQ ID NO: 1) bearing phage into the mouse circulation resulted in rapid binding of the phage to lung microvasculature with some diffuse staining on neighboring cells. The same results were obtained by injecting GFE-1 (SEQ ID NO: 1) bearing phage into rat circulation. In particular, the MDP-binding GFE-1 phage did not bind, for example, to the brush border of kidney proximal tubules, which expresses high levels of

MDP. These results indicate that expression of MDP on the luminal surface of lung endothelial cells can mediate homing of MDP-binding phage from the circulation to lung endothelium, while MDP-binding
5 phage cannot access and home to kidney MDP. Thus, MDP mediates selective homing of molecules to lung endothelium in preference to other endothelial cells.

Selective homing of GFE-1 (SEQ ID NO: 1) bearing phage to lung vasculature further demonstrates
10 that a moiety such as a phage can be linked to a MDP-binding homing molecule and thereby selectively directed to lung endothelium. Thus, the present invention provides methods of selectively targeting moieties, such as phage, gene therapy vectors or
15 antibiotics, to lung endothelium for treatment of lung disorders.

A method of the invention for selectively directing a moiety to lung endothelium in a subject involves administering to the subject a conjugate
20 containing a moiety linked to a MDP-binding homing molecule that selectively homes to lung endothelium, whereby the moiety is selectively directed to lung endothelium in the subject. The MDP-binding homing molecule is identified by contacting membrane
25 dipeptidase (MDP) with one or more molecules; and determining specific binding of a molecule to the MDP, where the presence of specific binding identifies the molecule as a MDP-binding homing molecule that selectively homes to lung endothelium. A method of the
30 invention can be useful for targeting genes or medications to the lung in a subject suffering, for example, from pneumonia; asthma; emphysema; respiratory

infection; chronic bronchitis; chronic interstitial lung disease; lung cancer; pleurisy or cystic fibrosis. If desired, a method of the invention can be used prophylactically, for example, to selectively direct a moiety to the lung endothelium of an individual with a family history of a lung disorder, for example, or an individual susceptible to lung infection.

A moiety to be selectively directed to lung endothelium can be a physical, chemical or biological material such as a virus, viral gene therapy vector, cell, liposome, microcapsule, micropump or other chambered microdevice, which can be used, for example, as a drug delivery system. Such microdevices generally are biologically inert and, if desired, can be biodegradable or excretable. Various moieties, including microcapsules, which can contain an agent, and methods for linking a moiety or chambered microdevice to an organic molecule are well known in the art and commercially available as described hereinabove. Exemplary moieties that can be linked to a MDP-binding homing molecule that selectively homes to lung endothelium to produce a therapeutic conjugate include therapeutic antimicrobial bacteriophage; antibiotics such as ampicillin; and antiviral agents such as ribavirin (see above).

A moiety to be selectively directed to lung endothelium according to a method of the invention can be, for example, a therapeutic bacteriophage ("phage"). Phage have been shown to be nontoxic (Ochs et al., J. Clin. Invest. 50:2559-2568 (1971), which is incorporated herein by reference), and the use of phage therapy is known in the art for treatment of bacterial

09676475-092900

infections such as antibiotic-resistant infections (Barrow and Soothill, Trends in Microbiology 5:268-271 (1997); Slopek et al., Arch. Immunol. Ther. Exp. 35:553-561 (1987); and Merrill et al., Proc. Natl. Acad. Sci., USA 93:3188-3192 (1996), each of which is incorporated herein by reference; see, also, Practical Applications of Bacteriophages CRC Press, Boca Raton, Florida). For example, in a series of 550 patients, the majority of whom had been unsuccessfully treated with antibiotic therapy, phage therapy resulted in 75-100% success in ameliorating a variety of infections including respiratory tract suppurative infections and broncopneumonia (Slopek et al., *supra*, 1987). Phage therapy can be particularly useful in treating nosocomial and multi-drug-resistant infections.

Studies have shown that both prophylaxis and treatment are possible using fewer phage than inoculating bacteria, indicating that phage multiply *in vivo*. Thus, phage therapy can be more effective than conventional treatment with antibiotics, such as streptomycin, tetracycline, ampicillin and sulfafurazole, because of the ability of phage to replicate *in vivo*. If desired, treatment with a phage conjugate containing a MDP-binding homing molecule can be combined with antibiotic drug therapy.

Preferably, a phage moiety to be selectively directed to lung endothelium is a lytic phage. Such a phage can be readily modified by standard genetic techniques to encode a MDP-binding homing peptide such as GFE-1 (SEQ ID NO: 1) to produce a conjugate that is selectively directed to lung endothelium. Phage useful in the methods of the invention include, for example,

006660" 52492960

T4-related phage, also known as members of the "T-Even family of phages." One skilled in the art understands that a phage moiety is selected with a receptor specificity for the bacteria characteristic of an infection to be treated, for example, phage with receptor specificity for *Staphylococcus*, *Klebsiella*, *Proteus*, *Escherichia*, *Shigella*, *Pseudomonas* or *Salmonella*. If desired, the pathogenic bacteria can be typed and monitored for phage sensitivity. For treatment of resistant bacteria, a phage conjugate can include, if desired, a mixture of phage with different receptor specificities against a variety of types of bacteria.

A phage/MDP-binding homing conjugate can be administered to a subject, for example, intravenously. Such a conjugate also can be administered orally, for example, as 10 ml sterile phage lysate half an hour before each meal, with gastric juices neutralized by Vichy water, baking soda or gelatin. After oral administration, phage/MDP-binding homing conjugates access the blood and subsequently are selectively directed to lung endothelium. Administration can be repeated, if needed, daily over a period of several weeks or months. An appropriate dose of a phage conjugate can readily be determined by the skilled person and generally will be in the range of about 100 to about 10^{10} plaque forming units (pfu), usually from about 100 to 10^6 pfu.

A moiety to be selectively directed to lung endothelium for gene therapy can be a gene therapy vector. As used herein, the term "gene therapy vector" means a vector containing a nucleic acid component,

which, when delivered to host cells, transiently or permanently expresses an encoded gene product in the host cells *in vivo*.

006260" 549,960

A variety of gene therapy vectors that can be selectively directed to lung endothelium using an MDP-binding homing molecule also are known in the art, including viral and non-viral vectors, for example, retroviral vectors, adenoviral vectors, adeno-associated vectors (AAV), herpesvirus vectors and liposome plasmid vectors (Chang, Somatic Gene Therapy CRC Press, Boca Raton, Florida (1995), each of which is incorporated herein by reference). Retroviral and AAV vectors can be useful, for example, for permanent expression, while adenovirus, herpesvirus and liposome-plasmid vectors generally give transient expression. Adenoviral vectors, for example, have been used to express the cystic fibrosis transmembrane receptor (CFTR) and recombinant α 1-antitrypsin in lung (Rosenfeld et al., Cell 68:143 (1992); Rosenfeld et al., Science 252: 431 (1991), each of which is incorporated herein by reference). Liposome DNA complexes also have been used to effect gene transfer to the lung (see, for example, Zhu et al., Science 261:209 (1993), which is incorporated herein by reference). Phage vectors also can be useful for expressing a desired nucleic acid *in vivo* (see, for example, Ivanenkov et al., Biochimica et Biophysica Acta 1448:450-462 (1999); Ivanekov et al., Biochimica et Biophysica Acta 1448:463-472 (1999), each of which is incorporated by reference herein).

The methods of the invention for selectively directing a moiety to lung endothelium using a

006260" 52492950

conjugate containing a MDP-binding homing molecule such as GFE-1 (SEQ ID NO: 1) can be useful in the therapeutic management of a variety of pulmonary disorders. For example, by selectively directing a
5 gene therapy vector encoding a cytokine to lung endothelium, the methods of the invention can be useful for immunotherapy. A variety of cytokines or chemokines can be useful in stimulating an immune response, such as an anti-cancer or anti-viral immune
10 response, when administered according to a method of the invention. Such cytokines and chemokines include GM-CSF, G-CSF, IFN- γ , IFN- α , TNF- α , TNF- β , IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-10, IL-12, lymphotactin or DC-CK1 (Pardoll, Annu. Rev. Immunol. 13:399-415 (1995;
15 Hunt et al., J. Immunotherapy 14:314-321 (1993); Chang, *supra*, 1995, each of which is incorporated herein by reference). The methods of the invention can be more effective than administration of recombinant cytokines, due to the short half-life of cytokines in the
20 circulation and the lack of their targeting to lung.


As discussed above, the methods of the invention can be useful for treating pulmonary infections by selectively directing a phage moiety or an antibiotic drug such as streptomycin, tetracycline,
25 ampicillin or sulfafurazole to lung endothelium. For example, the methods of the invention can be useful for treating infections secondary to acquired immunodeficiency syndrome (AIDS) or cystic fibrosis.

The methods of the invention for selectively
30 directing a moiety to lung endothelium also can be used for replacement gene therapy of lung disorders such as α 1-antitrypsin deficiency and cystic fibrosis (Alton

and Geddes, Brit. J. Hosp. Medicine 58:38-40 (1997); Wood, Radiology 204:1-10 (1997), each of which is incorporated herein by reference). Genes encoding wild type α 1-antitrypsin (α 1-AT) and the cystic fibrosis transmembrane receptor (CFTR) have been isolated (5 Riordan et al., Science 245:1066-1073 (1989); Rich et al., Nature 347:358-63 (1990; Rosenfeld et al., Science 252:431-434 (1991), each of which is incorporated herein by reference) and can be transferred selectively (10 to the lung in a gene therapy vector linked to a MDP-binding homing molecule such as GFE-1 (SEQ ID NO: 1).

In one embodiment, the invention provides a method for selectively directing a moiety to lung (15 endothelium where the MDP-binding homing molecule is a peptide including the sequence X_1 -G-F-E- X_2 (SEQ ID NO: 17), where X_1 and X_2 each is 1 to 10 independently selected amino acids. Such a MDP-binding homing peptide can include, for example, the sequence (20 CGFECVRQCPERC (SEQ ID NO: 1) or CGFELETC (SEQ ID NO: 2).

In another embodiment, the invention provides a method for selectively directing a moiety to lung endothelium where the MDP-binding homing molecule (25 contains the following Structure 1:



where R^2 and R^3 are hydrocarbon radicals in the range respectively of 3-10 and 1-15 carbon atoms; in either one of these R^2 or R^3 hydrocarbon chains 1-6 hydrogens may be

5 replaced by halogens or a nonterminal methylene may be replaced by oxygen or sulfur, including oxidized forms of the latter; additionally, a terminal hydrogen in R^3 can

10 also be replaced by hydroxyl or thiol, which may be acylated or carbamoylated; or the hydrogen can be replaced by amino, which may be derivatized as in an acylamino, ureido, amidino, guanidino, or alkyl or substituted amino group, including quaternary nitrogen

15 grouping; or, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, or cyanō; or combinations thereof, such as a terminal amino acid grouping; and R^1

20 is hydrogen or lower alkyl (C_{1-6}) or dialkylaminoalkyl, or a pharmaceutically acceptable cation. Such an MDP-binding homing molecule can be, for example, 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropane

25 carboxamido)-2-heptenoic acid, also known as cilastatin.

An MDP-binding homing molecule can be, for example, a compound having Structure 1 in which R^2 is branched alkyl or cycloalkyl

006260" 52492960

with a limitation that the carbon adjacent to the carbonyl cannot be tertiary.


An MDP-binding homing molecule also can be, for example, a compound having

- 5 Structure 1 in which R^2 is branched alkyl or cycloalkyl with a limitation that the carbon adjacent to the carbonyl cannot be tertiary, and in which R^3 is n-alkyl (1-9 carbons) or n-alkyl (1-9 carbons) having a terminal
- 10 substituent which is a quaternary nitrogen, amine derivative or amino acid derived group. An MDP-binding homing molecule can be, for example, a compound having Structure 1 in which R^2 is 2,2-dimethylcyclopropyl or
- 15 2,2-dichlorocyclopropyl and in which R^3 is a hydrocarbon chain of 3 to 7 carbon atoms without a terminal substituent or having a terminal substituent which is trimethylammonium, amidino, guanidino or
- 20 2-amino-2-carboethylthio.

- Exemplary MDP-binding homing molecules having Structure 1 useful in the invention include the following: Z-2-(2,2-dimethylcyclopropane carboxamido)-8-
- 25 trimethylammonium hydroxide-2-octenoic acid inner salt; Z-2-(2,2-dichlorocyclopropanecarboxamido)-8-trimethylammonium hydroxide-2-octenoic acid inner salt; Z-2-(2,2-dimethylcyclopropane carboxamido)-8-
- 30 guanidino-2-octenoic acid; Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-

guanidino-2-octenoic acid; Z-2-(2,2-
 dimethylcyclopropanecarboxamido)-8-ureido-2-
 octenoic acid; Z-8-(1-2-amino-2-carboxy
 ethylthio)-2-(2,2-dimethylcyclopropane
 5 carboxamido)-2-octenoic acid; Z-2-(2,2-
 dimethylcyclopropane carboxamido)-2-octenoic
 acid (racemic and dextrorotatory forms); Z-2-
 (2,2-dichloro cyclopropanecarboxamido)-2-
 octenoic acid; 7-(L-2-amino-2-carboxyethylthio)
 10 -2-(2,2-dimethylcyclopropane carboxamido)-2-
 heptenoic acid; and 6-(L-2-amino-2-
 carboxyethylthio)-2-(2,2-dimethylcyclopropane
 carboxamido)-2-hexenoic acid.

As set forth above, the methods of the
 15 invention for targeting treatment to the lungs can be
 practiced with an MDP-binding homing molecule, which is
 a Z-2-acylamino- 3-monosubstituted propenoate having
 Structure 1,



20 where R^2 and R^3 are hydrocarbon radicals in
 the range respectively of 3-10 and 1-15 carbon atoms.
 In either of these hydrocarbon radicals R^2 and R^3 , up
 to 6 hydrogens may be replaced by halogens, or a non-
 terminal methylene may be replaced by oxygen or sulfur,
 25 including oxidized forms of the latter.

A terminal hydrogen in R^3 also can be replaced by a hydroxyl or thiol group, which may be acylated, such as with an alkanoyl acid of 1-8 carbon atoms, or carbamoylated, including alkyl and dialkyl carbamate derivatives; or the hydrogen can be replaced by an amino group, which may be derivatized as in an acylamino, ureido, amidino, guanidino, or alkyl or substituted alkyl amino group, including quaternary nitrogen groupings; or, alternatively, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, as well as cyano; or combinations thereof, such as a terminal amino acid grouping.

In an MDP-binding homing molecule having Structure 1, R^2 is preferably a branched alkyl or cycloalkyl radical (C_{3-10}), with a limitation that the carbon adjacent to the carbonyl cannot be tertiary. R^2 cannot be phenyl or straight chain lower alkyl of 1-4 carbon atoms, where R^3 is straight chain lower alkyl of 1-4 carbon atoms. R^1 is hydrogen, loweralkyl (C_1-C_6) or dialkylaminoalkyl (e.g., $-CH_2CH_2N(C_2H_5)_2$, $-CH_2CH(CH_3)N(CH_3)_2$).

An MDP-binding homing molecule having Structure 1 above can have an asymmetric form. Racemic Z-2-(2,2 dimethylcyclopropane carboxamido)-2-octenoic acid has been resolved. Activity resides in the dextrorotatory isomer, which has the S-configuration.

Within the definition of R^2 of a compound having Structure 1, the following sub-groups are included:

-R⁴

wherein R⁴ is a straight, branched, or cyclic hydrocarbon radical of 3-10 carbon atoms which may be substituted

5 as specified above in the definition of R²;

-R⁵R⁶

wherein R⁵ is cycloalkyl of 3-6 carbon atoms and R⁶ is either 1 or 2 alkyl substituents which may be joined to form another ring on the cycloalkyl group, or R⁵ and R⁶
10 may be substituted as specified above in the definition of R²; and

-R⁷R⁸

wherein R⁷ is an alkylene group of 1-3 carbon atoms and R⁸ is cycloalkyl of 3-6 carbon atoms which may be
15 substituted as specified above in the definitions of R² and R³.

Particularly preferred substituents within the definition of R² in Structure 1 include the 2,2-dimethylcyclopropyl and the 2,2-dichlorocyclopropyl
20 groups.

Within the definition of R³ in Structure 1, particularly preferred groups of compounds include n-alkyl (1-9 carbons) and n-alkyl (1-9 carbons) having a terminal substituent which is a quaternary nitrogen,
25 amine derivative, or amino acid derived group.

The term "quaternary nitrogen" is used herein in reference to Structure 1 to mean a tetrasubstituted or heteroaromatic nitrogen which is positively charged. An ammonium moiety, substituted with hydrocarbon groups

006260" 52492960

having 1-7 carbon atoms, which can be the same or different, is signified.

As used herein in reference to Structure 1, the term "amino derivative" means a group such as amino, acylamino, ureido, amidino, guanidino and alkyl (1-7 carbon atoms) derivatives thereof.

As used herein in reference to Structure 1, the term "amino acid derived group" means a moiety such as cysteinyl ($-\text{SCH}_2\text{CH}(\text{NH}_2)\text{COOH}$) or sarcosyl ($-\text{N}(\text{CH}_3)\text{CH}_2\text{COOH}$) in which a hydrogen joined to O, N or S of known amino acids is replaced.

Particularly preferred MDP-binding homing molecules having Structure 1 are those in which R^2 is 2,2-dimethyl cyclopropyl or dichlorocyclopropyl, and R^3 is a hydrocarbon chain of 3 to 7 carbon atoms without a terminal substituent, or having a terminal substituent which is trimethylammonium, amidino, guanidino, or 2-amino-2-carboxyethylthio.


Exemplary MDP-binding homing molecules useful in the invention include Z-2-(2,2-dimethylcyclopropane carboxamido)-8-trimethylammonium hydroxide-2-octenoic acid inner salt; Z-2-(2,2-dichlorocyclopropane carboxamido)-8-trimethylammonium hydroxide-2-octenoic acid inner salt; Z-2-(2,2-dimethylcyclopropane carboxamido)-8-formamidino-2-octenoic acid; Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-guanidino-2-octenoic acid; Z-2-(2,2-dimethylcyclopropane carboxamido)-8-ureido-2-octenoic acid; Z-8-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethyl cyclopropanecarboxamido)-2-octenoic acid; Z-2-(2,2-

dimethylcyclopropanecarboxamido)-2-octenoic acid
 (racemic and dextrorotatory forms); Z-2-(2,2-
 dichlorocyclopropanecarboxamido)-2-octenoic acid; 7-(L-
 2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropane
 5 carboxamido)-2-heptenoic acid; and 6-(L-2-amino-2-
 carboxyethylthio)-2-(2,2-dimethylcyclopropane
 carboxamido)-2-hexenoic acid.

Methods for preparing an MDP-binding homing
 molecule having Structure 1 are disclosed herein and
 10 known in the art. Several methods for preparing such
 an MDP-binding homing molecule are set forth in Example
 VI (see, also, U.S. Patent No. 4,616,038 to Kahan et
 al., which is incorporated herein by reference).

Additional MDP-binding homing molecules known
 15 in the art also can be used to selectively target a
 gene or medication to lung endothelium according to a
 method of the invention. Such MDP-binding homing
 molecules include substituted 2-alkenoic acids
 including the following Structure 2:

20



wherein n is an integer from 3 to 5 and Y is a
 heterocyclic or phenyl group that may be substituted or
 unsubstituted, and the lower alkyl (C₁₋₆) esters and
 pharmaceutically acceptable salts thereof.

As used herein in reference to Structure 2, the term "heterocyclic" means pyridyl, pyrimidinyl, tetrazolyl, imidazolyl, thiazolyl and the like. Such heterocyclic rings and phenyl rings can be

5 unsubstituted or substituted with hydroxyl, oxo, carbonyl, or methyl. Y-groups in Structure 2 include, for example, 2-pyridinyl; 4-pyridinyl; 3-hydroxy-2-pyridinyl; 3-carboxy-2-pyridinyl; 5-carboxy-2-pyridinyl; 2-carboxyphenyl;

10 1-methyl-1,2,3,4-tetrazol-5-yl; and 4-carboxy-6-hydroxy-2-pyrimidinyl.

The configuration at the cyclopropyl center of a substituted 2-alkenoic acid MDP-binding homing molecule having Structure 2 preferably is S (+),

15 although an R,S (+/-) racemic mixture of the compound also can be used in a method of the invention.

Particularly active MDP-binding homing molecules of this class are those in which n is 4 and Y is 3-carboxy-2-pyridyl or 3-hydroxy-2-pyridyl, each in

20 the S-form. Exemplary MDP-binding homing molecules having Structure 2 include: Z-7-(3-hydroxy-2-pyridylthio)-2-(2,2-dimethylcyclopropane carboxyamido)-2-heptenoic acid and Z-(5-carboxy-2-pyridylthio)-2-(2,2-dimethylcyclopropanecarboxyamido)-

25 2-heptenoic acid.


An MDP-binding homing molecule having Structure 2, as well as various pharmaceutically acceptable derivatives such as alkali and alkaline earth metal, ammonium or amine salts, or the like,

30 which are also useful in the invention, can be prepared by the skilled person using routine methods. An


0067475-092900

MDP-binding homing molecule having Structure 2 can be prepared, for example, by condensation of a bromoalkenoic acid with the appropriate mercaptan, YSH, in water in the presence of sodium bicarbonate at ambient temperature as described, for example, in U.S. Patent No. 4,406,902 to Ashton et al., which is incorporated herein by reference.

An MDP-binding homing molecule useful in the invention also can be a phosphinic acid having the following Structure 3:



or the following Structure 4:



where:

- 15 R_1 is
- (a) C_2 - C_{12} linear or branched unsubstituted alkyl;
 - (b) C_2 - C_{12} linear or branched substituted alkyl;
 - (c) C_2 - C_{12} linear or branched monoalkenyl;
 - (d) C_2 - C_{12} linear or branched alkynyl;
 - 20 (e) C_7 - C_{20} aralkyl, wherein the alkyl chain is linear or branched C_1 - C_8 and the aryl moiety is C_6 - C_{12} ;

- (f) C₃-C₇ cycloalkyl;
 (g) C₄-C₁₀ cycloalkylalkyl, for structure 4 only;
 where the above values for R₁, excluding (a), can
 be substituted by one or more: C₁-C₄ alkoxy, C₆-C₁₂
 5 aryloxy, C₁-C₄ alkylthio, C₆-C₁₂ arylthio, C₃-C₆
 cycloalkyloxy, C₃-C₆ cycloalkylthio, C₇-C₁₀ aralkyloxy,
 C₇-C₁₆ aralkylthio;

R₂ is

- (a) H or C₁-C₁₂ linear or branched alkyl;
 10 (b) C₂-C₁₂ linear or branched monoalkenyl;
 (c) C₇-C₂₀ aralkyl, wherein the alkyl chain is linear or
 branched C₁-C₈ and the aryl moiety is C₆-C₁₂;
 (d) heterocyclic alkyl, wherein the alkyl chain is
 linear or branched C₁-C₈ and the heterocyclic ring
 15 is 5-6 membered, optionally fused with a benzene
 ring, fully aromatic, containing 1-2: O, N or S
 heteroatoms;
 (e) C₃-C₇ cycloalkyl;
 (f) C₄-C₁₀ cycloalkylalkyl;

- 20 where the above values for R₂ can be
 substituted by one or more: halo, hydroxy, carboxy, C₁-
 C₄ alkoxy, carbonyl, C₇-C₁₆ arylalkoxy, C₃-C₇
 cycloalkyl, C₁-C₄ alkoxy, C₆-C₁₂ aryloxy, C₃-C₆
 cycloalkyloxy, C₃-C₆ cycloalkylthio, amino, mono- or
 25 di-C₁-C₈ alkylamino, thio, C₁-C₄ alkylthio, C₆-C₁₂
 arylthio, C₇-C₁₆ aralkylthio, or the radical -S-(CH₂)_n-
 CH(NH₂)COOH;

R⁵ is

- (a) H or C₁-C₁₂ linear or branched alkyl;
 30 (b) C₂-C₁₂ linear or branched monoalkenyl;
 (c) C₇-C₂₀ aralkyl, wherein the alkyl chain is linear or
 branched C₁-C₈ and the aryl moiety is C₆-C₁₂;

(d) heterocyclic alkyl, wherein the alkyl chain is linear or branched C_1-C_8 and the heterocyclic ring is 5-6 membered, optionally fused with a benzene ring, fully aromatic, containing 1-2: O, N or S heteroatoms;

5 (e) C_4-C_{10} cycloalkylalkyl;

(f) C_3-C_7 cycloalkyl;

where the above value for R_5 can be substituted by one or more: halo, hydroxy, carboxy, C_1-C_4 alkoxycarbonyl, C_7-C_{16} arylalkoxycarbonyl, C_3-C_7 cycloalkyl, C_1-C_4 alkoxy, C_6-C_{12} aryloxy, C_3-C_6 cycloalkyloxy, C_3-C_6 cycloalkylthio, amino, mono-or di-
 10 C_1-C_8 alkylamino, thio, C_1-C_4 alkylthio, C_6-C_{12} arylthio, C_7-C_{16} aralkylthio, or the radical $-S-(CH_2)_n-CH(NH_2)COOH$; and including MDP-binding stereoisomers
 15 and racemates thereof Structures 3 and 4.

In an MDP-binding homing molecule having Structure 3 or 4, the values for R_1 for (a) C_2-C_{12} linear or branched unsubstituted alkyl include ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-
 20 butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, iso-octyl, n-decyl, n-undecyl, n-dodecyl and the like. Preferred in this series is n-butyl, isobutyl, n-pentyl and n-hexyl.

In an MDP-binding homing molecule having
 25 Structure 3 or 4, values for R_1 for (b) C_1-C_{12} linear or branched alkyl, where substituted, include the values above for $R_1(a)$, substituted by the above-defined substituents, including the following preferred substituents: methoxy, ethoxy, propoxy, butoxy,
 30 methylthio, ethylthio, propylthio, butylthio, cyclopentyloxy, cyclopentylthio, cyclopropylthio,

benzylthio, 2-phenethylthio, 2-phenethylthio and the like.

In an MDP-binding homing molecule having Structure 3 or 4, values for R₁ for (e) C₂-C₂ linear or branched monoalkenyl include ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 2-methyl-2-butenyl and the like.

In an MDP-binding homing molecule having
10 Structure 3 or 4, values for R₁ for (d) C₂-C₁₂ linear or
branched alkynyl include: ethynyl, propynyl, 1-butyngyl,
2-butyngyl, 2-methyl-3-pentyngyl and the like.

Values for R_1 for (d) C_2 - C_{12} linear or branched alkynyl include: ethynyl, propynyl, 1-butyne, 2-butyne, 2-methyl-3-pentyne and the like.

Values for R_1 for (e) C_7 - C_{20} aralkyl include benzyl, 2-phenylethyl, 1-phenylethyl, 4-methylphenyl-methyl and the like. Preferred in this series is benzyl.

20 Values for R₁ for (f) C₄-C₁₀ cycloalkylalkyl
include: cyclohexylmethyl, cyclopentylmethyl, 2-
cyclohexylethyl, 2-cyclooctylethyl, and the like.
Preferred in this series is cyclopentylmethyl and
cyclohexylmethyl.

25 Values for R₁ for(g) C₃-C₇ cycloalkyl include:
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and
the like. Preferred in this series is cyclopentyl and
cyclohexyl.

Preferred substituent values for R_1 include: methoxy, ethoxy, phenoxy, methylthio, ethylthio, phenylthio, benzyloxy, 2-phenylethyloxy, benxylthio, 2-phenylethylthio, and the like.

5 The values of the alkyl, alkenyl groups for R_2 and R_5 , except where noted otherwise, represented by any of the variables include linear or branched, alkyl and monoalkenyl and chain hydrocarbon radicals from two to twelve carbon atoms, for example, ethyl, n-propyl, 10 isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, n-heptyl, n-nonyl, 4,4-dimethylpentyl, or vinyl, allyl, 1-butenyl, 2-butenyl, 5-hexenyl and the like. Preferred are isopropyl, n-butyl, n-pentyl, n-heptyl or 1-butenyl.

15 Values of C_3 - C_7 cycloalkyl and C_4 - C_{10} cycloalkylalkyl include: cyclopentyl, cyclohexyl, cyclopentyl-methyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclopropyl, and the like.

20 The aralkyl group represented by the above variables has from one to eight carbon atoms in the alkyl portion and "aryl" where noted, represents phenyl, naphthyl, or biphenyl. Representative examples include benzyl, phenethyl, 4-phenyl-n-butyl, 1-phenyl-n-octyl, and the like.

25 In an MDP-binding homing molecule of the invention having Structure 3 or 4, the aromatic heterocyclic, i.e. "heteroaryl" substituent, are synonymous, and recited above represents a 5- or 6-membered aromatic ring containing from one to three O, 30 N or S heteroatoms, preferably one O or S or 1-3N

heteroatoms, such as for example, pyridyl, thienyl, furyl, imidazolyl, and thiazolyl as well as any bicyclic group derivable therefrom in which any of the above heterocyclic rings is fused to a benzene ring
 5 such as, for example, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzofuryl, and benzothienyl.

The named substituents on the R_2 and R_5 alkyl and alkenyl chains can be present on the aromatic rings
 10 in the aralkyl, heterocyclic alkyl and heteroaryl groupings as well. The site of substitution can be any available sites and the substitution can involve one or more of the same or different groups.

The substituents are: halo, meaning fluoro,
 15 chloro, bromo or iodo; hydroxy; carboxy; C_1 - C_4 linear or branched alkoxy-carboxy, e.g. methoxycarbonyl and ethoxycarbonyl; C_7 - C_{16} arylalkoxy carbonyl, e.g. benzyloxycarbonyl, n-butyloxycarbonyl; C_3 - C_7 cycloalkyl, e.g. cyclopentyl and cyclohexyl; C_1 - C_4
 20 alkoxy, e.g. t-butoxy and ethoxy; C_6 - C_{12} aryloxy, e.g. biphenyloxy, benzyloxy; amino; mono- or di- C_1 - C_8 dialkylamino, e.g. methylamino, isopropylamino, n-butylamino, isohexylamino, N,N-diethylamino, methylethylamino, methyl-t-butylamino, di-n-octylamino;
 25 thio; C_1 - C_4 alkylthio, e.g. methylthio, ethylthio C_6 - C_{12} arylthio, e.g. phenylthio; C_7 - C_{16} aralkylthio, e.g. benzylthio, naphthyl-methylthio; the radicals $-S-CH_2-CH(NH_2)COOH$ and $-S-(CH_2)_2-CH(NH_2)COOH$, both preferably in the L-configuration; and, where a thio substituent
 30 is present, R_2 or R_5 must be at least a C_2 alkyl grouping. Where an aryl or heteroaryl group is present in the substituent, the ring carbons can additionally

be substituted by one or more of linear or branched C₁-C₄ alkyl, e.g. methyl, ethyl, isopropyl, t-butyl; trihalomethyl, "halo" having the same meaning as described above, e.g. trichloromethyl, trifluoromethyl; 5 nitro, cyano or sulfonamide.

Preferred are the compounds wherein:

R₁ is cyclohexylmethyl, cyclopentylmethyl, n-pentyl, n-butyl, n-hexyl, isobutyl, R₂ and R₃ are: C₃-C₇ cycloalkyl; C₁-C₁₀ linear or branched alkyl, 10 substituted or unsubstituted; C₇-C₁₄ aralkyl, substituted or unsubstituted. Wherein these groups can be substituted with halo, amino, mono- or di-C₁-C₄ linear or branched alkylamino, carboxyl, C₁-C₄ alkoxy, C₅-C₆ cycloalkyl, 15 C₆-C₁₀ aryloxy, thio, C₁-C₄ linear or branched alkylthio, C₆-C₁₀ arylthio, C₇-C₁₄ aralkylthio, -S-(CH₂)_n-CH(NH₂)CO₂H; wherein the aryl group ring carbons can further be substituted by linear or branched C₁-C₄ alkyl; R₃ and R₄ are hydrogen, C₁-C₄ linear or branched 20 alkyl e.g. methyl, ethyl, or C₇-C₁₄ aralkyl e.g. benzyl.

In an MDP-binding homing molecule having Structure 3 or 4, the carbon preferably is attached to R₁ in the (R) or (RS) configuration, more preferably (R), and the carbon attached to R₂ is in the (R), (RS) 25 or (S) configuration, preferably (RS) or (S) and if R₅ is present, the double bond preferably is in the Z configuration. One skilled in the art understands that an MDP-binding homing molecule based on Structure 3 can be used in the form of salts derived from inorganic or 30 organic acids and bases.

Methods for preparing an MDP-binding homing molecule having Structure 3 or Structure 4 are well known in the art. See, for example, Parsons et al., Biochemistry International 23:1107-1115 (1991); and
5 U.S. Patent No. 5,145,990, each of which is incorporated herein by reference.

A variety of other MDP-binding homing molecules known in the art also can be useful for selectively directing a gene or medication to lung
10 endothelium according to a method of the invention. Such MDP-binding homing molecules include those described in Kahan et al., U.S. Patent No. 4,616,038; Ashton et al., U.S. Patent No. 4,406,902; Parsons et al., U.S. Patent No. 5,145,990; Parsons et al.,
15 Biochem. International 23:1107-1115 (1991); Uchida et al., U.S. Patent No. 5,061,730; Hashimoto et al., J. Antibiotics XLIII:281-285 (1990); and Takase et al., J. Antibiotics XLIII:38-42 (1990), each of which is incorporated herein by reference.

20 Metastatic cells display an altered repertoire of cell adhesion molecules, allowing escape from the primary tumor, adhesion and penetration of the extracellular matrix and entry into the microvasculature. Most such cells are destroyed by
25 geometric and hemodynamic forces in their first encounter with the narrow capillary net, usually in the lungs. Although the frequency of metastasis to the lungs has been attributed solely to mechanical entrapment of tumor cell emboli, it has long been
30 observed that certain tumor cell types prefer to metastasize to specific target organs.

Several lines of evidence indicate that the selection of a target organ for metastasis is mediated by specific interactions between blood-born cancer cells and the endothelium of that target organ

5 (Albelda, Lab. Invest. 68: 4-17 (1993); Auerbach et al., Cancer Res. 47:1492-1496 (1987); Johnson et al., Cancer Res. 51:394-399 (1991), each of which is incorporated herein by reference). In the lung, two

10 of metastatic cells. LuECAM-1, an endothelial surface protein with sequence homology to chloride channels, mediates adhesion of malignant melanoma cells to lung endothelium (Elble et al., J. Biol. Chem. 272:27853-27861 (1997), which is incorporated herein by

15 reference). Furthermore, a protease, lung endothelial dipeptidylpeptidase IV (DPP IV/CD 26), promotes homing of metastatic breast and prostate carcinoma cells to lung (Johnson et al., J. Cell Biol. 121: 1423-1432 (1993), which is incorporated herein by reference).

20 Fibronectin present on the surface of the metastatic cells was shown to be the ligand for DPP IV-dependent homing of the breast cancer cells to lung vasculature (Chen et al., J. Biol. Chem. 273:24207-24215 (1998), which is incorporated herein by reference). These

25 results indicate that organ-selective homing can be mediated by classical cell adhesion molecules as well as other molecules.

As disclosed herein, selective homing of GFE-1 (SEQ ID NO: 1) to lung endothelium *in vivo* is

30 mediated by the cell surface protease, MDP. As further disclosed herein, administration of GFE-1 (SEQ ID NO: 1) can inhibit experimental lung metastasis of two melanoma cell lines (human C8161 and mouse B16) in

mice, demonstrating that GFE-1 (SEQ ID NO; 1) can compete with metastasizing tumor cells for binding to the same receptor (see Figure 8). These results indicate that MDP serves as a receptor for
5 metastasizing tumor cells on lung vasculature and that an MDP-binding homing molecule can reduce or prevent the anchoring of lung metastases.

Thus, the present invention provides a method of reducing or preventing lung metastasis in a subject
10 having cancer by administering to the subject a membrane dipeptidase (MDP)-binding homing molecule. Primary tumors that commonly spread to the lungs include breast, colorectal, lung, testicular, pancreatic, esophageal, stomach, ovarian, renal cell
15 and prostate carcinomas, osteogenic and soft tissue sarcomas and melanoma (Smith, Seminars Oncology Nurs. 14:178-186 (1998), which is incorporated herein by reference). The methods of the invention can be used, for example, to reduce or prevent lung metastasis of
20 breast cancer, kidney cancer, melanoma, bladder cancer, cancer of the cervix, ovarian cancer, prostate cancer, colorectal cancer or lung cancer.

As used herein, the term "metastasis" means the transfer of malignant cells from one site to
25 another site not directly connected with it, after which the cells form a proliferative focus. Thus, metastatic cells become detached from a primary tumor, move to a different part of the body and grow as a separate mass of tumor. One skilled in the art
30 understands that a malignant cell can travel locally from a first site within an organ to a second site within the same organ or can travel distantly within

the body to a different organ. Furthermore, malignant cells of a metastasis can themselves give rise to additional metastases.

The term "lung metastasis," as used herein, refers to the transfer of malignant cells to one or more sites within lung not directly connected with the first site, after which the cells form a proliferative focus within the lung. The resulting detached masses of cancer cells within the lung are termed lung "metastases" or secondary tumors. Lung metastases can originate from a variety of primary cancers, which they generally will resemble histologically. Breast cancer, kidney cancer and melanoma, for example, frequently metastasize to lung. In addition, cancers of the bladder, cervix, ovary and prostate metastasize to lung and, less frequently, colorectal cancers or primary lung cancers metastasize to one or more secondary sites in lung.

The term "reducing or preventing," as used herein in reference to lung metastasis, means that the rate or extent of lung metastasis is diminished. Thus, lung metastasis is reduced or prevented where the development of lung metastasis is completely precluded or is significantly delayed; or where the size or number of lung metastases is significantly diminished. One skilled in the art understands that a delay in development of lung metastases or a decrease in the size or number of lung metastases is measured relative to the rate or extent of lung metastases in one or more control subjects not treated with an MDP-binding homing molecule according to a method of the invention.

If addition, a subject not having detectable cancer can be treated prophylactically with an MDP-binding homing molecule to reduce or prevent the future occurrence of lung metastases. Such a subject
5 can be, for example, suspected of having cancer or can have a family history of cancer.

As set forth above, an MDP-binding homing molecule exhibits selective homing to lung endothelium and is characterized, in part, by exhibiting specific
10 binding to membrane dipeptidase. An MDP-binding homing molecule useful in reducing or preventing lung metastasis can readily be identified by specific binding to MDP as described hereinabove. If desired, additional MDP-binding homing molecule also can be
15 identified by the ability to competitively inhibit binding of known MDP-binding peptides, for example, GFE-1 (SEQ ID NO: 1) or cells, for example, C8161 cells to membrane dipeptidase.

In one embodiment, an MDP-binding homing
20 molecule useful in reducing or preventing lung metastasis is a lung homing peptide including the sequence X_1 -G-F-E- X_2 (SEQ ID NO: 17), where X_1 and X_2 each is 1 to 10 independently selected amino acids, such as a peptide including the sequence CGFECVRQCPERC
25 (SEQ ID NO: 1) or CGFELETC (SEQ ID NO: 2). Such an MDP-binding homing molecule can be, for example, the peptide CGFECVRQCPERC (SEQ ID NO: 1) or CGFELETC (SEQ ID NO: 2). Additional MDP-binding homing molecules containing the sequence X_1 -G-F-E- X_2 (SEQ ID NO: 17),
30 where X_1 and X_2 each is 1 to 10 independently selected amino acids, can be identified as described below, for

006260" 549,960

example, by screening a combinatorial peptide library which includes the motif GFE as invariant residues.

In another embodiment, an MDP-binding homing molecule is a membrane dipeptidase inhibitor. As used
5 herein, the term "membrane dipeptidase inhibitor" is synonymous with "MDP inhibitor" and means an organic molecule that selectively decreases the enzymatic activity of membrane dipeptidase. In general, an MDP inhibitor is a molecule that binds to the active site
10 of MDP. An MDP inhibitor can be an organic molecule such as a drug; peptide; modified peptide or peptide mimetic; protein or protein fragment; nucleic acid molecule such as a ribonucleic or deoxyribonucleic acid; oligosaccharide; lipid; glycolipid; or
15 lipoprotein. Exemplary MDP inhibitors disclosed herein are CGFECVRQCPCRC (SEQ ID NO: 1) and cilastatin.

The term "selectively inhibits," as used herein in reference to an MDP inhibitor, means that the inhibitor decreases MDP activity in a manner that is
20 selective for the MDP enzyme as compared to related but different enzymes such as other proteases. Thus, an MDP inhibitor is distinct from a non-specific inhibitor of, for example, zinc metalloproteases. Thus, an MDP inhibitor can selectively decrease MDP activity while
25 having little or no effect on the activity of, for example, dipeptidyl peptidase IV.

Assays for measuring MDP enzymatic activity are known in the art. MDP cleaves dipeptide substrates in which the N-terminal amino acid is in the
30 L-configuration and is unblocked. The C-terminal amino acid is either in the L- or D-configuration, with the

09676475-096900

enzyme hydrolyzing substrates with a D-configuration C-terminal residue more rapidly. MDP activity can be assayed, for example, using glycyl-D-phenylalanine (Gly-D-Phe) as a substrate (Keynan et al., *supra*, 1996; Parsons et al., *supra*, 1991). A convenient specific fluorimetric assay for MDP enzymatic activity uses Gly-D-Phe as a substrate and subsequent reaction of D-amino acid oxidase with the released D-Phe (see Example IVE; see, also, Heywood and Hooper, Analyt. Biochem. 226:10-14 (1995), which is incorporated herein by reference).

A membrane dipeptidase inhibitor can be a molecule that exhibits structural homology to a natural MDP substrate. For example, following cleavage of the tripeptide glutathione by γ -glutamyl transpeptidase to form glutamate and cysteinylglycine (Cys-Gly), the dipeptide Cys-Gly is recognized and cleaved by MDP, which cleaves only dipeptides. The amino acid sequence of glutathione is similar to the N-terminal portion of GFE-1 (SEQ ID NO: 1), in which the first two amino acids are Cys-Gly. As shown in Figure 7, GFE-1 (SEQ ID NO: 1) inhibits hydrolysis of the Gly-D-Phe substrate in a dose-dependent manner, indicating that GFE containing peptides such as GFE-1 (SEQ ID NO: 1) can be MDP inhibitors. These results further indicate that an MDP inhibitor can be structurally similar to a naturally occurring MDP substrate.

A variety of MDP inhibitors are known in the art. For example, an MDP inhibitor can be an MDP-binding homing molecule such as an MDP-binding molecule having Structure 1, Structure 2, Structure 3 or Structure 4, described hereinabove.

An MDP inhibitor useful in the invention can have, for example, a K_i for membrane dipeptidase of about 10^{-4} M to about 10^{-12} M. For example, a MDP inhibitor including the sequence X_1 -G-F-E- X_2 (SEQ ID NO: 17), where X_1 and X_2 each is 1 to 10 independently selected amino acids, can have, for example, a K_i for membrane dipeptidase of about 2×10^{-5} M to 10^{-7} M, for example, a K_i of about 10^{-6} to 10^{-7} M.

An MDP inhibitor useful in the invention can exhibit, for example, a K_i against MDP of 1000 nM or less. An MDP inhibitor useful in reducing or preventing lung metastasis also can exhibit, for example, a K_i against MDP of 100 nM or less or a K_i of 1 nM or less. For example, an MDP inhibitor having Structure 3 or Structure 4 can be a tight binding inhibitor with a K_i from, for example, about 0.5 nM to 10 nM. MDP inhibitors having Structure 3 or Structure 4 therefore can be particularly useful in the methods of the invention for reducing or preventing lung metastasis by administering an MDP inhibitor to a subject having cancer.

In another preferred embodiment, an MDP inhibitor comprises Structure 1, where R^2 and R^3 are hydrocarbon radicals in the range respectively of 3-10 and 1-15 carbon atoms; in either one of these R^2 or R^3 hydrocarbon chains 1-6 hydrogens may be replaced by halogens or a nonterminal methylene may be replaced by oxygen or sulfur, including oxidized forms of the latter; additionally, a terminal hydrogen in R^3 can also be replaced by hydroxyl or thiol, which may be acylated or carbamoylated; or the hydrogen can be replaced by amino, which may be derivatized as in an

acylamino, ureido, amidino, guanidino, or alkyl or substituted amino group, including quaternary nitrogen grouping; or, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, or cyano; or combinations thereof, such as a terminal amino acid grouping; and R¹ is hydrogen or lower alkyl (C₁₋₆) or dialkylaminoalkyl, or a pharmaceutically acceptable cation. Such an MDP inhibitor for reducing or preventing lung metastasis can be, for example, 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropane carboxamido)-2-heptenoic acid, also known as cilastatin.

An MDP inhibitor can be, for example, a compound having Structure 1 in which R² is branched alkyl or cycloalkyl with a limitation that the carbon adjacent to the carbonyl cannot be tertiary.

An MDP inhibitor also can be, for example, a compound having Structure 1 in which R² is branched alkyl or cycloalkyl with a limitation that the carbon adjacent to the carbonyl cannot be tertiary, and in which R³ is n-alkyl (1-9 carbons) or n-alkyl (1-9 carbons) having a terminal substituent which is a quaternary nitrogen, amine derivative or amino acid derived group. An MDP inhibitor can be, for example, a compound having Structure 1 in which R² is 2,2-dimethylcyclopropyl or 2,2-dichlorocyclopropyl and in which R³ is a hydrocarbon chain of 3 to 7 carbon atoms without a terminal substituent or having a terminal substituent which is trimethylammonium, amidino, guanidino or 2-amino-2-carboethylthio.

Exemplary MDP inhibitors having Structure 1 useful in the invention include the following: Z-2-(2,2-dimethylcyclopropane carboxamido)-8-trimethylammonium hydroxide-2-octenoic acid inner salt;

5 Z-2-(2,2-dichlorocyclopropanecarboxamido)-8-trimethylammonium hydroxide-2-octenoic acid inner salt; Z-2-(2,2-dimethylcyclopropane carboxamido)-8-guanidino-2-octenoic acid; Z-2-(2,2-

10 dimethylcyclopropanecarboxamido)-8-guanidino-2-octenoic acid; Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-ureido-2-octenoic acid; Z-8-(1-2-amino-2-carboxy ethylthio)-2-

(2,2-dimethylcyclopropane carboxamido)-2-octenoic acid; Z-2-(2,2-dimethylcyclopropane carboxamido)-2-octenoic

15 acid (racemic and dextrorotatory forms); Z-2-(2,2-dichloro cyclopropanecarboxamido)-2-octenoic acid; 7-(L-2-amino-2-carboxyethylthio) -2-(2,2-

dimethylcyclopropane carboxamido)-2-heptenoic acid; and 6-(L-2-amino-2-carboxyethylthio)-2-(2,2-

20 dimethylcyclopropane carboxamido)-2-hexenoic acid.

The present invention also provides a method of reducing or preventing lung metastasis in a subject having cancer by administering to the subject a MDP negative regulatory agent. A MDP negative regulatory

25 agent useful in the invention can be, for example, a soluble MDP polypeptide or an antibody that selectively reacts with MDP.

Further provided herein are methods of reducing or preventing cell homing to lung endothelium

30 in a subject by administering to the subject a MDP negative regulatory agent. A MDP negative regulatory agent useful for reducing or preventing cell homing to

006260" 5475 . 092900

lung endothelium can be, for example, a soluble MDP polypeptide or an antibody that selectively reacts with MDP.

As used herein, the term "MDP negative
5 regulatory agent" means an organic molecule that, directly or indirectly, selectively reduces MDP expression or activity. Such MDP negative regulatory agents can be, for example, drugs; nucleic acid molecules, including ribonucleic acid molecules and
10 deoxyribonucleic acid molecules; peptides; variants or modified peptides or peptide mimetics; proteins or fragments thereof; antibodies or fragments thereof; oligosaccharides; lipids; glycolipids; or lipoproteins.

One skilled in the art understands that a MDP
15 negative regulatory agent can act by a variety of mechanisms to selectively reduce MDP expression or activity. An MDP negative regulatory agent can be, for example, an organic molecule that acts to reduce the amount of functional MDP expressed in lung endothelium.
20 Such an agent can selectively reduce MDP transcription or translation and can be, for example, an antisense oligonucleotide, a transcription factor that negatively regulates MDP expression, or a nucleic acid molecule encoding such a transcription factor.

25 An MDP negative regulatory agent also can be, for example, a fragment of MDP that effectively competes with wild type membrane dipeptidase to reduce or prevent metastatic or other cells from selectively homing to MDP in lung endothelium. A soluble,
30 extracellularly expressed form of MDP or other dominant negative fragment of MDP can be a MDP negative

regulatory agent useful in the invention. A MDP
regulatory agent also can be an MDP mimic, which is a
protein or other organic molecule that shares tertiary
structural homology with MDP or a subpart thereof, and
5 which, when expressed, competes with endogenous MDP for
binding to metastatic or other homing cells such as
lymphocytes. An MDP mimic can structurally resemble
the region of MDP that contacts a metastatic cell; an
MDP mimic can structurally resemble, for example, the
10 active site of MDP.

In one embodiment, a MDP negative regulatory
agent is an antibody that selectively reacts with MDP.
As used herein, an antibody that "selectively reacts
with MDP" binds with substantially higher affinity to
15 membrane dipeptidase than to an unrelated polypeptide
such as another zinc metalloprotease. The term
"antibody" is used herein in its broadest sense to
include polyclonal and monoclonal antibodies, as well
as polypeptide fragments of antibodies that retain a
20 selective affinity for membrane dipeptidase of at least
about $1 \times 10^5 \text{ M}^{-1}$. Antibody fragments such as Fab,
 F(ab')_2 and Fv fragments can selectively react with
membrane dipeptidase and, therefore, are included
within the meaning of the term antibody as defined
25 herein. The term antibody as used herein includes
naturally occurring antibodies, as well as non-
naturally occurring antibodies and fragments such as
chimeric antibodies and humanized antibodies that are
selectively reactive with membrane dipeptidase.

30 Methods for producing antibodies are routine
in the art. Membrane dipeptidase, which can be
prepared from natural sources or produced recombinantly

as described above, or a fragment thereof, such as a synthetic peptide, can be used as an immunogen. Non-immunogenic fragments or synthetic peptides can be made immunogenic by coupling the hapten to a carrier molecule such as bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). In addition, various other carrier molecules and methods for coupling a hapten to a carrier molecule are well known in the art as described, for example, by Harlow and Lane, Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1988), which is incorporated herein by reference. Antibodies, including non-naturally occurring antibodies such as, chimeric and humanized antibodies, also can be constructed using solid phase peptide synthesis, produced recombinantly or obtained, for example, by screening combinatorial libraries consisting of variable heavy chains and variable light chains as described by Borrebaeck (Ed.), Antibody Engineering (Second edition) New York: Oxford University Press (1995), which is incorporated herein by reference.

In another embodiment, a MDP negative regulatory agent is a soluble MDP polypeptide. As used herein, the term "soluble polypeptide" means a polypeptide that is not membrane bound. A soluble MDP polypeptide useful in the invention is secreted and, thus, expressed extracellularly.

A soluble MDP polypeptide useful in the invention can be, for example, a truncated or mutated MDP polypeptide lacking one or more C-terminal residues required for GPI anchor addition (see Figure 9). To determine whether a particular truncated or mutated MDP

derivative is soluble, the derivative can be expressed, for example, in COS cells, and the transfected cells and supernatant subsequently assayed for MDP activity to determine whether the MDP is membrane bound or
5 soluble.

The present invention also provides a method of identifying a molecule that reduces or prevents lung metastasis by contacting membrane dipeptidase (MDP) with one or more molecules; and determining MDP
10 activity in the presence of the molecule as compared to a control value, where diminished MDP activity in the presence of the molecule identifies the molecule as a molecule that reduces or prevents lung metastasis. The membrane dipeptidase can be, for example, substantially
15 purified. MDP activity can be determined, for example, by release of D-Phe from Gly-D-Phe.

In one embodiment of the invention, a molecule that reduces or prevents lung metastasis can be identified by contacting membrane dipeptidase (MDP)
20 with one or more molecules; determining MDP activity in the presence of the molecule as compared to a control value; administering the molecule to a subject having cancer; and assaying lung metastasis in the subject as compared to a control level of metastasis, where
25 diminished MDP activity in the presence of the molecule identifies the molecule as a molecule that reduces or prevents lung metastasis.

The following examples are intended to
30 illustrate but not limit the present invention.

EXAMPLE I

IN VIVO PANNING

This example demonstrates methods for preparing a phage display library and screening the
 5 library using *in vivo* panning to identify phage expressing peptides that home to a selected organ or tissue.

A. Preparation of phage libraries:

Phage display libraries were constructed
 10 using the fuse 5 vector as described by Koivunen et al., *supra*, 1995; see, also, Koivunen et al., *supra*, 1994b). Libraries encoding peptides designated CX₆C (SEQ ID NO: 26), CX₇C (SEQ ID NO: 24), CX₁₀C (SEQ ID NO: 30)) CX₃CX₃CX₃C (SEQ ID NO: 25), X₂CX₄CX (SEQ ID
 15 NO: 23), and X₇ (SEQ ID NO: 29), were prepared, where "C" indicates cysteine and "X_N" indicates the given number of individually selected amino acids. These libraries can display cyclic peptides when at least two cysteine residues are present in the peptide.

20 The libraries containing the defined cysteine residues were generated using oligonucleotides constructed such that "C" was encoded by the codon TGT and "X_N" was encoded by NNK, where "N" is equal molar mixtures of A, C, G and T, and where "K" is equal molar
 25 mixtures of G and T. Thus, the peptide represented by CX₆C (SEQ ID NO: 26) can be represented by an oligonucleotide having the sequence TGT(NNK)₆TGT (SEQ ID NO: 31). Oligonucleotides were made double stranded by 3 cycles of PCR amplification, purified and ligated
 30 to the nucleic acid encoding the gene III protein in

006260" 52492960

the fuse 5 vector such that, upon expression, the peptide is present as a fusion protein at the N-terminus of the gene III protein.

The vectors were transfected by
 5 electroporation into MC1061 cells. Bacteria were cultured for 24 hr in the presence of 20 µg/ml tetracycline, then phage were collected from the supernatant by precipitation twice using polyethylene glycol. Each library contained about 10^{12} transducing
 10 units/ml (TU; individual recombinant phage).

B. In vivo panning of phage:

For lung and pancreas, a mixture of phage libraries containing 10^{10} TU was diluted in 200 µl DMEM and injected into the tail vein of anesthetized BALB/c
 15 mice (2 month old; Harlan Sprague Dawley; San Diego CA); AVERTIN (0.017 ml/g) was used as anesthetic (Pasqualini and Ruoslahti, *supra*, 1996). After 1-4 minutes, mice were snap frozen in liquid nitrogen or, after about 5 minutes of phage circulation, the
 20 mice were perfused through the heart with 5-10 ml of DMEM (SIGMA; St. Louis MO). To recover the phage, the organs from the perfused mice or partially thawed organs from snap frozen mice were collected and weighed, then were homogenized in 1 ml DMEM-PI (DMEM
 25 containing protease inhibitors (PI); phenylmethyl sulfonyl fluoride (PMSF; 1 mM), aprotinin (20 µg/ml), leupeptin (1 µg/ml)).

Organ samples were washed 3 times with ice cold DMEM-PI containing 1% bovine serum albumin (BSA),
 30 then directly incubated with 1 ml K91-kan bacteria for

1 hr. Ten ml NZY medium containing 0.2 µg/ml tetracycline (NZY/tet) was added to the bacterial culture, the mixture was incubated in a 37°C shaker for 1 hr, then 200 µl aliquots were plated in agar plates containing 40 µg/ml tetracycline (tet/agar).

For *in vivo* panning of skin, two month old BALB/c nude mice were used to avoid contamination by hair. The mice were injected intravenously with phage as described above and, after perfusion through the heart, the skin was removed in large sections and placed on an ice cold plate with the hypodermis facing up. The skin was scraped with a scalpel to remove mostly hypodermis, which was then processed for phage recovery as described below.

For *in vivo* panning of retina, two month old female Simonson Albino rats were used to provide larger tissue samples than mice. The rats were anesthetized with phenobarbital (50 mg/kg body weight), and, while under deep anesthesia, the abdominal cavity of the rats was opened and 10^{10} TU of a phage library was injected into the left ventricle of the heart through the diaphragm. After 2-5 minutes of phage circulation, the eyes were removed, then washed once in 70% EtOH and once in PBS. The anterior chamber, with cornea and lens, was removed and the retina was peeled from the remaining posterior chamber. The tissue was weighed, homogenized with a syringe bulb in 1 ml of ice cold DMEM containing protease inhibitors (1 mM PMSF, 20 µg/ml aprotinin and 1 µg/ml of leupeptin; all from SIGMA; St. Louis MO). The tissue was washed 3 times with 1 ml of DMEM and the phage were rescued as described below.

Approximately 250 to 300 individual bacterial colonies containing phage recovered from the various organs or tissues were grown for 16 hr in 5 ml NZY/tet. In some experiments, approximately 1000 individual bacteria containing phage were picked and the phage were amplified in 2 ml of NZY/tet or the entire plate containing phage was scraped, pooled and grown in bulk and processed for injection. Where phage were cultured separately, the cultures were pooled and the phage were injected into mice or rats as described above for a second round of *in vivo* panning. In some experiments, a third or fourth round of panning was performed. Phage DNA was purified from individual bacterial colonies obtained and the DNA sequences encoding the peptides expressed by selected phage were determined (see Koivunen et al., *supra*, 1994b).

EXAMPLE II

CHARACTERIZATION OF PEPTIDES THAT HOME TO A SELECTED ORGAN

This example demonstrates that an organ or tissue homing peptide of the invention selectively homes to a selected organ or tissue including an organ containing a component of the RES.

A. Lung is the selected organ

After two or three rounds of *in vivo* panning of mice injected with a cyclic CX₃CX₃CX₃C (SEQ ID NO: 25) or a cyclic CX₆C (SEQ ID NO: 26) phage display library, four peptides that homed to lung were identified. The peptide sequences CGFECVRQCPERC (SEQ ID NO: 1; GFE-1) and CGFELETC (SEQ ID NO: 2; GFE-2)

appeared repeatedly in the lung and two peptide sequences from the CX₆C (SEQ ID NO: 26) library CTLRDRNC (SEQ ID NO: 15) and CIGEEVC (SEQ ID NO: 16) also were found to home to lung (see Table 2, below).

5 To determine the specificity of lung homing of the individual peptides identified, phage displaying the peptides were amplified individually, diluted to the same input titer and administered to mice. Following administration, control kidney and brain
10 organ was removed and the number of TU of phage in lung, kidney and brain was determined. The results shown in Figure 2 reveal that 10x and 35x more phage having the peptide sequence CGFECVRQCPERC (SEQ ID NO: 1; GFE-1) bound to lung than to kidney and brain,
15 respectively. Figure 2 also reveals that CGFELETC (SEQ ID NO: 2; GFE-2) was found in lung at a 12x and 20x greater level than in kidney and brain, respectively. The lung homing peptides CGFECVRQCPERC (SEQ ID NO: 1; GFE-1), CGFELETC (SEQ ID NO: 2; GFE-2), CTLRDRNC (SEQ
20 ID NO: 15) and CIGEEVC (SEQ ID NO: 16) are enriched in lung at 35x, 9x, 6x and 5x, respectively, over unselected phage (see Figure 2). Thus, substantial enrichment of phage binding to the lung was observed in comparison to control brain and kidney and in
25 comparison to unselected phage.

Specificity for the lung homing peptides was also determined by competition experiments with GST-fusion peptides. A GST-GFE-1 (SEQ ID NO: 1) fusion
30 peptide coadministered with GFE-1 (SEQ ID NO: 1) inhibited GFE-1 (SEQ ID NO: 1) homing to the lung, whereas GST had no effect on homing (Figure 3A). In addition, the inhibitory effect of the GST-GFE-1 (SEQ

006260"52492560

ID NO: 1) on homing was dose dependent; 70% inhibition of homing occurred when injecting 500 µg of the GST-GFE-1 (SEQ ID NO: 1) fusion protein (Figure 3B). Coinjection of GST-GFE-2 (SEQ ID NO: 2) with GFE-2 (SEQ ID NO: 2) inhibited homing to a lesser extent; 30% inhibition of homing occurred when injecting 500 µg of the GST-GFE-2 (SEQ ID NO: 2) fusion protein (Figure 3B). Interestingly, the GST-GFE-1 (SEQ ID NO: 1) fusion was more efficient at inhibiting GFE-2 (SEQ ID NO: 2) homing to the lung; 60% inhibition of GFE-2 (SEQ ID NO: 2) homing occurred when injecting 500 µg of the GST-GFE-1 (SEQ ID NO: 1) fusion protein (Figure 3B). However, no inhibitory effect of GFE-1 (SEQ ID NO: 1) homing was observed when coinjecting GST-GFE-2 (SEQ ID NO: 2). This can be explained by GFE-1 (SEQ ID NO: 1) having a higher affinity for a shared target molecule than GFE-2 (SEQ ID NO: 2).

Additional lung homing peptides were obtained and the amino acid sequences were determined for the inserts (see Table 2). Peptides containing a GFE motif predominated (see Table 1; SEQ ID NOS: 1 and 2). Other peptides that were present more than once in lung are indicated by an asterisk in Table 2 (below), and the remaining peptides were identified one time each.

These results indicate that the selection of the peptides containing the GFE motif represents the selective binding of several independent phage displaying peptides having the GFE sequence and is not an artifact due, for example, to phage amplification. In addition, in some cases, phage that expressed peptides having the same amino acid sequence were encoded by oligonucleotides having different sequences,

09675475-092900

therefore confirming that homing of a particular phage to a lung is due to the specific peptide expressed on the phage.

These results demonstrate that *in vivo* panning can be used to screen phage display libraries in order to identify phage expressing peptides that home to lung, which contain a component of the RES.

B. Skin is the selected tissue:

After two or three rounds of *in vivo* panning of mice injected with a cyclic CX₃CX₃CX₃C (SEQ ID NO: 25) phage display library, the peptide sequence CVALCREACGEGC (SEQ ID NO: 3), which appeared repeatedly in skin, was identified (Table 1). To determine the specificity of skin homing of the sequence CVALCREACGEGC (SEQ ID NO: 3), phage displaying the peptide was amplified individually, diluted to the same input titer and administered to mice. Following administration, control kidney and brain organ were removed and the number of TU of phage in skin, kidney and brain was determined.

The results revealed that 7x more phage displaying the peptide sequence CVALCREACGEGC (SEQ ID NO: 3) bound to skin than to kidney or brain (see Figure 2; Table 1). The peptide CVALCREACGEGC (SEQ ID NO: 3) was enriched in skin 7x over unselected phage (Figure 2). Thus, substantial enrichment of phage binding to the skin was observed in comparison to control brain and kidney and in comparison to unselected phage.

09676475-096900

Additional skin homing peptides were obtained by screening the cyclic CX₃CX₃CX₃C (SEQ ID NO: 25) or CX₁₀C (SEQ ID NO: 30) phage display libraries; amino acid sequences were determined for the inserts as shown in Table 5, below. Peptides that were identified more than one time during screening are indicated by an asterisk. For example, 14% of recovered CX₃CX₃CX₃C (SEQ ID NO: 25) phage that homed to head skin had the sequence CVDVCCDGCVPCC (SEQ ID NO: 437). Phage having the sequence RVPLSGDVEH (SEQ ID NO: 438), LRVMSFTSGQ (SEQ ID NO: 439), or RFSVGSFLFGS (SEQ ID NO: 440) each constituted 14% of recovered CX₁₀C (SEQ ID NO: 30) phage that homed to head skin. Screening against homing to tail skin revealed that 12% of recovered CX₃CX₃CX₃C (SEQ ID NO: 25) phage had the sequence CGATCEMQCPSGC (SEQ ID NO: 441).

Specificity for the skin homing peptides was also determined by competition experiments with GST-fusion peptides. Figure 3B shows that a GST-CVALCREACGEGC (SEQ ID NO: 3) fusion peptide coadministered with CVALCREACGEGC (SEQ ID NO: 3) inhibited homing to the skin, whereas GST had no effect on homing. The inhibitory effect of the GST-GFE-1 on homing was about 55% when injecting 500 µg of the GST-CVALCREACGEGC (SEQ ID NO: 3) fusion protein (Figure 3B).

These results demonstrate that *in vivo* panning can be used to screen phage display libraries in order to identify phage expressing peptides that home to skin and that such homing is specific.

C. Pancreas is the selected organ:

After two or three rounds of *in vivo* panning of mice injected with a cyclic CX₇C (SEQ ID NO: 24) phage display library, various pancreas homing peptides
5 were identified (Table 3). In particular, the peptide sequence SWCEPGWCR (SEQ ID NO: 4) appeared repeatedly in the pancreas. To determine the specificity of SWCEPGWCR (SEQ ID NO: 4), a phage displaying the sequence was amplified individually, diluted to the
10 same input titer and administered to mice. Following administration, control brain organ was removed and the number of TU of phage in each pancreas and was determined. The results shown in Figure 2, reveal that 10x more phage displaying the peptide sequence
15 SWCEPGWCR (SEQ ID NO: 4) bound to pancreas than to brain and additional experiments revealed up to 20x enrichment in pancreas as compared to brain (Table 1). In addition, SWCEPGWCR (SEQ ID NO: 4) exhibited a 22x enrichment of phage to the pancreas as compared to
20 unselected phage (see Figure 2). Thus, substantial enrichment of phage binding to the pancreas was observed in comparison to control tissue (brain) and to unselected phage.

These results demonstrate that *in vivo*
25 panning can be used to identify molecules that selectively home to pancreas. In addition, the results indicate that *in vivo* panning identifies independent phage encoding the same peptide.

006260" 52492960

D. Retina is the selected tissue

Rats injected with a cyclic CX₂C (SEQ ID NO: 24) phage display library were subjected to *in vivo* panning and, after three rounds, the peptide sequences
5 CSCFRDVCC (SEQ ID NO: 5) and CRDVVSVIC (SEQ ID NO: 6) were identified in retina. Because of small tissue sample size, the phage isolated could not be accurately quantitated. Thus, the selectivity of phage displaying the peptides was determined by individually amplifying
10 the phage displaying the sequence and administering the phage to rats with a control phage fdAMPLAY88. This fd-ampicillin phage is similar to fd-tetracycline (fuse 5-based) in that it has the same infectivity.

Rats were injected with an equal amount of
15 the CSCFRDVCC (SEQ ID NO: 5) or CRDVVSVIC (SEQ ID NO: 6) and the fdAMPLAY88 phage. Following administration, homing to retina was evaluated by comparing the number of TU of the selected phage on tetracycline plates and fdAMPLAY88 on ampicillin plates
20 recovered from retina.

The results revealed that CSCFRDVCC (SEQ ID NO: 5) showed a 3x enrichment and CRDVVSVIC (SEQ ID NO: 6) showed a 2x enrichment in retina compared to control fdAMPLAY88 phage. Thus, substantial enrichment
25 of phage binding to the retina was observed in comparison to control phage.

Additional retina homing peptides were obtained and the amino acid sequences were determined for the inserts (Table 6, below). Peptides that
30 appeared more than one time are indicated. In

particular, the RDV tripeptide motif was present in several different sequence contexts, indicating that the nucleic acids encoding the peptides were derived from a number of independent phage.

5 These results indicate that the selection of the peptides containing the RDV motif represents the selective binding of several independent phage displaying peptides having the RDV sequence and is not an artifact due, for example, to phage amplification.
10 In addition, in some cases, phage that expressed peptides having the same amino acid sequence were encoded by oligonucleotides having different sequences, therefore confirming that homing of a particular phage to retina is due to the specific peptide expressed on
15 the phage.

These results further demonstrate that the *in vivo* panning method is a generally applicable method for screening a library to identify, for example, phage expressing peptides that home to a selected organ or
20 tissue, including organs and tissues containing a component of the RES. Database searches did not reveal any significant homology of the pancreas, lung, skin or retina homing peptides to known ligands for endothelial cell receptors.

25

EXAMPLE III

IMMUNOHISTOLOGIC ANALYSIS OF LUNG, PANCREAS AND SKIN HOMING PEPTIDES

This example demonstrates the localization of lung, pancreas and skin homing molecules using
30 immunohistologic examination.

Phage displaying homing peptides were detected in lung, pancreas and skin by immunostaining histologic sections obtained 5 min after administration of phage expressing a lung, pancreas or skin homing peptide ("peptide-phage") to a mouse. Following administration of the peptide-phage, mice were handled as described above and various organs, including lung, pancreas and skin, were removed and fixed in Bouin's solution (SIGMA). Histologic sections were prepared and reacted with anti-M13 (phage) antibodies (Pharmacia Biotech; see U.S. Patent No. 5,622,699, *supra*, 1997; Pasqualini and Ruoslahti, *supra*, 1996). Visualization of the bound anti-M13 antibody was performed using a second antibody conjugated to peroxidase (SIGMA) according to the manufacturer's instructions.

Phage displaying the lung homing peptide, GFE-1 (SEQ ID NO: 1), were administered intravenously to mice and, after 5 minutes of circulation, the lung was isolated and processed as described above. Immunohistochemical staining of the alveolar capillaries was observed and no preference for any anatomical portion was detected. However, staining of bronchiolar walls and some larger blood vessels was absent. Mice injected with unselected phage did not exhibit lung staining, and no staining was observed in pancreas and skin after injection of GFE-1 (SEQ ID NO: 1).

Similar experiments were performed in pancreas using phage displaying the pancreas homing peptide, SWCEPGWCR (SEQ ID NO: 4). In these experiments, histological samples of the pancreas as

well as control organs and tissues including lung and skin were prepared and examined by immunostaining as described above. The results revealed staining in the capillaries and larger blood vessels of the exocrine pancreas whereas little if any staining of the endocrine pancreas was detected. Again, unselected phage did not stain pancreas, nor was any staining observed in lung and skin of mice injected with phage displaying SWCEPGWCR (SEQ ID NO: 4). Interestingly, some staining of blood vessels within the uterus was observed for the SWCEPGWCR (SEQ ID NO: 4) peptide. Moreover, after intravenous injection of phage displaying SWCEPGWCR (SEQ ID NO: 4), the phage was recovered from uterus at a 6x higher level in comparison to unselected phage. Thus, SWCEPGWCR (SEQ ID NO: 4) homes to both pancreas and uterus.

Experiments were performed in skin using phage displaying the skin homing peptide CVALCREACGEGC (SEQ ID NO: 3). In these experiments, histological samples from the skin as well as control organs and tissues including lung and pancreas were prepared and examined by immunostaining as described above. The results revealed staining in blood vessels of the hypodermis whereas little if any staining of the dermis was detected. Again, unselected phage did not stain these blood vessels, and no staining was observed in control the lung and pancreas of mice injected with phage displaying CVALCREACGEGC (SEQ ID NO: 3).

All phage, including unselected phage, caused staining of the liver and spleen. This result is consistent with the capture of phage by a component of the RES which was previously described.

These results demonstrate that lung, pancreas and skin homing peptides selectively home to lung, pancreas and skin, particularly to the vasculature. In addition, these results reveal that organs and tissues can exhibit differences of the staining patterns within particular regions, presumably reflecting the differential expression of a target molecule within the organ or tissue. Immunohistochemical analysis provides a convenient assay for identifying the localization and distribution of phage expressing lung, pancreas and skin homing peptides.

EXAMPLE IV

THE RECEPTOR FOR THE GFE-1 LUNG HOMING PEPTIDE IS MEMBRANE DIPEPTIDASE

This example demonstrates that the receptor for "GFE" containing peptides such as GFE-1 (SEQ ID NO: 1) is membrane dipeptidase. This example further demonstrates that GFE-1 (SEQ ID NO: 1) binds and inhibits membrane dipeptidase activity.

A. GFE-1 phage bind selectively to lung primary cells

As described above, CGFECVRQCPERC (SEQ ID NO: 1; GFE-1) phage bind to mouse lung vasculature when injected *in vivo*. A phage binding assay on lung primary cells was performed to determine if the specificity of CGFECVRQCPERC (SEQ ID NO: 1; GFE-1) phage binding to lung tissue *in vivo* could be reconstituted *in vitro*.

Phage binding to primary cells was performed as follows. Briefly, Balb/c mice (Harlan Sprague

006260" 57492960

006260" 52492960

Dawley) were anesthetized with 0.017 ml/g of Avertin as described in Gardner et al., Lab. Animal Sci. 45:199-204 (1995), which is incorporated herein by reference. Under deep anesthesia, mice were perfused
5 through the heart with 10 ml Dulbecco's modified Eagle's medium (DMEM; Irvine Scientific; Santa Ana, CA). The lungs, kidneys and brain were then collected, minced, placed in 2 ml of DMEM containing 0.5 % BSA (Intergen; Purchase, NY) and 0.5 µg/ml collagenase V
10 (SIGMA) and incubated at 37 °C for 25 minutes. Following collagenase treatment, the tissue was forced through a 70 µm pore cell strainer (Becton Dickinson; Franklin Lake, NJ). The filtered cells were washed once with 10 ml DMEM supplemented with 10% serum. The
15 phage particles used in the binding assay were amplified and purified, and the phage-displayed inserts were sequenced as described in Smith and Scott, *supra*, 1993. To ensure an equal input of the different phage to be tested, phage were titered several times using
20 K91Kan bacteria (Smith and Scott, *supra*, 1993).

For the binding reaction, 10⁹ transducing units (TU) of phage were incubated with 5 X 10⁶ cells in 1 ml DMEM supplemented with 10% serum. The binding was performed at 4 °C for 2 hours with gentle
25 agitation. After the binding reaction, the cells were washed four times with 1 ml of DMEM supplemented with 10% serum at room temperature for 5 to 10 minutes each time. The cells were centrifuged, and the cell pellet resuspended in 100 µl of DMEM and transferred to a new
30 tube. The phage bound to the cells were rescued by adding 1 ml of K91Kan bacterial culture (Smith and Scott, *supra*, 1993) followed by incubation at room temperature for 30 minutes. The bacteria were then

diluted in 10 ml of LB culture media supplemented with 0.2 µg/ml tetracycline, and incubated for another 30 minutes at room temperature. Serial dilutions of the bacterial culture were plated on LB plates containing 40 µg/ml tetracycline. Plates were incubated at 37 °C overnight before the colonies were counted (transducing units, TU).

The results of the phage binding assay on primary lung cells *in vitro* showed that primary lung cells bound about 60-fold more CGFECVRQCPERC (SEQ ID NO: 1; GFE-1) phage than insertless fd-tet phage. Binding of CGFECVRQCPERC (SEQ ID NO: 1; GFE-1) phage to kidney cells was also higher than fd-tet binding (t test, $p < 0.02$) although this binding was much lower than the GFE-1 (SEQ ID NO: 1) binding on lung cells. In *in vivo* studies, no specific phage homing to kidney was detected when the GFE-1 (SEQ ID NO: 1) phage was injected intravenously. The GFE-1 (SEQ ID NO: 1) phage showed no specific binding to primary brain cells *in vitro*.

GFE-1 (SEQ ID NO: 1) phage binding to lung cells was inhibited by almost 70% in the presence of 150 µM GFE-1 (SEQ ID NO: 1) peptide, whereas the same concentration of a control peptide, GRGESP (SEQ ID NO: 442), had no effect. The non-specific binding of the insertless fd-tet phage was not affected by the presence of GFE-1 (SEQ ID NO: 1) or control peptides. These results demonstrate that the selective *in vivo* binding of the GFE-1 (SEQ ID NO: 1) peptide sequence to lung endothelium can be reconstituted in an *in vitro* assay on total lung primary cells and that whole lung

cell extracts contain sufficient amounts of GFE-1 receptor for isolation.

B. The GFE-1 (SEQ ID NO: 1) peptide binds a 55 kDa
5 surface protein

To detect only the cell surface molecules that bind to GFE-1 (SEQ ID NO: 1), mouse lung endothelial surface proteins were biotinylated *in vivo*, and a total lung extract prepared. The labeled extract
10 was first fractionated on a GFE-1 (SEQ ID NO: 1) peptide affinity column; subsequently, the column was washed, and bound proteins were eluted with a GFE-1 (SEQ ID NO: 1) peptide solution.

In vivo biotinylation of endothelial cell
15 surface proteins was performed as previously described in De La Fuente et al., Am. J. Physiol. 272: L461-L470 (1997), which is incorporated herein by reference, with several modifications. Briefly, Balb/c mice were anesthetized with Avertin and perfused slowly through
20 the heart for 10 to 15 minutes with approximately 15 ml of PBS containing 0.5 mg/ml of sulfo-NHS-LC-biotin (Pierce; Rockford, IL). Well perfused lungs or control tissues such as brain were then collected and incubated on ice for 20 minutes. The tissues were then
25 homogenized for preparation of extracts as described further below.

For preparation of extracts, mouse or rat lungs were first minced and then homogenized with a Brinkman homogenizer (Brinkman; Wesbury, NY) in a
30 minimal volume (2.5 ml/g of tissue) of cold PBS containing 100 mM N-octyl- β -D-glucopyranoside

006660" 52492960

(Calbiochem; La Jolla, CA) with 1 mM phenylmethylsulfonyl fluoride (PMSF), 20 µg/ml aprotinin and 1 µg/ml leupeptin (PBS/octylglucoside). The homogenized tissue was incubated on ice for 2 hours, and then centrifuged at 12,000 x g for 30 minutes to remove cell debris. The pooled supernatants were cleared of any debris prior to affinity chromatography.

GFE-1 (SEQ ID NO: 1) affinity chromatography was performed according to the general principles established by Pytela et al. for the isolation of integrins by RGD peptide chromatography (Pytela et al., Cell 40:191-198 (1985); Pytela et al., Methods Enzym. 144:475-489 (1987), each of which is incorporated herein by reference). All steps were performed at 4 °C. Briefly, GFE-1 (SEQ ID NO: 1) or control peptides (AnaSpec; San Jose, CA) were coupled to CNBr-activated Sepharose 4B according to the manufacturer's instructions (Pharmacia Biotech; Uppsala, Sweden). The matrix contained approximately 2 mg/ml of peptide. The biotin-labeled extract from 2 mouse lungs was applied to 500 µl of the affinity matrix equilibrated in column buffer (PBS containing 50 mM octylglucoside and 1 mM PMSF). The extract was applied to the column, and the flow-through re-applied over a period of 90 minutes. The column was then washed with 20 volumes of column buffer. Elution with the synthetic GFE-1 (SEQ ID NO: 1) peptide was carried out by slowly washing the column over a period of 1 hour with 2 volumes of column buffer supplemented with 1 mg/ml of GFE-1 peptide (SEQ ID NO: 1). The remaining proteins bound to the column were eluted with 8 M urea.

05676475.092900

Eluates were concentrated 5-fold using a Centricon 10,000 MWCO column (Amicon; Beverly, MA). Aliquots of each elution were then separated by SDS-PAGE using pre-cast polyacrylamide 4-12% gels (Novex; San Diego, CA). For the experiments done with biotin-labeled extracts, the proteins were transferred to a PVDF membrane (Millipore; Bedford, MA), blotted with streptavidin-HRP (Pierce; Rockford, IL) and developed with the ECL chemiluminescence system (NEN; Boston, MA).

As shown in Figure 4 (left panel), a 55 kDa biotinylated protein was selectively eluted by GFE-1 (SEQ ID NO: 1). Prior to elution, the washes from the column showed no detectable biotinylated proteins; subsequent addition of 8 M urea eluted many biotinylated proteins that were retained non-specifically in the column. No proteins in the 55 kDa range were detected after performing the same procedure on a control peptide (GRGESF; SEQ ID NO: 442) column (Figure 4; right panel). As an additional control, an *in vivo* biotinylated brain cell extract was fractionated through a GFE-1 (SEQ ID NO: 1) peptide column under the same conditions; no biotinylated proteins from the brain extract specifically bound to the GFE-1 (SEQ ID NO: 1) peptide column (data not shown).

These results indicate that GFE-1 peptide (SEQ ID NO: 1) specifically binds to a 55 kDa lung vascular surface protein. Under non-reducing conditions, the 55 kDa protein migrated as a 110 kDa band (data not shown). Thus, these results further

indicate that the GFE receptor is a disulfide-linked homodimer.

C. The 55 kDa GFE-1 (SEQ ID NO: 1) receptor is membrane dipeptidase

5 GFE-1 (SEQ ID NO: 1) phage can selectively target rat lung blood vessels when injected in the circulation. To purify a larger amount of the 55 kDa protein than could be obtained from mouse tissues, a non-biotinylated extract was prepared from 100 frozen
10 rat lungs (Pel-Freez Biologicals; Rogers, AR). The large scale extract was prepared essentially as described above with the addition of a second extraction of the pellet with a minimal volume of PBS/octylglucoside.

15 The large scale extract was fractionated on a GFE-1 (SEQ ID NO: 1) peptide affinity column as described above using 3 ml of affinity matrix. A 55 kDa protein that was detectable by Coomassie blue staining was eluted from the column by GFE-1 peptide
20 SEQ ID NO: 1 (data not shown). This protein, which co-migrated with the 55 kDa surface protein isolated from mouse lung, was subjected to tryptic digestion and sequenced by mass spectrometry at the Harvard University Microchemistry Facility (Boston, MA) by
25 microcapillary reverse phase HPLC tandem mass spectrometry (μ LC/MS/MS) on a Finnigan LCQ quadrupole ion trap mass spectrometer.

Two tryptic peptides derived from the 55 kDa protein, YPDLIAELLR (SEQ ID NO: 444) and
30 TTPVIDGHNDLPWQMLTLFNNQLR (SEQ ID NO: 445), showed

complete identity with rat membrane dipeptidase (EC 3.4.13.19), also known as microsomal dipeptidase, dehydropeptidase-1 or MDP. Several other peptides sequences indicated the presence of rat IgG in the sample. Contamination of the sample with IgG is expected in this molecular weight range, given the abundance of IgG in an extract from unperfused lungs.

To confirm that membrane dipeptidase (MDP) is the GFE-1 (SEQ ID NO: 1) peptide binding protein, the 55 kDa protein was assayed for membrane dipeptidase activity. Samples from the affinity chromatography wash fraction and the GFE-1 (SEQ ID NO: 1) peptide eluate (Figure 4) were incubated in the presence of the specific MDP substrate Gly-D-Phe, and D-Phe detected fluorimetrically exactly as described in Heywood and Hooper, *supra*, 1995 (see, also, Keynan et al., *supra*, 1996). Briefly, the samples were first incubated at 37 °C for 3 hours with the MDP substrate Gly-D-Phe (1 mM; SIGMA). The released D-Phe was then converted to 6,6'-dihydroxy-[1,1'-biphenyl]-3,3'-diacetic acid in the presence of D-amino acid oxydase (Type I; SIGMA) and peroxidase (Type VI; SIGMA; Heywood and Hooper, *supra*, 1995). Fluorescence was measured using an *fmax* fluorescence microplate reader from Molecular Devices (Sunnyvale, CA).

Figure 5 shows a time course of the conversion of D-Phe into a fluorescent compound in samples from the affinity chromatography wash fraction and GFE-1 peptide eluate described above (Figure 4). While the wash fraction showed only a baseline level of fluorescence, the GFE-1 (SEQ ID NO: 1) peptide eluate contained high membrane dipeptidase activity as

illustrated by the time-dependent conversion of D-Phe (see Figure 5). In addition, GFE-1 (SEQ ID NO: 1) peptide eluate isolated from the rat lung extract also showed strong MDP activity (data not shown). MDP activity also was detected in the total lung extract, although the specific activity was about 600-fold higher for the GFE-1 peptide (SEQ ID NO: 1) eluate (200 nmol D-Phe/min/mg) than for the total rat lung extract (0.34 nmol D-Phe/min/mg).

10 D. GFE-1 (SEQ ID NO: 1) and GFE-2 (SEQ ID NO: 2) phage bind to cells transfected with MDP

The COS-1 cell line, which is known to have low or no detectable level of MDP activity, has been used extensively to study MDP structure and function (Keynan et al., *supra*, 1996; Keynan et al., Biochem. J. 15 326:47-51 (1997)). COS-1 cells were trasfected with murine MDP and used to assay binding to SEQ ID NOS: 1 and 2 as described below.

For transfection into COS-1 cells, a murine MDP expression vector was prepared as follows. Total mouse lung RNA was isolated using Qiagen RNA purification columns (Qiagen; Santa Clarita, CA) and used as a template for first strand cDNA synthesis with reverse transcriptase and a mixture of random hexamers and poly-dT oligonucleotides (GIBCO/BRL; Grand Island, NY). Mouse MDP cDNA (Pasqualini et al., J. Cell Biol. 130:1189-1196 (1995)) was amplified from the cDNA pool by PCR using the oligonucleotide pair:
CCGCTGGTACCGCAGATCCCTGGGGACCTTG (SEQ ID NO: 446), which
contains a Kpn I adaptor, and
TCTTTCTAGAGCTCAGAGAGCACTGGAGGAG (SEQ ID NO: 447), which

contains an Xba I adaptor, using Taq polymerase from GIBCO/BRL. The amplified 1.3 kb murine MDP cDNA was digested with Kpn I and Xba I, and inserted into the same sites of the pcDNA3 expression vector (Invitrogen; Carlsbad, CA) using DNA restriction enzymes and T4 DNA ligase from New England Biolabs (Beverly, MA). Successful cloning of the murine MDP cDNA was confirmed by DNA sequencing. Transfection of the COS-1 cells was performed with the Superfect Reagent from Qiagen as recommended by the manufacturer.

Phage binding to COS-1 cells transfected with MDP was determined as follows. Briefly, 10^7 COS-1 cells were transfected with 10 μ g of either the MDP expression vector or the vector alone. After 48 hours, cells were scraped gently from the dish, washed once, and subjected to the phage binding assay or membrane dipeptidase activity assay described above. For the phage binding assay, 5×10^6 cells and 10^{10} transducing units (TU) of phage input were used. For measurement of membrane dipeptidase activity, 10^6 cells were lysed in 100 μ l of PBS/octylglycoside without protease inhibitors. A 10 μ l aliquot of the extract was used to measure MDP activity.

As shown in Figure 6A, COS-1 cells transfected with murine MDP showed at least 15-fold higher MDP activity than mock transfected cells. Furthermore, GFE-1 (SEQ ID NO: 1) phage bound COS-1 cells transfected with MDP. As shown in Figure 6B, the GFE-1 (SEQ ID NO: 1) phage bound 4-fold more to MDP transfected cells than to mock transfected cells. Negative control phage, the fd-tet phage and a skin-homing phage (CVALCREACGEGC; SEQ ID NO: 3)

displaying a peptide with structural features similar to those of the GFE-1 (SEQ ID NO: 1) peptide, showed no specific binding to cells expressing MDP as compared to mock transfected cells. In addition, Figure 6B shows
 5 that GFE-2 (SEQ ID NO: 2) phage also bound MDP transfected cells; the binding was weaker than the GFE-1 (SEQ ID NO: 1) binding in agreement with the *in vivo* lung homing data described above. The binding of both GFE-1 (SEQ ID NO: 1) and GFE-2 (SEQ ID NO: 2)
 10 phage to MDP-transfected cells was completely inhibited by GFE-1 peptide (SEQ ID NO: 1; data not shown). These results indicate that the GFE-1 (SEQ ID NO: 1) and GFE-2 (SEQ ID NO: 2) peptides bind the same receptor.

E. GFE-1 (SEQ ID NO: 1) can inhibit MDP activity

15

The metabolism of the tripeptide glutathione involves cleavage of the tripeptide by γ -glutamyl transpeptidase to form glutamate and cysteinylglycine (Cys-Gly). The dipeptide Cys-Gly is subsequently
 20 recognized and cleaved by MDP, which cleaves only dipeptides. The amino acid sequence of glutathione is similar to the N-terminal portion of the GFE-1 peptide CGFECVRQCPCRC (SEQ ID NO: 1), with the first two first amino acids of GFE-1 being Cys-Gly.

25

GFE-1 (SEQ ID NO: 1) was assayed for the ability to inhibit hydrolysis of Gly-D-Phe by MDP. Fluorimetric detection of D-Phe was performed as described above. Figure 7 shows that GFE-1 (SEQ ID NO: 1) inhibited hydrolysis of the Gly-D-Phe substrate
 30 (0.5 mM) in a dose-dependent manner. A control cyclic peptide (CARAC; SEQ ID NO: 443) did not inhibit the enzyme.

These results indicate that GFE-1 (SEQ ID NO: 1) can act as a competitive inhibitor of MDP activity.

EXAMPLE V

5 GFE-1 (SEQ ID NO: 1) INHIBITS LUNG METASTASIS

This example demonstrates that the GFE-1 peptide SEQ ID NO: 1 can inhibit experimental lung metastasis in mice.

Experimental lung metastasis was induced in
10 mice using C8161 human melanoma cells essentially as described in Arap et al., Science 279:377-380 (1998) and Pasqualini et al., Nature Med. 11:1197-1203, each of which is incorporated herein by reference. Briefly, C8161 cells were cultured to 75% confluence and then
15 collected with 2.5 mM EDTA/PBS. The C8161 cancer cells were injected into the tail vein of female nude BALB/c mice (two months old) at a concentration of 10^5 cells per animal. Two sets of five mice were injected with the cells alone; cells with 250 µg control CARAC
20 peptide (SEQ ID NO: 443) or cells with 250 µg GFE-1 peptide (SEQ ID NO: 1). Each injection was in a total volume of 200 µl.

Aliquots of the melanoma cells and peptide mixture were cultured overnight to confirm that the
25 peptides do not affect viability of the tumor cells. Neither the GFE-1 (SEQ ID NO: 1) or CARAC (SEQ ID NO: 443) peptides exhibited toxicity to the melanoma cells (data not shown).

006260" 52492960

Mice were sacrificed five weeks after injection, and the lungs collected and weighed. As shown in Figure 8, the lung weight of mice administered GFE-1 (SEQ ID NO: 1) peptide was significantly less than the lung weight seen in mice administered melanoma cells alone ("vehicle") or melanoma cells with control peptide CARAC SEQ ID NO: 443 ("control peptide"). These results indicate that GFE-1 can inhibit lung metastasis of human cancer cells.

A similar lung metastasis experiment was performed using a GFE-1 (SEQ ID NO: 1) glutathione S-transferase fusion protein prepared as described in Rajotte et al., J. Clinical Invest. 102:430-437 (1998), which is incorporated herein by reference. The GFE-1 (SEQ ID NO: 1) glutathione S-transferase fusion protein inhibited the increase in lung weight resulting from injection of C8161 human melanoma cells in a manner similar to the results observed with peptide SEQ ID NO: 1 as shown in Figure 8.

These results indicate that GFE-1 (SEQ ID NO: 1) can inhibit lung metastasis and that MDP serves as a receptor for metastasizing tumor cells on lung vasculature.


EXAMPLE VI

PREPARATION OF Z-2-ACYLAMINO-3-MONOSUBSTITUTED PROPENOATE MDP-BINDING HOMING MOLECULES


This example demonstrates several methods for preparation of MDP-binding molecules having Structure 1.

A. Method for preparation of an MDP-binding homing molecule having Structure 1

An MDP-binding homing molecule having Structure 1 is made by condensing directly the appropriate 2-keto acid and amide as follows:



+




wherein R^2 and R^3 are as defined. The general reaction conditions involve mixing approximately 14: 1 parts of the acid to the amide in an inert solvent such as toluene or methyl isovalerate and heating at reflux with azeotropic removal of water for 3-48 hours, preferably 5-24 hours. The solution when cooled normally yields the product in crystalline form. If desired, the product is isolated using a base extraction process. The product is recrystallized using generally known techniques.

An optional modification of this procedure requires an additional small amount of p-toluenesulfonic acid as catalyst during the reaction.


006260" 54494360

B. Method for preparation of an MDP-binding homing molecule having Structure 1

An MDP-binding homing molecule having Structure 1 is prepared using an α -amino acid, t-butyl ester in reaction with an acid chloride as follows:






+




The reaction takes place in the presence of base, such as triethylamine, in a solvent such as methylene chloride. The resulting N-acylated product is then oxidized by treatment with t-butyl hypochlorite followed by addition of sodium methoxide. This yields the 2-methoxy derivative or its elimination product, the α,β -unsaturated ester. Further treatment with anhydrous hydrochloric acid converts either the 2-methoxy derivative or the unsaturated ester (or the mixture of both) to the desired α,β -unsaturated free acid.

006260" 52492850



Some compounds in which R^3 has a terminal substituent
 5 which is an amino, quaternary nitrogen, thiol or
 carboxyl, derivative can be made most conveniently
 from an intermediate having a terminal bromine. In
 this case the intermediate has the structure




10 where n is the number of carbons in the desired
 hydrocarbon chain (e.g., from 3-7).


In order to prepare R^3 having a terminal trimethylammonium substituent, the bromo intermediate is reacted with trimethylamine; to yield the amino, the bromo intermediate is reacted with ammonia; the
 5 guanidino reaction is with guanidine; to prepare the thio derivatives, including 2-amino-2-carboxyethylthio, the bromo compound is reacted with cysteine HCl, or the appropriate mercaptan. Derivatized amino, such as formamidino, ureido, and acylamide (acetamido) are
 10 made from the compounds having an amino group by reacting with o-benzyl formimidate HCl, potassium cyanate and the appropriate acyl anhydride (acetic anhydride) respectively.

C. Method for preparation of an MDP-binding homing
 15 molecule having Structure 1

Another route for preparing compounds when R^3 is a terminally substituted thio derivative utilizes a chloroketo ester intermediate as follows:



20 in reaction with the desired amide,



in toluene at reflux in the presence of a catalytic amount of p-toluenesulfonic acid. The resulting

intermediate is hydrolyzed to the acid; the chloro group is then displaced in reaction with the appropriate mercaptan. This reaction is valuable since it permits use of the chiral amide, thereby preparing a functionalized side chain. Alternatively, the mixture of Z+E isomers prepared after the mercaptan condensation is directly isomerized into the Z form by adding acid to a pH of about 3, and heating to about 90 °C for 30 minutes. Only the Z form remains, and recovery is simple and straight-forward.

D. Preparation of Sodium Z-7-(L-amino-2-carboxyethylthio)-2- (2,2-dimethylcyclopropane carboxamido)-2-heptenoic acid

1. Grignard preparation of ethyl-7-chloro-2-oxoheptanoate

Equimolar amounts (8 moles each) of I-bromo-5-chloropentane and magnesium are reacted in tetrahydrofuran (THF) (960 ml) at 25 °C. The flask is charged with the magnesium in the THF, and the bromochloropentane added over 1 hour, then aged 2 hours. After the reaction is judged complete, the reaction solution is added (cooled -15 °C, to 16 moles of diethyloxalate in 1856 ml THF, while maintaining the temperature at 10 degrees C. 3N HCl is added to quench, keeping the temperature below 25 °C. After stripping solvents, the calculated yield is 48.8% of the ethyl-1-chloro-6-oxoheptenoate.

2. Condensation and Hydrolysis

S-2,2-dimethylcyclopropyl carboxamide (1017 g),

006260" 543350

2143.6 g of ethyl-7-chloro-2-ketoheptanoate, 9 liters of toluene and 12 g of p-toluene sulfonic acid are charged to a 22 L flask, and heated to reflux with stirring. After 23 hours, liquid chromatography shows the expected product ratio, and 4 L of toluene are removed under slightly reduced pressure. The pot is charged with water, neutralized to pH 7 with 2 N NaOH, and vacuum distilled leaving a final pot volume of about 5 liters. This is hydrolyzed by adding 1760 g of 50% aqueous NaOH (4 liters water) and stirring overnight. The flask is charged with 4 L methylene chloride, and pH adjusted to 8.8 using HCl. Unreacted amide crystallizes out. The organic layers are separated from water, and then evaporated. The gummy residue is dissolved in 8 L water containing 720 g, 50% NaOH, and to this solution is charged 1818 g L-cysteine Hcl, H₂O, 2 kg ice, 2484 g 50% NaOH and 1 L water. The pH of this solution, after aging overnight at room temperature, is adjusted to 3.0 with concentrated HCl, and the resulting gummy suspension is heated to 95 °C to afford a clear solution. After 30 minutes, no E isomer is detected by lc. After work-up and purification, the overall yield is 2060 g, 87% yield. This material is recrystallized from acetonitrile. 1500 g of the recrystallized material is dissolved in 6 L water and 910 ml 3.88 N NaOH, then neutralized to pH 7, and lyophilized to afford 1569 g (98.6%) of the title compound. Analysis: Calcd,: C, 50.52; H, 6.62; N, 7.36; S, 8.43; Na, 6.04. Found: C, 50.71; H, 6.78; N, 7.49; S, 8.52; Na, 5.92

All journal article, reference, and patent citations provided above, in parentheses or otherwise,

whether previously stated or not, are incorporated herein by reference.

Although the invention has been described
5 with reference to the examples provided above, it
should be understood that various modifications can be
made without departing from the spirit of the
invention. Accordingly, the invention is limited only
by the claims.

006260" 52492950

TABLE 2

5 PEPTIDES FROM PHAGE RECOVERED FROM LUNG

10	CIKGNVNC (32)	CRHESSSC (33)
	CLYIDRRC (34)	CYSLGADC (35)
	CSKLMMTC (349)	CGFELETC* (2)
	CNSDVDLC (36)	CVGNLSMC* (37)
	CEKKLLYC (38)	CKGQRDFC* (39)
15	CTFRNASC (40)	CNMGLTRC* (41)
	CHEGYLTC* (42)	CGTFGARC (43)
	CIGEVEVC* (16)	CRISAHPC (44)
	CLRPYLNC* (45)	CSYPKILC (46)
	CMELSKQC* (47)	CSEPSGTC (48)
20	CGNETLRC (49)	CTLSNRFC (50)
	CMGSEYWC (51)	CLFSDENC* (52)
	CAHQHIQC (53)	CKGQGDWC (54)
	CAQNMLCC (55)	CWRGDRKIC* (56)
	CLAKENVVC* (13)	CIFREANVC (57)
25	CRTHGYQGC (58)	CERVVGSSC (59)
	CKTNHMESC (60)	CYEEKSQSC (61)
	CKDSAMTIC (62)	CTRSTNTGC (63)
	CMSWDAVSC* (64)	CKWSRLHSC* (65)
	CMSPQRSDC (66)	CLHSPRSKC (67)
30	CPQDIRRNC (68)	CLYTKEQRC (69)
	CQTRNFAQC (70)	CTGHLSTDC (71)
	CQDLNIMQC (72)	TRRTNNPLT (73)
	CGYIDPNRISQC (74)	CTVNEAYKTRMC* (75)
	CRLRSYGTLSLC* (76)	CAGTCATGCNGVC (77)
35	CADYDLALGLMC (78)	CPKARPAPQYKC (79)
	CSSHQGGFQHGC (80)	CQETRTEGRKKC (81)
	CRPWHNQAHTC* (82)	CSFGTHDTEPHC (83)

006260" 52492960

TABLE 2 (cont.)

	CSEAASRMIGVC*	(84)		CWEEHPSIKWWC*	(85)
	CWDADQIFGIKC	(86)		CVDSQSMKGLVC	(87)
	CRLQTMGQGQSC	(88)		CRPAQRDAGTSC	(89)
5	CGGRDRGTYGPC	(90)		CGEVASNERIQC	(91)
	CNSKSSAELEKC	(92)		CVLNFKNQARDC	(93)
	CRGKPLANFEDC	(94)		CEGHSMRGYGLC	(95)
	CRDRGDRMKSLC	(96)		CDNTCTYGVDDC	(97)
	CSAHSQEMNVNC	(98)		CGAACGVGCRGRC	(99)
10	CGFECVRQCPERC*	(1)		CLVGCRLSCGGE	(100)
	CRSGCVEGCGGRC	(101)		CIARCGGACGRHC	(102)
	CGGECGWECEVSC	(103)		CGVGCPGLCGGAC*	(104)
	CKWLCLLLCAVAC	(105)		CSEGCGPVCWPEC	(106)
	CGAACGVGCGGRC	(107)		CSGSCRRGCGIDC	(108)
15	CGASCALGCRAVC	(109)		CDTSCENNCQGPC	(110)
	CSRQCRGACGQPC	(111)		CYWWCDGVICALQC	(112)
	CAGGCAVRCGGTC	(113)		CGGACGGVCTGGC*	(114)
	CGRPCVGECRMGC	(115)		CLVGCEVGCSPAC	(116)
	CPRTCGAACASPC	(117)		CRGDCGIGCRRLC	(118)
20	CCFTNFDCYLGC	(435)			

Parentheses contain SEQ ID NO:.

* indicates sequences isolated more than once.

TABLE 3

PEPTIDES FROM PHAGE RECOVERED FROM PANCREAS

5

	EICQLGSCT	(119)	WRCEGFNCQ	(120)
10	RKCLRPDCG	(121)	SWCEPGWCR*	(4)
	LACFVTGCL	(122)	GLCNGATCM*	(123)
	DMCWLIGCG	(124)	SGCRTMVCV	(125)
	QRCPRSFCL	(126)	LSCAPVICG	(127)
	RECTNEICY	(128)	NECLMISCR	(129)
15	SCVFCDWLS	(130)	WACEELSCF	(131)
	QNCPVTRCV	(132)	CATLTNDEC	(133)
	CDNREMSC	(134)	CFMDHSNC	(135)
	CGEYGREC	(136)	CHMKRDRTC	(137)
	CKKRLLNVC	(138)	CLDYHPKC	(139)
20	CMTGRVTC	(140)	CNKIVRRC	(141)
	CPDLLVAC	(142)	CSDTQSIGC	(143)
	CSKAYDLAC	(144)	CSKKGPSYC	(145)
	CTLKHTAMC	(146)	CTQHIANC	(147)
	CTTEIDYC	(148)	CVGRSGELC	(149)

25 Parentheses contain SEQ ID NO:.

* indicates sequences isolated more than once.

006260" 549260

TABLE 4

PEPTIDES FROM PHAGE RECOVERED FROM GUT

5		
	YAGFFLV* (150)	RSGARSS (151)
	CVESTVA (152)	SRRQPLS* (153)
	SKVWLLL (154)	QVRRVPE (155)
10	YSGKWGW* (156)	MVQSVG (157)
	LRAVGRA (158)	MSPQLAT* (159)
	GAVLPGE (160)	WIEEAER* (161)
	LVSEQLR (162)	RGDRPPY (163)
	VRRGSPQ (164)	RVRGPER (165)
15	GISAVLS* (166)	GGRGSWE (167)
	GVSASDW (168)	FRVRGSP (169)
	SRLSGGT (170)	WELVARS (171)
	MRRDEQR (172)	GCRCWA (173)
	LSPPYMW (7)	LCTAMTE (18)

20 Parentheses contain SEQ ID NO:.

* indicates sequences isolated more than once.

006260" 5249/950

TABLE 5

PEPTIDES FROM PHAGE RECOVERED FROM SKIN

5			
	CYADCEGTCGMVC	(174)	CWNICPGGCRA LC* (175)
10	GPGCEE ECQPAC	(176)	CKGTCVLGCSEEC* (177)
	CSTLCGLRCMGTC	(178)	CMPRCGVNCKWAC (179)
	CVGACDLKCTGGC	(180)	CVALCREACGEGC* (3)
	CSSGCSKNCLEMC*	(181)	CGRPCRGGCAASC (182)
	CQGGCGVSCPIFC	(183)	CAVRCDGSCVPEC* (184)
15	CGFGCSGSCQM QC	(185)	CRVVCADGCRFIC (186)
	CTMGCTAGCAFAC	(187)	CEGKCGLTCECTC (188)
	CNQGCSGSCDVMC	(189)	CASGCSESCYVGC (190)
	CGGGCQWGCAGEC*	(191)	CSV RCKSVCIGLC (192)
	CPSNCVALCTSGC	(193)	CVEGCSSGCGPGC (194)
20	CRVVCADGCRLIC	(195)	CSTLCGLRCMGTC (196)
	CFTFCEYHCQLTC	(197)	CVDVCCDGC PVCC (437)
	RVPLSGDVEH	(438)	LRVMSFTSGQ (439)
	RFSVGS LFGS	(440)	CGATCEMQCPSGC (441)

Parenttheses contain SEQ ID NO:.

25 * indicates sequences isolated more than once.

005250"52492350

TABLE 6

PEPTIDES FROM PHAGE RECOVERED FROM RETINA

5

	CRRIWYAVC (198)	CSAYTTSPC (199)
	CSCFRDVCC* (5)	CTDKSWPC (200)
	CTDNRVGS (201)	CTIADFPC (202)
10	CTSDISWWDYKC (203)	CTVDNELC (204)
	CVGDCIGSCWMFC (205)	CVKFTYDC ² (206)
	CVSGHLNC (207)	CYGESQQMC (208)
	CYTGETWTC (209)	CAVSIPRC (210)
	CDCRGDCFC (211)	CDSLCCGACAARC (212)
15	CERSQSKGVHHC (213)	CFKSTLLC (214)
	CFWHNRAC (215)	CGDVCPSECPGWC (216)
	CGEFKVGC* (14)	CGLDCLGDCSGAC (217)
	CGPGYQAQCSLRC (218)	CGSHCGQLCKSLC (219)
	CHMGCVSPCAYVC (220)	CILSYDNPC (221)
20	CISRPYFC (222)	CKERLEYTRGVC (223)
	CKERPSNGLSAC (224)	CKPFRTEC (225)
	CKSGCGVACRHMC (226)	CLKPGGQEC (227)
	CMDSQSSC* (228)	CMNILSGC (229)
	CNIPVTTPIFGC (230)	CNQRTNRESGNC* (231)
25	CNRKNSNEQRAC (232)	CNRMEMPC (233)
	CQIRPIDKC (234)	CAIDIGGAC (235)
	CGRFDTAPQRC (236)	CKRANRLSC (237)
	CLLNYTYC* (238)	CLNGLVSMC (239)
	CMSLGNNC (240)	CNRNRMTPC (241)
30	CQASASDHC* (242)	CQLINSSPC (243)
	CQRVNSVENASC (244)	CRKEHYPC (245)
	CRRHMERC (246)	CSGRPFKYC (247)
	CTHLVTLC (248)	CTSSPAYNC (249)
	CVTSNLRVC* (250)	CWDSGSHIC (251)
35	CERSHGRLC ¹ (252)	CGNLLTRRC (253)
	CINCLSQC (254)	CLRHDFYVC (255)

TABLE 6 (cont.)

	CNSRSENC (256)	CRYKGPSC (257)	
	CSHHDNTNC (258)	CSRWYTTC (259)	
	CYAGSPLC (260)	CQTTSWNC* (261)	
5	CQWSMNVC (262)	CRARIRAEDISC* (263)	
	CRDVVSVIC (6)	CRREYSAC (264)	

Blast-Search:

- ¹rat retinal guanylcyclase precursor EC4.6.1.2
- 10 ²rat glutamate receptor subunit epsilon 1 precursor
- No stainings for any motif tested, only evidence for preferential homing are the RDV-containig phages in comparison to an ampicillin-phage.

Parentheses contain SEQ ID NO:.

- 15 * indicates sequences isolated more than once.

TABLE 7

5 PEPTIDES FROM PHAGE RECOVERED FROM PROSTATE

	EVQSAKW (265)	KRVYVLG (266)
10	GRLSVQV (267)	WKPASLS (268)
	FAVRVVG (269)	LVRPLEG (270)
	GFYRMLG (271)	EGRPMVY (272)
	GSRSLGA (273)	RVWQGDV (274)
	GDELLA (275)	FVWLVGs (276)
15	GSEPMFR (277)	VSFLEYR (22)
	WHQPL (278)	SMSIARL* (21)
	RGRWLAL* (279)	QVEEFPC (280)
	LWLsgNW (281)	GPMLsVM (282)
	WTFLERL (283)	VLPGGQW (284)
20	REVKES (285)	RTPAAVM (286)
	GEWLGEc (287)	PNPLMPL (288)
	SLWYLGA (289)	YVGGWEL (290)

Parentheses contain SEQ ID NO:.

* indicates sequences isolated more than once.

005260 "543"960

TABLE 8

5 PEPTIDES FROM PHAGE RECOVERED FROM OVARY

	EVRSRLS* (10)	RVGLVAR* (11)
	AVKDYFR (291)	GVRTSIW (292)
10	RPVGMRK (293)	RVRLVNL (294)
	FFAAVRS (295)	KLVNSSW (296)
	LCERVWR (297)	FGSQAFV (298)
	WLERPEY (299)	GGDVMWR (300)
	VRARLMS (301)	TLRESGP (302)

15 Parentheses contain SEQ ID NO:.

* indicates sequences isolated more than once.

005250 "549360

TABLE 9

PEPTIDES FROM PHAGE RECOVERED FROM LYMPH NODE

5	WGCKLRFC	(303)	MECIKYSCL	(304)
	GICATVKCS	(305)	PRCQLWACT	(306)
	TTCMSQLCL	(307)	SHCPMASLC	(308)
10	GCVRRLLCN	(309)	TSCRLFSCA	(310)
	KYCTPVECL	(311)	RGCNGSRCS	(312)
	MCPQRNCL	(313)	PECEGVSCI	(314)
	AGCSVTVCG*	(315)	IPCYWESCR	(316)
	GSCSMFPCS*	(317)	QDCVKRPCV	(318)
15	SECAYRACS*	(319)	WSCARPLCG*	(320)
	SLCGSDGCR	(321)	RLCPSSPCT	(322)
	MRCGFSGCT	(323)	RYCYPDGCL	(324)
	STCGNWTCT	(325)	LPCTGASCP	(326)
	CSCTGQLCR	(327)	LECRRWRCD	(328)
20	GLCQIDECR*	(329)	TACKVAACH	(330)
	DRCLDIWCL*	(331)	XXXQGSPCL	(332)
	PLCMATRCA*	(333)	RDCSHRSCE*	(334)
	NPCLRAACI*	(335)	PTCAYGWCA*	(336)
	LECVANLCT*	(337)	RKCGEEVCT*	(338)
25	EPCTWNACL*	(339)	LVCPGTACV	(340)
	LYCLDASCL	(341)	ERCPMAKCY	(342)
	LVCQGSPCL	(343)	QQCQDPYCL*	(344)
	DXCXDIWCL	(345)	QPCRSMVCA	(346)
	KTCVGVRV	(347)	WSCHEFMCR	(348)
30	LTCWDWSCR	(350)	SLCRLSTCS	(351)
	KTCAGSSCI	(352)	VICTGRQCG	(353)
	NPCFGLLV	(354)	SLCTAFNCH	(355)
	RTCTPSRCM	(356)	QSCLWRICI	(357)
	QYCWSKGCR	(358)	LGCFPSWCG	(359)

006260" 52492360

TABLE 9 (cont.)

	VTCSEWCL	(360)	RLCSWGGCA	(361)
	STCISVHCS	(362)	EVCLVLSCQ	(363)
	IACDGYLCG	(364)	RDCVKNLCR	(365)
5	XGCIYQKRCT	(366)	LGCFXSWCG	(367)
	IRCWGGRCs	(368)	IPCSLLGCA	(369)
	AGCVQSQCY	(370)	PRCWERVCS	(371)
	KACFGADCX	(372)	TLCPLVACE	(373)
	SACWLSNCA	(374)	SECYTGSCP	(375)
10	GLCQEHRCW	(376)	VECGFSASF	(377)
	EDCREWGCR	(378)	HWCRLACR	(379)

Parentheses contain SEQ ID NO:.

* indicates sequences isolated more than once.

15 X = Not known.

005250"52492960

TABLE 10

PEPTIDES FROM PHAGE RECOVERED FROM ADRENAL GLAND

5			
	HKGQVYS	(380)	FSDVHFW* (381)
	RGIFVSS	(382)	PKVKLSE (383)
10	LRFWQES	(384)	IWTVVGQ (385)
	DKVGLSV	(386)	SETWRQF (387)
	LDGMIVK	(388)	RYPLAGG (389)
	FTDGEDK	(390)	RSTEHMS (391)
	SGRRHEL	(392)	LMLPRAD* (27)
15	SSSRVRS	(393)	YHRSVGR (394)
	PLLRPPH	(395)	SDKLGFV* (396)
	LPRYLLS	(28)	AGSRTNR (397)
	ITQLHKT	(398)	ARCLVYR (399)
	GYVAVMT*	(400)	GLQVKWV (401)
20	IFTPGWL	(402)	KQTSRFL (403)
	R(Y/F)LLAGG	(404)	

Parentheses contain SEQ ID NO:.

* indicates sequences isolated more than once.

005250"52492960

TABLE 11

PEPTIDES FROM PHAGE RECOVERED FROM LIVER

5			
	ARRGWTL	(405)	SRRFVGG* (406)
	QLTGGCL	(407)	ALERRSL (408)
10	KAYFRWR	(409)	RWLAWTV (410)
	VGSFIYS*	(411)	LSLLGIA (412)
	LSTVLWF	(413)	SLAMRDS (414)
	GRSSLAC	(415)	SELLGDA (416)
	CGGAGAR	(417)	WRQNMPL* (418)
15	DFLRCRV	(419)	QAGLRCH (420)
	RALYDAL	(421)	WVSVLGF (422)
	GMAVSSW	(423)	SWFFLVA (424)
	WQSVVRV	(425)	VKSVCRT* (12)
	CGNGHSC	(426)	AEMEGRD (427)
20	SLRPDNG	(428)	PAMGLIR (429)

Parentheses contain SEQ ID NO:.

* indicates sequences isolated more than once.

006250 5432960

We claim:

1. A method of identifying a MDP-binding
homing molecule that selectively homes to lung
5 endothelium, comprising:

(a) contacting membrane dipeptidase (MDP)
with one or more molecules; and

(b) determining specific binding of a
molecule to said MDP,

10 wherein the presence of specific binding
identifies said molecule as a MDP-binding homing
molecule that selectively homes to lung endothelium.

2. The method of claim 1, wherein said
MDP is substantially purified.


15 3. The method of claim 2, wherein said
substantially purified MDP is immobilized to a
support.

4. The method of claim 1, wherein said
MDP is human MDP having SEQ ID NO: 448.

20 5. A method of selectively directing a
moiety to lung endothelium in a subject, comprising
administering to said subject a conjugate comprising
a moiety linked to a MDP-binding homing molecule
identified by the method of claim 1,
25 whereby said moiety is selectively directed
to lung endothelium in said subject.

006260" 5475" 092900


6. The method of claim 5, wherein said MDP-binding homing molecule is a peptide comprising the sequence:



5 wherein X_1 and X_2 each is 1 to 10 independently selected amino acids.

7. The method of claim 6, wherein said MDP-binding homing peptide comprises a sequence selected from the group consisting of CGFECVRQCPCRC
10 (SEQ ID NO: 1) and CGFELETC (SEQ ID NO: 2).

8. The method of claim 5, wherein said MDP-binding homing molecule comprises the following Structure 1:



15 wherein R^2 and R^3 are hydrocarbon radicals in the range respectively of 3-10 and 1-15 carbon atoms; in either one of these R^2 or R^3 hydrocarbon chains 1-6 hydrogens may be replaced by halogens or a nonterminal
20 methylene may be replaced by oxygen or sulfur, including oxidized forms of the latter; additionally, a terminal hydrogen in R^3 can also be replaced by hydroxyl or thiol, which

006260" 52492860

may be acylated or carbamoylated; or the hydrogen can be replaced by amino, which may be derivatized as in an acylamino, ureido, amidino, guanidino, or alkyl or substituted amino group, including quaternary nitrogen grouping; or, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, or cyano; or combinations thereof, such as a terminal amino acid grouping; and R¹ is hydrogen or lower alkyl (C₁₋₆) or dialkylaminoalkyl, or a pharmaceutically acceptable cation.

9. The method of claim 8, wherein said MDP-binding homing molecule is 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropane carboxamido)-2-heptenoic acid.

10. The method of claim 8, wherein R² is branched alkyl or cycloalkyl with a limitation that the carbon adjacent to the carbonyl cannot be tertiary.

11. The method of claim 10, wherein R³ is n-alkyl (1-9 carbons) or n-alkyl (1-9 carbons) having a terminal substituent which is a quaternary nitrogen, amine derivative or amino acid derived group.

12. The method of claim 11, wherein R² is 2,2-dimethylcyclopropyl or 2,2-dichlorocyclopropyl and R³ is a hydrocarbon chain of 3 to 7 carbon atoms without a terminal substituent or having a

006260" 52492960

terminal substituent which is
trimethylammonium, amidino, guanidino or
2-amino-2-carboethylthio.

13. The method of claim 12, wherein
5 said MDP-binding homing molecule is selected
from the group consisting of:

Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-
trimethylammonium hydroxide-2-octenoic acid
inner salt;

- 10 Z-2-(2,2-dichlorocyclopropanecarboxamido)-8-
trimethylammonium hydroxide-2-octenoic acid
inner salt;

Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-
guanidino-2-octenoic acid;

- 15 Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-
guanidino-2-octenoic acid;

Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-
ureido-2-octenoic acid;

- 20 Z-8-(1-2-amino-2-carboxyethylthio)-2-(2,2-
dimethylcyclopropanecarboxamido)-2-octenoic
acid;

Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-
octenoic acid (racemic and dextrorotatory
forms);

- 25 Z-2-(2,2-dichlorocyclopropanecarboxamido)-2-
octenoic acid;

7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxamido)-2-heptenoic acid; and

6-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxamido)-2-hexenoic acid.

14. The method of claim 5, wherein said moiety is a gene therapy vector.

10 15. The method of claim 5, wherein said moiety is a drug.

16. A method of reducing or preventing lung metastasis in a subject having cancer, comprising administering to said subject a membrane dipeptidase (MDP)-binding homing molecule.

17. The method of claim 16, wherein said MDP-binding homing molecule is a lung homing peptide comprising the sequence:

X_1 -G-F-E- X_2 (SEQ ID NO: 17)

20 wherein X_1 and X_2 each is 1 to 10 independently selected amino acids.

18. The method of claim 17, wherein said MDP-binding homing peptide comprises a sequence selected from the group consisting of CGFECVRQCPERC (SEQ ID NO: 1) and CGFELETC (SEQ ID NO: 2).


19. The method of claim 18, wherein said MDP-binding homing peptide is a peptide selected from the group consisting of CGFECVRQCPERC (SEQ ID NO: 1)

09676475-092900

and CGFELETC (SEQ ID NO: 2).

20. The method of claim 16, wherein said MDP-binding homing molecule comprises the following Structure 1:

5



wherein R² and R³ are hydrocarbon radicals in the range respectively of 3-10 and 1-15 carbon atoms; in either one of these R² or R³ hydrocarbon chains 1-6 hydrogens may be replaced by halogens or a nonterminal methylene may be replaced by oxygen or sulfur, including oxidized forms of the latter; additionally, a terminal hydrogen in R³ can also be replaced by hydroxyl or thiol, which may be acylated or carbamoylated; or the hydrogen can be replaced by amino, which may be derivatized as in an acylamino, ureido, amidino, guanidino, or alkyl or substituted amino group, including quaternary nitrogen grouping; or, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, or cyano; or combinations thereof, such as a terminal amino acid grouping; and R¹ is hydrogen or lower alkyl (C₁₋₆) or dialkylaminoalkyl, or a pharmaceutically

09676475-092900

acceptable cation.

21. The method of claim 20, wherein
said MDP-binding homing molecule is 7-(L-2-
amino-2-carboxyethylthio)-2-(2,2-
5 dimethylcyclopropane carboxamido)-2-heptenoic
acid.

22. The method of claim 20, wherein
 R^2 is branched alkyl or cycloalkyl with a
limitation that the carbon adjacent to the
10 carbonyl cannot be tertiary.

23. The method of claim 22, wherein
 R^3 is n-alkyl (1-9 carbons) or n-alkyl (1-9
carbons) having a terminal substituent which
is a quaternary nitrogen, amine derivative or
15 amino acid derived group.

24. The method of claim 23, wherein
 R^2 is 2,2-dimethylcyclopropyl or
2,2-dichlorocyclopropyl and R^3 is a
hydrocarbon chain of 3 to 7 carbon atoms
20 without a terminal substituent or having a
terminal substituent which is
trimethylammonium, amidino, guanidino or
2-amino-2-carboethylthio.

25. The method of claim 24, wherein
25 said MDP-binding homing molecule is selected
from the group consisting of:

Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-
trimethylammonium hydroxide-2-octenoic acid
inner salt;

006260" 52492650

Z-2-(2,2-dichlorocyclopropanecarboxamido)-8-trimethylammonium hydroxide-2-octenoic acid inner salt;

5 Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-guanidino-2-octenoic acid;

Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-guanidino-2-octenoic acid;

Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-ureido-2-octenoic acid;

10 Z-8-(1-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid;

15 Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid (racemic and dextrorotatory forms);

Z-2-(2,2-dichlorocyclopropanecarboxamido)-2-octenoic acid;

20 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxamido)-2-heptenoic acid; and

6-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxamido)-2-hexenoic acid.

26. The method of claim 16, wherein
25 said MDP-binding homing molecule is an MDP inhibitor.

006260 52492960

27. The method of claim 26, wherein said MDP inhibitor exhibits a K_i against MDP of at most 1000 nM.

28. The method of claim 27, wherein said
5 MDP inhibitor exhibits a K_i against MDP of at most 100 nM.

29. The method of claim 28, wherein said MDP inhibitor exhibits a K_i against MDP of at most 1 nM.

10 30. The method of claim 16, wherein said cancer is melanoma.

31. A method of reducing or preventing lung metastasis in a subject having cancer,
15 comprising administering to said subject a membrane dipeptidase (MDP) negative regulatory factor.

32. The method of claim 31, wherein said MDP negative regulatory factor is a soluble MDP polypeptide.

20 33. The method of claim 31, wherein said MDP negative regulatory factor is an antibody that selectively reacts with MDP.

34. A method of reducing or preventing cell homing to lung endothelium in a subject,
25 comprising administering to said subject a membrane dipeptidase (MDP) negative regulatory factor.

35. The method of claim 34, wherein said MDP negative regulatory factor is a soluble MDP polypeptide.

006260" 52492350

36. The method of claim 34, wherein said MDP negative regulatory factor is an antibody that selectively reacts with MDP.

37. A method of identifying a molecule
5 that reduces or prevents lung metastasis, comprising the steps of:

(a) contacting membrane dipeptidase (MDP) with one or more molecules; and

(b) determining MDP activity in the
10 presence of said molecule as compared to a control value,

wherein diminished MDP activity in the presence of said molecule identifies said molecule as a molecule that reduces or prevents lung metastasis.

38. The method of claim 37, wherein said
15 MDP is substantially purified.

39. The method of claim 37, wherein MDP activity is determined by release of D-Phe from Gly-D-Phe.

40. The method of claim 37, further
20 comprising the steps of:

(c) administering said molecule to a subject having cancer; and

(d) assaying lung metastasis in said
25 subject as compared to a control level of metastasis.

00660" 52492350

ABSTRACT OF THE INVENTION**METHODS OF IDENTIFYING LUNG HOMING MOLECULES
USING MEMBRANE DIPEPTIDASE**

The present invention provides a method of
5 identifying a membrane dipeptidase (MDP)-binding
homing molecule that selectively homes to lung
endothelium. The method includes the steps of
contacting MDP with one or more molecules; and
determining specific binding of a molecule to the
10 MDP, where the presence of specific binding
identifies the molecule as a MDP-binding homing
molecule that selectively homes to lung endothelium.
Such MDP-binding homing molecules can be linked to a
moiety and, when administered to a subject as a
15 conjugate, can selectively direct the moiety to lung
endothelium in the subject.

006360" 52494960




Figure 1




Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 3A





Figure 3B



Column: GFE-1 Peptide

Control Peptide

Figure 4B

Figure 4A




Figure 5




Figure 6A




Figure 6B




Figure 7




Figure 8




Figure 9A




Figure 9B

DECLARATION FOR PATENT APPLICATION

As the below-named inventors, we hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled METHODS OF IDENTIFYING LUNG HOMING MOLECULES USING MEMBRANE DIPEPTIDASE, the specification of which

_____ is attached hereto as Attorney Docket No. _____).

XX was filed on February 26, 1999, as Application Serial No. 09/258,754 (Attorney Docket No. P-LJ 3443)

and was amended on (or amended through) _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to myself to be material to patentability as defined in Title 37, Code of Federal Regulations, Sec. 1.56.

Under Sec. 1.56, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and (1)

006250-5492980

Inventors: Rajotte et al.
Serial No.: 09/258,754
Filed: February 26, 1999
Page 2 of 3

It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or (2) It refutes, or is inconsistent with, a position the applicant takes in: (I) Opposing an argument of unpatentability relied on by the U.S. Patent and Trademark Office, or (ii) Asserting an argument of patentability.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
09/042,107	March 13, 1998	Pending

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors: Rajotte et al.
Serial No.: 09/258,754
Filed: February 26, 1999
Page 3 of 3

Full name of first inventor: Daniel Rajotte

Inventor's signature: 

Date: March 26, 1999

Residence: Del Mar, California, USA

Citizenship: Canada

Post Office Address: 517 1/2 Stratford Court
Del Mar, CA, 92014 USA

Full name of second inventor: ~~Renata Pasqualini~~

Inventor's signature: 

Date: 4/14/99

Residence: Solana Beach, California, USA

Citizenship: Brazil

Post Office Address: 707 S. Sierra Ave., #29
Solana Beach, CA, 92075 USA

Full name of third inventor: ~~Erkki Ruoslahti~~

Inventor's signature: 

Date: 4-15-99

Residence: Rancho Santa Fe, California, USA

Citizenship: USA

Post Office Address: Post Office Box 1054
Rancho Santa Fe, CA, 92067 USA

006260" 5492960

SEQUENCE LISTING

<110> Ruoslahti, Erkki
 Pasqualini, Renata
 Rajotte, Daniel

<120> Methods of Identifying Lung Homing Molecules Using
 Membrane Dipeptidase

<130> P-L 4377

<140>

<141>

<150> 09/042,107

<151> 1998-03-13

<160> 452

<170> PatentIn Ver. 2.0

<210> 1

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 1

Cys	Gly	Phe	Glu	Cys	Val	Arg	Gln	Cys	Pro	Glu	Arg	Cys
1				5					10			

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 2

Cys	Gly	Phe	Glu	Leu	Glu	Thr	Cys
1				5			

<210> 3

<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 3
Cys Val Ala Leu Cys Arg Glu Ala Cys Gly Glu Gly Cys
1 5 10

<210> 4
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 4
Ser Trp Cys Glu Pro Gly Trp Cys Arg
1 5

<210> 5
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 5
Cys Ser Cys Phe Arg Asp Val Cys Cys
1 5

<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 6
Cys Arg Asp Val Val Ser Val Ile Cys

1

5

<210> 7

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 7

Leu Ser Pro Pro Tyr Met Trp

1

5

<210> 8

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 8

Gly Ile Gly Glu Val Glu Val Cys

1

5

<210> 9

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 9

Tyr Ser Gly Lys Trp Gly Lys

1

5

<210> 10

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 10

Glu Val Arg Ser Arg Leu Ser
1 5

<210> 11

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 11

Arg Val Gly Leu Val Ala Arg
1 5

<210> 12

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 12

Val Lys Ser Val Cys Arg Thr
1 5

<210> 13

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 13

Cys Leu Ala Lys Glu Asn Val Val Cys
1 5

<210> 14

<211> 8

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 14
Cys Gly Glu Phe Lys Val Gly Cys
1 5

<210> 15
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 15
Cys Thr Leu Arg Asp Arg Asn Cys
1 5

<210> 16
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 16
Cys Ile Gly Glu Val Glu Val Cys
1 5

<210> 17
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)..(10)
<223> Xaa may be present or absent

<220>

<221> SITE
<222> (14)..(23)
<223> Xaa may be present or absent.

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 17
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Phe Glu Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20

<210> 18
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 18
Leu Cys Thr Ala Met Thr Glu
1 5

<210> 19
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 19
Gly Ile Ser Ala Leu Val Leu Ser
1 5

<210> 20
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 20

Cys Gly Lys Arg Tyr Arg Asn Cys
1 5

<210> 21

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 21

Ser Met Ser Ile Ala Arg Leu
1 5

<210> 22

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 22

Val Ser Phe Leu Glu Tyr Arg
1 5

<210> 23

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> UNSURE

<222> (1)..(2)

<223> Unsure

<220>

<221> UNSURE

<222> (4)..(7)

<223> Unsure

<220>

<221> UNSURE

<222> (8)

<223> Unsure

<400> 23

Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa

1

5

<210> 24

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> UNSURE

<222> (2) .. (8)

<223> Unsure

<400> 24

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys

1

5

<210> 25

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<221> UNSURE

<222> (2) .. (4)

<223> Unsure

<220>

<221> UNSURE

<222> (6) .. (8)

<223> Unsure

<220>

<221> UNSURE

<222> (10) .. (12)

<223> Unsure

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 25

Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys
1 5 10

<210> 26

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> UNSURE

<222> (2)..(7)

<223> Unsure

<400> 26

Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5

<210> 27

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 27

Leu Met Leu Pro Arg Ala Asp
1 5

<210> 28

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 28

Leu Pro Arg Tyr Leu Leu Ser

1

5

<210> 29

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> UNSURE

<222> (1)..(7)

<223> individually selected amino acid

<400> 29

Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1

5

<210> 30

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<220>

<221> UNSURE

<222> (2)..(11)

<400> 30

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys

1

5

10

<210> 31

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<221> variation

<222> (4)..(21)
<223> N is equal molar mixtures of A, C, G and T; K is
equal molar mixtures of G and T.

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 31
tgtnnknknkn nknnknknkn ktgt

24

<210> 32
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 32
Cys Ile Lys Gly Asn Val Asn Cys
1 5

<210> 33
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 33
Cys Arg His Glu Ser Ser Ser Cys
1 5

<210> 34
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 34
Cys Leu Tyr Ile Asp Arg Arg Cys
1 5

<210> 35
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 35
 Cys Tyr Ser Leu Gly Ala Asp Cys
 1 5

<210> 36
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 36
 Cys Asn Ser Asp Val Asp Leu Cys
 1 5

<210> 37
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 37
 Cys Val Gly Asn Leu Ser Met Cys
 1 5

<210> 38
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

<400> 38
Cys Glu Lys Lys Leu Leu Tyr Cys
1 5

<210> 39
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 39
Cys Lys Gly Gln Arg Asp Phe Cys
1 5

<210> 40
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 40
Cys Thr Phe Arg Asn Ala Ser Cys
1 5

<210> 41
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 41
Cys Asn Met Gly Leu Thr Arg Cys
1 5

<210> 42
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 42
Cys His Glu Gly Tyr Leu Thr Cys
1 5

<210> 43
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 43
Cys Gly Thr Phe Gly Ala Arg Cys
1 5

<210> 44
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 44
Cys Arg Ile Ser Ala His Pro Cys
1 5

<210> 45
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 45
Cys Leu Arg Pro Tyr Leu Asn Cys
1 5

<210> 46
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 46
 Cys Ser Tyr Pro Lys Ile Leu Cys
 1 5

<210> 47
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 47
 Cys Met Glu Leu Ser Lys Gln Cys
 1 5

<210> 48
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 48
 Cys Ser Glu Pro Ser Gly Thr Cys
 1 5

<210> 49
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 49

Cys Gly Asn Glu Thr Leu Arg Cys
1 5

<210> 50
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 50
Cys Thr Leu Ser Asn Arg Phe Cys
1 5

<210> 51
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 51
Cys Met Gly Ser Glu Tyr Trp Cys
1 5

<210> 52
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 52
Cys Leu Phe Ser Asp Glu Asn Cys
1 5

<210> 53
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 53
Cys Ala His Gln His Ile Gln Cys
1 5

<210> 54
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 54
Cys Lys Gly Gln Gly Asp Trp Cys
1 5

<210> 55
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 55
Cys Ala Gln Asn Met Leu Cys Cys
1 5

<210> 56
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 56
Cys Trp Arg Gly Asp Arg Lys Ile Cys
1 5

<210> 57

<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 57
Cys Ile Phe Arg Glu Ala Asn Val Cys
1 5

<210> 58
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 58
Cys Arg Thr His Gly Tyr Gln Gly Cys
1 5

<210> 59
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 59
Cys Glu Arg Val Val Gly Ser Ser Cys
1 5

<210> 60
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 60
Cys Lys Thr Asn His Met Glu Ser Cys

1

5

<210> 61

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 61

Cys Tyr Glu Glu Lys Ser Gln Ser Cys

1

5

<210> 62

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 62

Cys Lys Asp Ser Ala Met Thr Ile Cys

1

5

<210> 63

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 63

Cys Thr Arg Ser Thr Asn Thr Gly Cys

1

5

<210> 64

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 64

Cys Met Ser Trp Asp Ala Val Ser Cys
1 5

<210> 65

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 65

Cys Lys Trp Ser Arg Leu His Ser Cys
1 5

<210> 66

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 66

Cys Met Ser Pro Gln Arg Ser Asp Cys
1 5

<210> 67

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 67

Cys Leu His Ser Pro Arg Ser Lys Cys
1 5

<210> 68

<211> 9

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 68

Cys Pro Gln Asp Ile Arg Arg Asn Cys
1 5

<210> 69

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 69

Cys Leu Tyr Thr Lys Glu Gln Arg Cys
1 5

<210> 70

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 70

Cys Gln Thr Arg Asn Phe Ala Gln Cys
1 5

<210> 71

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 71

Cys Thr Gly His Leu Ser Thr Asp Cys
1 5

<210> 72
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 72
Cys Gln Asp Leu Asn Ile Met Gln Cys
1 5

<210> 73
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 73
Thr Arg Arg Thr Asn Asn Pro Leu Thr
1 5

<210> 74
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 74
Cys Gly Tyr Ile Asp Pro Asn Arg Ile Ser Gln Cys
1 5 10

<210> 75
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 75

Cys Thr Val Asn Glu Ala Tyr Lys Thr Arg Met Cys
1 5 10

<210> 76

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 76

Cys Arg Leu Arg Ser Tyr Gly Thr Leu Ser Leu Cys
1 5 10

<210> 77

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 77

Cys Ala Gly Thr Cys Ala Thr Gly Cys Asn Gly Val Cys
1 5 10

<210> 78

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 78

Cys Ala Asp Tyr Asp Leu Ala Leu Gly Leu Met Cys
1 5 10

<210> 79

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 79

Cys Pro Lys Ala Arg Pro Ala Pro Gln Tyr Lys Cys
1 5 10

<210> 80

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 80

Cys Ser Ser His Gln Gly Gly Phe Gln His Gly Cys
1 5 10

<210> 81

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 81

Cys Gln Glu Thr Arg Thr Glu Gly Arg Lys Lys Cys
1 5 10

<210> 82

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 82

Cys Arg Pro Trp His Asn Gln Ala His Thr Glu Cys
1 5 10

<210> 83
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 83
Cys Ser Phe Gly Thr His Asp Thr Glu Pro His Cys
1 5 10

<210> 84
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 84
Cys Ser Glu Ala Ala Ser Arg Met Ile Gly Val Cys
1 5 10

<210> 85
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 85
Cys Trp Glu Glu His Pro Ser Ile Lys Trp Trp Cys
1 5 10

<210> 86
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 86

Cys Trp Asp Ala Asp Gln Ile Phe Gly Ile Lys Cys
1 5 10

<210> 87

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 87

Cys Val Asp Ser Gln Ser Met Lys Gly Leu Val Cys
1 5 10

<210> 88

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 88

Cys Arg Leu Gln Thr Met Gly Gln Gly Gln Ser Cys
1 5 10

<210> 89

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 89

Cys Arg Pro Ala Gln Arg Asp Ala Gly Thr Ser Cys
1 5 10

<210> 90

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 90

Cys Gly Gly Arg Asp Arg Gly Thr Tyr Gly Pro Cys
1 5 10

<210> 91

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 91

Cys Gly Glu Val Ala Ser Asn Glu Arg Ile Gln Cys
1 5 10

<210> 92

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 92

Cys Asn Ser Lys Ser Ser Ala Glu Leu Glu Lys Cys
1 5 10

<210> 93

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 93

Cys Val Leu Asn Phe Lys Asn Gln Ala Arg Asp Cys
1 5 10

<210> 94
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 94
Cys Arg Gly Lys Pro Leu Ala Asn Phe Glu Asp Cys
1 5 10

<210> 95
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 95
Cys Glu Gly His Ser Met Arg Gly Tyr Gly Leu Cys
1 5 10

<210> 96
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 96
Cys Arg Asp Arg Gly Asp Arg Met Lys Ser Leu Cys
1 5 10

<210> 97
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 97

Cys Asp Asn Thr Cys Thr Tyr Gly Val Asp Asp Cys
1 5 10

<210> 98

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 98

Cys Ser Ala His Ser Gln Glu Met Asn Val Asn Cys
1 5 10

<210> 99

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 99

Cys Gly Ala Ala Cys Gly Val Gly Cys Arg Gly Arg Cys
1 5 10

<210> 100

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 100

Cys Leu Val Gly Cys Arg Leu Ser Cys Gly Gly Glu Cys
1 5 10

<210> 101

<211> 13

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 101
Cys Arg Ser Gly Cys Val Glu Gly Cys Gly Gly Arg Cys
1 5 10

<210> 102
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 102
Cys Ile Ala Arg Cys Gly Gly Ala Cys Gly Arg His Cys
1 5 10

<210> 103
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 103
Cys Gly Gly Glu Cys Gly Trp Glu Cys Glu Val Ser Cys
1 5 10

<210> 104
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 104
Cys Gly Val Gly Cys Pro Gly Leu Cys Gly Gly Ala Cys
1 5 10

<210> 105

<211> 13
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 105

Cys Lys Trp Leu Cys Leu Leu Leu Cys Ala Val Ala Cys
1 5 10

<210> 106

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 106

Cys Ser Glu Gly Cys Gly Pro Val Cys Trp Pro Glu Cys
1 5 10

<210> 107

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 107

Cys Gly Ala Ala Cys Gly Val Gly Cys Gly Gly Arg Cys
1 5 10

<210> 108

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 108

Cys Ser Gly Ser Cys Arg Arg Gly Cys Gly Ile Asp Cys

1 5 10

<210> 109

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 109

Cys Gly Ala Ser Cys Ala Leu Gly Cys Arg Ala Tyr Cys
1 5 10

<210> 110

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 110

Cys Asp Thr Ser Cys Glu Asn Asn Cys Gln Gly Pro Cys
1 5 10

<210> 111

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 111

Cys Ser Arg Gln Cys Arg Gly Ala Cys Gly Gln Pro Cys
1 5 10

<210> 112

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 112

Cys Tyr Trp Trp Cys Asp Gly Val Cys Ala Leu Gln Cys
1 5 10

<210> 113

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 113

Cys Ala Gly Gly Cys Ala Val Arg Cys Gly Gly Thr Cys
1 5 10

<210> 114

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 114

Cys Gly Gly Ala Cys Gly Gly Val Cys Thr Gly Gly Cys
1 5 10

<210> 115

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 115

Cys Gly Arg Pro Cys Val Gly Glu Cys Arg Met Gly Cys
1 5 10

<210> 116

<211> 13

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 116

Cys Leu Val Gly Cys Glu Val Gly Cys Ser Pro Ala Cys
1 5 10

<210> 117

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 117

Cys Pro Arg Thr Cys Gly Ala Ala Cys Ala Ser Pro Cys
1 5 10

<210> 118

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 118

Cys Arg Gly Asp Cys Gly Ile Gly Cys Arg Arg Leu Cys
1 5 10

<210> 119

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 119

Glu Ile Cys Gln Leu Gly Ser Cys Thr
1 5

<210> 120
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 120
Trp Arg Cys Glu Gly Phe Asn Cys Gln
1 5

<210> 121
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 121
Arg Lys Cys Leu Arg Pro Asp Cys Gly
1 5

<210> 122
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 122
Leu Ala Cys Phe Val Thr Gly Cys Leu
1 5

<210> 123
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 123

Gly Leu Cys Asn Gly Ala Thr Cys Met
1 5

<210> 124

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 124

Asp Met Cys Trp Leu Ile Gly Cys Gly
1 5

<210> 125

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 125

Ser Gly Cys Arg Thr Met Val Cys Val
1 5

<210> 126

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 126

Gln Arg Cys Pro Arg Ser Phe Cys Leu
1 5

<210> 127

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 127

Leu Ser Cys Ala Pro Val Ile Cys Gly

1

5

<210> 128

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 128

Arg Glu Cys Thr Asn Glu Ile Cys Tyr

1

5

<210> 129

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 129

Asn Glu Cys Leu Met Ile Ser Cys Arg

1

5

<210> 130

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 130

Ser Cys Val Phe Cys Asp Trp Leu Ser

1

5

<210> 131
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 131
 Trp Ala Cys Glu Glu Leu Ser Cys Phe
 1 5

<210> 132
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 132
 Gln Asn Cys Pro Val Thr Arg Cys Val
 1 5

<210> 133
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 133
 Cys Ala Thr Leu Thr Asn Asp Glu Cys
 1 5

<210> 134
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

<400> 134

Cys Asp Asn Arg Glu Met Ser Cys

1

5

<210> 135

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 135

Cys Phe Met Asp His Ser Asn Cys

1

5

<210> 136

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 136

Cys Gly Glu Tyr Gly Arg Glu Cys

1

5

<210> 137

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 137

Cys His Met Lys Arg Asp Arg Thr Cys

1

5

<210> 138

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 138

Cys Lys Lys Arg Leu Leu Asn Val Cys

1

5

<210> 139

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 139

Cys Leu Asp Tyr His Pro Lys Cys

1

5

<210> 140

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 140

Cys Met Thr Gly Arg Val Thr Cys

1

5

<210> 141

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 141

Cys Asn Lys Ile Val Arg Arg Cys

1

5

<210> 142
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 142
 Cys Pro Asp Leu Leu Val Ala Cys
 1 5

<210> 143
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 143
 Cys Ser Asp Thr Gln Ser Ile Gly Cys
 1 5

<210> 144
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 144
 Cys Ser Lys Ala Tyr Asp Leu Ala Cys
 1 5

<210> 145
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 145

Cys Ser Lys Lys Gly Pro Ser Tyr Cys
1 5

<210> 146

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 146

Cys Thr Leu Lys His Thr Ala Met Cys
1 5

<210> 147

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 147

Cys Thr Gln His Ile Ala Asn Cys
1 5

<210> 148

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 148

Cys Thr Thr Glu Ile Asp Tyr Cys
1 5

<210> 149

<211> 9

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 149
Cys Val Gly Arg Ser Gly Glu Leu Cys
1 5

<210> 150
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 150
Tyr Ala Gly Phe Phe Leu Val
1 5

<210> 151
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 151
Arg Ser Gly Ala Arg Ser Ser
1 5

<210> 152
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 152
Cys Val Glu Ser Thr Val Ala
1 5

<210> 153

<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 153

Ser Arg Arg Gln Pro Leu Ser
1 5

<210> 154

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 154

Ser Lys Val Trp Leu Leu Leu
1 5

<210> 155

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 155

Gln Val Arg Arg Val Pro Glu
1 5

<210> 156

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 156

Tyr Ser Gly Lys Trp Gly Trp

1

5

<210> 157

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 157

Met Val Gln Ser Val Gly

1

5

<210> 158

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 158

Leu Arg Ala Val Gly Arg Ala

1

5

<210> 159

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 159

Met Ser Pro Gln Leu Ala Thr

1

5

<210> 160

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 160

Gly Ala Val Leu Pro Gly Glu

1

5

<210> 161

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 161

Trp Ile Glu Glu Ala Glu Arg

1

5

<210> 162

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 162

Leu Val Ser Glu Gln Leu Arg

1

5

<210> 163

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 163

Arg Gly Asp Arg Pro Pro Tyr

1

5

<210> 164

<211> 7

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 164

Val Arg Arg Gly Ser Pro Gln
1 5

<210> 165

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 165

Arg Val Arg Gly Pro Glu Arg
1 5

<210> 166

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 166

Gly Ile Ser Ala Val Leu Ser
1 5

<210> 167

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 167

Gly Gly Arg Gly Ser Trp Glu
1 5

<210> 168
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 168
Gly Val Ser Ala Ser Asp Trp
1 5

<210> 169
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 169
Phe Arg Val Arg Gly Ser Pro
1 5

<210> 170
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 170
Ser Arg Leu Ser Gly Gly Thr
1 5

<210> 171
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 171

Trp Glu Leu Val Ala Arg Ser
1 5

<210> 172

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 172

Met Arg Arg Asp Glu Gln Arg
1 5

<210> 173

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 173

Gly Cys Arg Cys Trp Ala
1 5

<210> 174

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 174

Cys Tyr Ala Asp Cys Glu Gly Thr Cys Gly Met Val Cys
1 5 10

<210> 175

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 175

Cys Trp Asn Ile Cys Pro Gly Gly Cys Arg Ala Leu Cys
1 5 10

<210> 176

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 176

Gly Pro Gly Cys Glu Glu Glu Cys Gln Pro Ala Cys
1 5 10

<210> 177

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 177

Cys Lys Gly Thr Cys Val Leu Gly Cys Ser Glu Glu Cys
1 5 10

<210> 178

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 178

Cys Ser Thr Leu Cys Gly Leu Arg Cys Met Gly Thr Cys
1 5 10

<210> 179
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 179
Cys Met Pro Arg Cys Gly Val Asn Cys Lys Trp Ala Cys
1 5 10

<210> 180
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 180
Cys Val Gly Ala Cys Asp Leu Lys Cys Thr Gly Gly Cys
1 5 10

<210> 181
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 181
Cys Ser Ser Gly Cys Ser Lys Asn Cys Leu Glu Met Cys
1 5 10

<210> 182
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 182

Cys Gly Arg Pro Cys Arg Gly Gly Cys Ala Ala Ser Cys

1

5

10

<210> 183

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 183

Cys Gln Gly Gly Cys Gly Val Ser Cys Pro Ile Phe Cys

1

5

10

<210> 184

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 184

Cys Ala Val Arg Cys Asp Gly Ser Cys Val Pro Glu Cys

1

5

10

<210> 185

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 185

Cys Gly Phe Gly Cys Ser Gly Ser Cys Gln Met Gln Cys

1

5

10

<210> 186

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 186

Cys Arg Val Val Cys Ala Asp Gly Cys Arg Phe Ile Cys

1

5

10

<210> 187

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 187

Cys Thr Met Gly Cys Thr Ala Gly Cys Ala Phe Ala Cys

1

5

10

<210> 188

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 188

Cys Glu Gly Lys Cys Gly Leu Thr Cys Glu Cys Thr Cys

1

5

10

<210> 189

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 189

Cys Asn Gln Gly Cys Ser Gly Ser Cys Asp Val Met Cys

1

5

10

<210> 190
<211> 13
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 190

Cys Ala Ser Gly Cys Ser Glu Ser Cys Tyr Val Gly Cys
1 5 10

<210> 191

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 191

Cys Gly Gly Gly Cys Gln Trp Gly Cys Ala Gly Glu Cys
1 5 10

<210> 192

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 192

Cys Ser Val Arg Cys Lys Ser Val Cys Ile Gly Leu Cys
1 5 10

<210> 193

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 193

Cys Pro Ser Asn Cys Val Ala Leu Cys Thr Ser Gly Cys
1 5 10

<210> 194
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 194
Cys Val Glu Gly Cys Ser Ser Gly Cys Gly Pro Gly Cys
1 5 10

<210> 195
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 195
Cys Arg Val Val Cys Ala Asp Gly Cys Arg Leu Ile Cys
1 5 10

<210> 196
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 196
Gly Ser Thr Leu Cys Gly Leu Arg Cys Met Gly Thr Cys
1 5 10

<210> 197
<211> 13
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 197

Cys Phe Thr Phe Cys Glu Tyr His Cys Gln Leu Thr Cys
1 5 10

<210> 198

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 198

Cys Arg Arg Ile Trp Tyr Ala Val Cys
1 5

<210> 199

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 199

Cys Ser Ala Tyr Thr Thr Ser Pro Cys
1 5

<210> 200

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 200

Cys Thr Asp Lys Ser Trp Pro Cys
1 5

<210> 201

[illegible]

<223> Description of Artificial Sequence: Synthetic

Cys Thr Asp Asn Arg Val Gly Ser
1 5

<213> Artificial Sequence

<223> Description of Artificial Sequence: Synthetic

Cys Thr Ile Ala Asp Phe Pro Cys
1 5

<213> Artificial Sequence

<223> Description of Artificial Sequence: Synthetic

Cys Thr Ser Asp Ile Ser Trp Trp Asp Tyr Lys Cys
1 5 10

<213> Artificial Sequence

<223> Description of Artificial Sequence: Synthetic

Cys Thr Val Asp Asn Glu Leu Cys

1

5

<210> 205

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 205

Cys Val Gly Asp Cys Ile Gly Ser Cys Trp Met Phe Cys
1 5 10

<210> 206

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 206

Cys Val Lys Phe Thr Tyr Asp Cys
1 5

<210> 207

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 207

Cys Val Ser Gly His Leu Asn Cys
1 5

<210> 208

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 208

Cys Tyr Gly Glu Ser Gln Gln Met Cys
1 5

<210> 209

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 209

Cys Tyr Thr Gly Glu Thr Trp Thr Cys
1 5

<210> 210

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 210

Cys Ala Val Ser Ile Pro Arg Cys
1 5

<210> 211

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 211

Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> 212

<211> 13

<210> 216
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 216
Cys Gly Asp Val Cys Pro Ser Glu Cys Pro Gly Trp Cys
1 5 10

<210> 217
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 217
Cys Gly Leu Asp Cys Leu Gly Asp Cys Ser Gly Ala Cys
1 5 10

<210> 218
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 218
Cys Gly Pro Gly Tyr Gln Ala Gln Cys Ser Leu Arg Cys
1 5 10

<210> 219
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 219

Cys Gly Ser His Cys Gly Gln Leu Cys Lys Ser Leu Cys
1 5 10

<210> 220

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 220

Cys His Met Gly Cys Val Ser Pro Cys Ala Tyr Val Cys
1 5 10

<210> 221

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 221

Cys Ile Leu Ser Tyr Asp Asn Pro Cys
1 5

<210> 222

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 222

Cys Ile Ser Arg Pro Tyr Phe Cys
1 5

<210> 223

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 223

Cys Lys Glu Arg Leu Glu Tyr Thr Arg Gly Val Cys
1 5 10

<210> 224

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 224

Cys Lys Glu Arg Pro Ser Asn Gly Leu Ser Ala Cys
1 5 10

<210> 225

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 225

Cys Lys Pro Phe Arg Thr Glu Cys
1 5

<210> 226

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 226

Cys Lys Ser Gly Cys Gly Val Ala Cys Arg His Met Cys
1 5 10

<210> 227
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 227
 Cys Leu Lys Pro Gly Gly Gln Glu Cys
 1 5

<210> 228
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 228
 Cys Met Asp Ser Gln Ser Ser Cys
 1 5

<210> 229
 <211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 229
 Cys Met Asn Ile Leu Ser Gly Cys
 1 5

<210> 230
 <211> 12
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

<400> 230

Cys Asn Ile Pro Val Thr Thr Pro Ile Phe Gly Cys

1 5 10

<210> 231

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 231

Cys Asn Gln Arg Thr Asn Arg Glu Ser Gly Asn Cys

1 5 10

<210> 232

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 232

Cys Asn Arg Lys Asn Ser Asn Glu Gln Arg Ala Cys

1 5 10

<210> 233

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 233

Cys Asn Arg Met Glu Met Pro Cys

1 5

<210> 234

<211> 9

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 234
Cys Gln Ile Arg Pro Ile Asp Lys Cys
1 5

<210> 235
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 235
Cys Ala Ile Asp Ile Gly Gly Ala Cys
1 5

<210> 236
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 236
Cys Gly Arg Phe Asp Thr Ala Pro Gln Arg Gly Cys
1 5 10

<210> 237
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 237
Cys Lys Arg Ala Asn Arg Leu Ser Cys
1 5

<210> 238
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 238
Cys Leu Leu Asn Tyr Thr Tyr Cys
1 5

<210> 239
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 239
Cys Leu Asn Gly Leu Val Ser Met Cys
1 5

<210> 240
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 240
Cys Met Ser Leu Gly Asn Asn Cys
1 5

<210> 241
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 241

Cys Asn Arg Asn Arg Met Thr Pro Cys
1 5

<210> 242
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 242
Cys Gln Ala Ser Ala Ser Asp His Cys
1 5

<210> 243
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 243
Cys Gln Leu Ile Asn Ser Ser Pro Cys
1 5

<210> 244
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 244
Cys Gln Arg Val Asn Ser Val Glu Asn Ala Ser Cys
1 5 10

<210> 245
<211> 8
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 245

Cys Arg Lys Glu His Tyr Pro Cys

1

5

<210> 246

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 246

Cys Arg Arg His Met Glu Arg Cys

1

5

<210> 247

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 247

Cys Ser Gly Arg Pro Phe Lys Tyr Cys

1

5

<210> 248

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 248

Cys Thr His Leu Val Thr Leu Cys

1

5

<210> 249

<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 249
Cys Thr Ser Ser Pro Ala Tyr Asn Cys
1 5

<210> 250
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 250
Cys Val Thr Ser Asn Leu Arg Val Cys
1 5

<210> 251
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 251
Cys Trp Asp Ser Gly Ser His Ile Cys
1 5

<210> 252
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 252
Cys Glu Arg Ser His Gly Arg Leu Cys

1

5

<210> 253

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 253

Cys Gly Asn Leu Leu Thr Arg Arg Cys

1

5

<210> 254

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 254

Cys Ile Asn Cys Leu Ser Gln Cys

1

5

<210> 255

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 255

Cys Leu Arg His Asp Phe Tyr Val Cys

1

5

<210> 256

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 256

Cys Asn Ser Arg Ser Glu Asn Cys

1

5

<210> 257

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 257

Cys Arg Tyr Lys Gly Pro Ser Cys

1

5

<210> 258

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 258

Cys Ser His His Asp Thr Asn Cys

1

5

<210> 259

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 259

Cys Ser Arg Trp Tyr Thr Thr Cys

1

5

<210> 260

<211> 8

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 260

Cys Tyr Ala Gly Ser Pro Leu Cys
1 5

<210> 261

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 261

Cys Gln Thr Thr Ser Trp Asn Cys
1 5

<210> 262

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 262

Cys Gln Trp Ser Met Asn Val Cys
1 5

<210> 263

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 263

Cys Arg Ala Arg Ile Arg Ala Glu Asp Ile Ser Cys
1 5 10

<210> 264
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 264
Cys Arg Arg Glu Tyr Ser Ala Cys
1 5

<210> 265
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 265
Glu Val Gln Ser Ala Lys Trp
1 5

<210> 266
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 266
Lys Arg Val Tyr Val Leu Gly
1 5

<210> 267
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 267

Gly Arg Leu Ser Val Gln Val

1

5

<210> 268

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 268

Trp Lys Pro Ala Ser Leu Ser

1

5

<210> 269

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 269

Phe Ala Val Arg Val Val Gly

1

5

<210> 270

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 270

Leu Val Arg Pro Leu Glu Gly

1

5

<210> 271

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 271

Gly Phe Tyr Arg Met Leu Gly
1 5

<210> 272

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 272

Glu Gly Arg Pro Met Val Tyr
1 5

<210> 273

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 273

Gly Ser Arg Ser Leu Gly Ala
1 5

<210> 274

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 274

Arg Val Trp Gln Gly Asp Val
1 5

<210> 275
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 275
Gly Asp Glu Leu Leu Ala
1 5

<210> 276
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 276
Phe Val Trp Leu Val Gly Ser
1 5

<210> 277
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 277
Gly Ser Glu Pro Met Phe Arg
1 5

<210> 278
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 278

Trp His Gln Pro Leu

1

5

<210> 279

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 279

Arg Gly Arg Trp Leu Ala Leu

1

5

<210> 280

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 280

Gln Val Glu Glu Phe Pro Cys

1

5

<210> 281

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 281

Leu Trp Leu Ser Gly Asn Trp

1

5

<210> 282

<211> 7

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 282
Gly Pro Met Leu Ser Val Met
1 5

<210> 283
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 283
Trp Thr Phe Leu Glu Arg Leu
1 5

<210> 284
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 284
Val Leu Pro Gly Gly Gln Trp
1 5

<210> 285
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 285
Arg Glu Val Lys Glu Ser
1 5

<210> 286
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 286
Arg Thr Pro Ala Ala Val Met
1 5

<210> 287
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 287
Gly Glu Trp Leu Gly Glu Cys
1 5

<210> 288
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 288
Pro Asn Pro Leu Met Pro Leu
1 5

<210> 289
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 289

Ser Leu Trp Tyr Leu Gly Ala
1 5

<210> 290

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 290

Tyr Val Gly Gly Trp Glu Leu
1 5

<210> 291

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 291

Ala Val Lys Asp Tyr Phe Arg
1 5

<210> 292

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 292

Gly Val Arg Thr Ser Ile Trp
1 5

<210> 293

<211> 7

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 293
Arg Pro Val Gly Met Arg Lys
1 5

<210> 294
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 294
Arg Val Arg Leu Val Asn Leu
1 5

<210> 295
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 295
Phe Phe Ala Ala Val Arg Ser
1 5

<210> 296
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 296
Lys Leu Val Asn Ser Ser Trp
1 5

<210> 297

<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 297

Leu Cys Glu Arg Val Trp Arg
1 5

<210> 298

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 298

Phe Gly Ser Gln Ala Phe Val
1 5

<210> 299

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 299

Trp Leu Glu Arg Pro Glu Tyr
1 5

<210> 300

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 300

Gly Gly Asp Val Met Trp Arg

1

5

<210> 301

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 301

Val Arg Ala Arg Leu Met Ser

1

5

<210> 302

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 302

Thr Leu Arg Glu Ser Gly Pro

1

5

<210> 303

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 303

Trp Gly Cys Lys Leu Arg Phe Cys Ser

1

5

<210> 304

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 304

Met Glu Cys Ile Lys Tyr Ser Cys Leu
1 5

<210> 305

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 305

Gly Ile Cys Ala Thr Val Lys Cys Ser
1 5

<210> 306

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 306

Pro Arg Cys Gln Leu Trp Ala Cys Thr
1 5

<210> 307

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 307

Thr Thr Cys Met Ser Gln Leu Cys Leu
1 5

<210> 308

<211> 9

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 308

Ser His Cys Pro Met Ala Ser Leu Cys
1 5

<210> 309

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 309

Gly Cys Val Arg Arg Leu Leu Cys Asn
1 5

<210> 310

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 310

Thr Ser Cys Arg Leu Phe Ser Cys Ala
1 5

<210> 311

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 311

Lys Tyr Cys Thr Pro Val Glu Cys Leu
1 5

<210> 312
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 312
Arg Gly Cys Asn Gly Ser Arg Cys Ser
1 5

<210> 313
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 313
Met Cys Pro Gln Arg Asn Cys Leu
1 5

<210> 314
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 314
Pro Glu Cys Glu Gly Val Ser Cys Ile
1 5

<210> 315
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 315

Ala Gly Cys Ser Val Thr Val Cys Gly

1

5

<210> 316

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 316

Ile Pro Cys Tyr Trp Glu Ser Cys Arg

1

5

<210> 317

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 317

Gly Ser Cys Ser Met Phe Pro Cys Ser

1

5

<210> 318

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 318

Gln Asp Cys Val Lys Arg Pro Cys Val

1

5

<210> 319

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 319

Ser Glu Cys Ala Tyr Arg Ala Cys Ser
1 5

<210> 320

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 320

Trp Ser Cys Ala Arg Pro Leu Cys Gly
1 5

<210> 321

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 321

Ser Leu Cys Gly Ser Asp Gly Cys Arg
1 5

<210> 322

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 322

Arg Leu Cys Pro Ser Ser Pro Cys Thr
1 5

<210> 323
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 323
 Met Arg Cys Gly Phe Ser Gly Cys Thr
 1 5

<210> 324
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 324
 Arg Tyr Cys Tyr Pro Asp Gly Cys Leu
 1 5

<210> 325
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 325
 Ser Thr Cys Gly Asn Trp Thr Cys Arg
 1 5

<210> 326
 <211> 9
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 330
Thr Ala Cys Lys Val Ala Ala Cys His
1 5

<210> 331
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 331
Asp Arg Cys Leu Asp Ile Trp Cys Leu
1 5

<210> 332
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> UNSURE
<222> (1)..(3)
<223> Unsure

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 332
Xaa Xaa Xaa Gln Gly Ser Pro Cys Leu
1 5

<210> 333
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 333

Pro Leu Cys Met Ala Thr Arg Cys Ala

1

5

<210> 334

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 334

Arg Asp Cys Ser His Arg Ser Cys Glu

1

5

<210> 335

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 335

Asn Pro Cys Leu Arg Ala Ala Cys Ile

1

5

<210> 336

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 336

Pro Thr Cys Ala Tyr Gly Trp Cys Ala

1

5

<210> 337

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 337

Leu Glu Cys Val Ala Asn Leu Cys Thr

1

5

<210> 338

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 338

Arg Lys Cys Gly Glu Glu Val Cys Thr

1

5

<210> 339

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 339

Glu Pro Cys Thr Trp Asn Ala Cys Leu

1

5

<210> 340

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 340

Leu Val Cys Pro Gly Thr Ala Cys Val

1

5

<210> 341
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 341
Leu Tyr Cys Leu Asp Ala Ser Cys Leu
1 5

<210> 342
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 342
Glu Arg Cys Pro Met Ala Lys Cys Tyr
1 5

<210> 343
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 343
Leu Val Cys Gln Gly Ser Pro Cys Leu
1 5

<210> 344
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 344

Gln Gln Cys Gln Asp Pro Tyr Cys Leu
1 5

<210> 345
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> UNSURE
<222> (2)
<223> Unsure

<220>
<221> UNSURE
<222> (4)
<223> Unsure

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 345
Asp Xaa Cys Xaa Asp Ile Trp Cys Leu
1 5

<210> 346
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 346
Gln Pro Cys Arg Ser Met Val Cys Ala
1 5

<210> 347
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 347

Lys Thr Cys Val Gly Val Arg Val

1

5

<210> 348

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 348

Trp Ser Cys His Glu Phe Met Cys Arg

1

5

<210> 349

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 349

Cys Ser Lys Leu Met Met Thr Cys

1

5

<210> 350

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 350

Leu Thr Cys Trp Asp Trp Ser Cys Arg

1

5

<210> 351

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 351

Ser Leu Cys Arg Leu Ser Thr Cys Ser

1

5

<210> 352

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 352

Lys Thr Cys Ala Gly Ser Ser Cys Ile

1

5

<210> 353

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 353

Val Ile Cys Thr Gly Arg Gln Cys Gly

1

5

<210> 354

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 354

Asn Pro Cys Phe Gly Leu Leu Val

1

5

<210> 355
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 355
Ser Leu Cys Thr Ala Phe Asn Cys His
1 5

<210> 356
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 356
Arg Thr Cys Thr Pro Ser Arg Cys Met
1 5

<210> 357
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 357
Gln Ser Cys Leu Trp Arg Ile Cys Ile
1 5

<210> 358
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 358

Gln Tyr Cys Trp Ser Lys Gly Cys Arg
1 5

<210> 359

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 359

Leu Gly Cys Phe Pro Ser Trp Cys Gly
1 5

<210> 360

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 360

Val Thr Cys Ser Ser Glu Trp Cys Leu
1 5

<210> 361

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 361

Arg Leu Cys Ser Trp Gly Gly Cys Ala
1 5

<210> 362

<211> 9

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 362
Ser Thr Cys Ile Ser Val His Cys Ser
1 5

<210> 363
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 363
Glu Val Cys Leu Val Leu Ser Cys Gln
1 5

<210> 364
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 364
Ile Ala Cys Asp Gly Tyr Leu Cys Gly
1 5

<210> 365
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 365
Arg Asp Cys Val Lys Asn Leu Cys Arg
1 5

<210> 366

<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> UNSURE
<222> (1)
<223> Unsure

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 366
Xaa Gly Cys Tyr Gln Lys Arg Cys Thr
1 5

<210> 367
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> UNSURE
<222> (5)
<223> Unsure

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 367
Leu Gly Cys Phe Xaa Ser Trp Cys Gly
1 5

<210> 368
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 368
Ile Arg Cys Trp Gly Gly Arg Cys Ser
1 5

<210> 369
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 369
Ile Pro Cys Ser Leu Leu Gly Cys Ala
1 5

<210> 370
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 370
Ala Gly Cys Val Gln Ser Gln Cys Tyr
1 5

<210> 371
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 371
Pro Arg Cys Trp Glu Arg Val Cys Ser
1 5

<210> 372
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> UNSURE
<222> (9)

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 372
Lys Ala Cys Phe Gly Ala Asp Cys Xaa
1 5

<210> 373
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 373
Thr Leu Cys Pro Leu Val Ala Cys Glu
1 5

<210> 374
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 374
Ser Ala Cys Trp Leu Ser Asn Cys Ala
1 5

<210> 375
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 375
Ser Glu Cys Tyr Thr Gly Ser Cys Pro
1 5

<210> 376

<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 376
Gly Leu Cys Gln Glu His Arg Cys Trp
1 5

<210> 377
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 377
Val Glu Cys Gly Phe Ser Ala Val Phe
1 5

<210> 378
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 378
Glu Asp Cys Arg Glu Trp Gly Cys Arg
1 5

<210> 379
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 379
His Trp Cys Arg Leu Leu Ala Cys Arg

1

5

<210> 380

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 380

His Lys Gly Gln Val Tyr Ser

1

5

<210> 381

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 381

Phe Ser Asp Val His Phe Trp

1

5

<210> 382

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 382

Arg Gly Ile Phe Val Ser Ser

1

5

<210> 383

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 383

Pro Lys Val Lys Leu Ser Glu

1

5

<210> 384

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 384

Leu Arg Phe Trp Gln Glu Ser

1

5

<210> 385

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 385

Ile Trp Thr Val Val Gly Gln

1

5

<210> 386

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 386

Asp Lys Val Gly Leu Ser Val

1

5

<210> 387

<211> 7

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 387

Ser Glu Thr Trp Arg Gln Phe
1 5

<210> 388

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 388

Leu Asp Gly Met Ile Val Lys
1 5

<210> 389

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 389

Arg Tyr Pro Leu Ala Gly Gly
1 5

<210> 390

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 390

Phe Thr Asp Gly Glu Asp Lys
1 5

<210> 391
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 391
Arg Ser Thr Glu His Met Ser
1 5

<210> 392
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 392
Ser Gly Arg Arg His Glu Leu
1 5

<210> 393
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 393
Ser Ser Ser Arg Val Arg Ser
1 5

<210> 394
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 394

Tyr His Arg Ser Val Gly Arg

1

5

<210> 395

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 395

Pro Leu Leu Arg Pro Pro His

1

5

<210> 396

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 396

Ser Asp Lys Leu Gly Phe Val

1

5

<210> 397

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 397

Ala Gly Ser Arg Thr Asn Arg

1

5

<210> 398

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 398

Ile Thr Gln Leu His Lys Thr
1 5

<210> 399

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 399

Ala Arg Cys Leu Val Tyr Arg
1 5

<210> 400

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 400

Gly Tyr Val Ala Val Met Thr
1 5

<210> 401

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 401

Gly Leu Gln Val Lys Trp Val
1 5

<210> 402
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 402
Ile Phe Thr Pro Gly Trp Leu
1 5

<210> 403
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 403
Lys Gln Thr Ser Arg Phe Leu
1 5

<210> 404
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (2)
<223> Tyrosine or Phenylalanine

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 404
Arg Xaa Leu Leu Ala Gly Gly
1 5

<210> 405
<211> 7
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 405

Ala Arg Arg Gly Trp Thr Leu
1 5

<210> 406

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 406

Ser Arg Arg Phe Val Gly Gly
1 5

<210> 407

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 407

Gln Leu Thr Gly Gly Cys Leu
1 5

<210> 408

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 408

Ala Leu Glu Arg Arg Ser Leu
1 5

<210> 409
 <211> 7
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 409
 Lys Ala Tyr Phe Arg Trp Arg
 1 5

<210> 410
 <211> 7
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 410
 Arg Trp Leu Ala Trp Thr Val
 1 5

<210> 411
 <211> 7
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

 <400> 411
 Val Gly Ser Phe Ile Tyr Ser
 1 5

<210> 412
 <211> 7
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic

<400> 412

Leu Ser Leu Leu Gly Ile Ala

1

5

<210> 413

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 413

Leu Ser Thr Val Leu Trp Phe

1

5

<210> 414

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 414

Ser Leu Ala Met Arg Asp Ser

1

5

<210> 415

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 415

Gly Arg Ser Ser Leu Ala Cys

1

5

<210> 416

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 416

Ser Glu Leu Leu Gly Asp Ala

1

5

<210> 417

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 417

Cys Gly Gly Ala Gly Ala Arg

1

5

<210> 418

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 418

Trp Arg Gln Asn Met Pro Leu

1

5

<210> 419

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 419

Asp Phe Leu Arg Cys Arg Val

1

5

<210> 420
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 420
Gln Ala Gly Leu Arg Cys His
1 5

<210> 421
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 421
Arg Ala Leu Tyr Asp Ala Leu
1 5

<210> 422
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 422
Trp Val Ser Val Leu Gly Phe
1 5

<210> 423
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 423

Gly Met Ala Val Ser Ser Trp
1 5

<210> 424
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 424
Ser Trp Phe Phe Leu Val Ala
1 5

<210> 425
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 425
Trp Gln Ser Val Val Arg Val
1 5

<210> 426
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 426
Cys Gly Asn Gly His Ser Cys
1 5

<210> 427
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 427

Ala Glu Met Glu Gly Arg Asp

1

5

<210> 428

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 428

Ser Leu Arg Pro Asp Asn Gly

1

5

<210> 429

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 429

Pro Ala Met Gly Leu Ile Arg

1

5

<210> 430

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 430

Leu Ala Gly Gly

1

<210> 431

<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)
<223> 1 to 10 independently selected amino acids

<220>
<221> SITE
<222> (14)..(23)
<223> 1 to 10 independently selected amino acids

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 431
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Pro Arg Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20

<210> 432
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)..(10)
<223> 1 to 10 independently selected amino acids

<220>
<221> SITE
<222> (15)..(25)
<223> 0 to 10 independently selected amino acids

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 432
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Ala Gly Gly Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

<210> 433
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> SITE
 <222> (6)..(15)
 <223> 1 to 10 independently selected amino acids

<220>
 <223> Description of Artificial Sequence: Synthetic

<400> 433
 Tyr Ser Gly Lys Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10 15

<210> 434
 <211> 23
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> SITE
 <222> (1)..(10)
 <223> 1 to 10 independently selected amino acids

<220>
 <221> SITE
 <222> (14)..(23)
 <223> 1 to 10 independently selected amino acids

<220>
 <223> Description of Artificial Sequence: Synthetic

<400> 434
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Gly Ser Xaa Xaa Xaa
 1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 20

<210> 435

<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 435

Cys Cys Phe Thr Asn Phe Asp Cys Tyr Leu Gly Cys
1 5 10

<210> 436

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> UNSURE

<222> (1)..(10)

<223> 1 to 10 independently selected amino acids

<220>

<221> UNSURE

<222> (14)..(23)

<223> 1 to 10 independently selected amino acids

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 436

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Asp Val Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20

<210> 437

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 437

Cys Val Asp Val Cys Cys Asp Gly Cys Pro Val Cys Cys
 1 5 10

<210> 438
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

<400> 438
 Arg Val Pro Leu Ser Gly Asp Val Glu His
 1 5 10

<210> 439
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

<400> 439
 Leu Arg Val Met Ser Phe Thr Ser Gly Gln
 1 5 10

<210> 440
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

<400> 440
 Arg Phe Ser Val Gly Ser Leu Phe Gly Ser
 1 5 10

<210> 441
 <211> 13

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 441

Cys Gly Ala Thr Cys Glu Met Gln Cys Pro Ser Gly Cys
1 5 10

<210> 442

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 442

Gly Arg Gly Glu Ser Pro
1 5

<210> 443

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 443

Cys Ala Arg Ala Cys
1 5

<210> 444

<211> 10

<212> PRT

<213> Rattus sp.

<400> 444

Tyr Pro Asp Leu Ile Ala Glu Leu Leu Arg
1 5 10

<210> 445
 <211> 24
 <212> PRT
 <213> Rattus sp.

<400> 445
 Thr Thr Pro Val Ile Asp Gly His Asn Asp Leu Pro Trp Gln Met Leu
 1 5 10 15
 Thr Leu Phe Asn Asn Gln Leu Arg
 20

<210> 446
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Nucleotide

<400> 446
 ccgctgggtac cgcagatccc tggggacctt g 31

<210> 447
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 Nucleotide

<400> 447
 tctttctaga gctcagagag cactggagga g 31

<210> 448
 <211> 411
 <212> PRT
 <213> Homo sapiens

<400> 448
 Met Trp Ser Gly Trp Trp Leu Trp Ser Leu Val Ala Val Cys Thr Ala
 1 5 10 15

Asp	Phe	Phe	Arg	Asp	Glu	Ala	Glu	Arg	Ile	Met	Arg	Asp	Ser	Pro	Val			
			20					25					30					
Ile	Asp	Gly	His	Asn	Asp	Leu	Pro	Trp	Gln	Leu	Leu	Asp	Met	Phe	Asn			
		35					40					45						
Asn	Arg	Leu	Gln	Asp	Glu	Arg	Ala	Asn	Leu	Thr	Thr	Leu	Ala	Gly	Thr			
		50				55					60							
His	Thr	Asn	Ile	Pro	Lys	Leu	Arg	Ala	Gly	Phe	Val	Gly	Gly	Gln	Phe			
		65			70					75					80			
Trp	Ser	Val	Tyr	Thr	Pro	Cys	Asp	Thr	Gln	Asn	Lys	Asp	Ala	Val	Arg			
				85					90						95			
Arg	Thr	Leu	Glu	Gln	Met	Asp	Val	Val	His	Arg	Met	Cys	Arg	Met	Tyr			
			100					105					110					
Pro	Glu	Thr	Phe	Leu	Tyr	Val	Thr	Ser	Ser	Ala	Gly	Ile	Arg	Gln	Ala			
			115					120					125					
Phe	Arg	Glu	Gly	Lys	Val	Ala	Ser	Leu	Ile	Gly	Val	Glu	Gly	Gly	His			
		130				135					140							
Ser	Ile	Asp	Ser	Ser	Leu	Gly	Val	Leu	Arg	Ala	Leu	Tyr	Gln	Leu	Gly			
		145			150				155						160			
Met	Arg	Tyr	Leu	Thr	Leu	Thr	His	Ser	Cys	Asn	Thr	Pro	Trp	Ala	Asp			
			165						170					175				
Asn	Trp	Leu	Val	Asp	Thr	Gly	Asp	Ser	Glu	Pro	Gln	Ser	Gln	Gly	Leu			
		180						185					190					
Ser	Pro	Phe	Gly	Gln	Arg	Val	Val	Lys	Glu	Leu	Asn	Arg	Leu	Gly	Val			
		195					200					205						
Leu	Ile	Asp	Leu	Ala	His	Val	Ser	Val	Ala	Thr	Met	Lys	Ala	Thr	Leu			
		210				215					220							
Gln	Leu	Ser	Arg	Ala	Pro	Val	Ile	Phe	Ser	His	Ser	Ser	Ala	Tyr	Ser			
		225			230				235						240			
Val	Cys	Ala	Ser	Arg	Arg	Asn	Val	Pro	Asp	Asp	Val	Leu	Arg	Leu	Val			
			245					250					255					
Lys	Gln	Thr	Asp	Ser	Leu	Val	Met	Val	Asn	Phe	Tyr	Asn	Asn	Tyr	Ile			
			260					265					270					

Ser Cys Thr Asn Lys Ala Asn Leu Ser Gln Val Ala Asp His Leu Asp
 275 280 285

His Ile Lys Glu Val Ala Gly Ala Arg Ala Val Gly Phe Gly Gly Asp
 290 295 300

Phe Asp Gly Val Pro Arg Val Pro Glu Gly Leu Glu Asp Val Ser Lys
 305 310 315 320

Tyr Pro Asp Leu Ile Ala Glu Leu Leu Arg Arg Asn Trp Thr Glu Ala
 325 330 335

Glu Val Lys Gly Ala Leu Ala Asp Asn Leu Leu Arg Val Phe Glu Ala
 340 345 350

Val Glu Gln Ala Ser Asn Leu Thr Gln Ala Pro Glu Glu Glu Pro Ile
 355 360 365

Pro Leu Asp Gln Leu Gly Gly Ser Cys Arg Thr His Tyr Gly Tyr Ser
 370 375 380

Ser Gly Ala Ser Ser Leu His Arg His Trp Gly Leu Leu Leu Ala Ser
 385 390 395 400

Leu Ala Pro Leu Val Leu Cys Leu Ser Leu Leu
 405 410

<210> 449

<211> 409

<212> PRT

<213> Sus scrofa

<400> 449

Met Trp Thr Ser Trp Trp Leu Trp Pro Leu Val Ala Val Cys Ala Ala
 1 5 10 15

Asp Gln Phe Arg Asp Leu Ala Val Arg Ile Met Gln Asp Thr Pro Val
 20 25 30

Ile Asp Gly His Asn Asp Leu Pro Trp Gln Leu Leu Asn Leu Phe Asn
 35 40 45

Asn Gln Leu Gln Asp Pro Gly Ala Asn Leu Ser Ser Leu Ala His Thr
 50 55 60

His Thr Asn Ile Pro Lys Leu Lys Ala Gly Phe Val Gly Gly Gln Phe
 65 70 75 80

Trp Ser Ala Tyr Val Pro Cys Asp Thr Gln Asn Arg Asp Ala Val Lys
 85 90 95

Arg Thr Leu Glu Gln Ile Asp Val Ile Gln Arg Met Cys Gln Ala Tyr
 100 105 110

Pro Glu Thr Phe Ala Cys Val Thr Ser Ser Thr Gly Ile Arg Gln Ala
 115 120 125

Phe Arg Glu Gly Lys Val Ala Ser Leu Val Gly Val Glu Gly Gly His
 130 135 140

Ser Ile Asp Ser Ser Leu Gly Val Leu Arg Ala Leu Tyr His Leu Gly
 145 150 155 160

Met Arg Tyr Met Thr Leu Thr His Ser Cys Asn Thr Pro Trp Ala Asp
 165 170 175

Asn Trp Leu Val Asp Thr Gly Asp Asp Lys Ala Gln Ser Gln Gly Leu
 180 185 190

Ser His Phe Gly Gln Ser Val Val Lys Glu Met Asn Arg Leu Gly Val
 195 200 205

Met Ile Asp Leu Ala His Val Ser Val Ala Thr Met Arg Ala Ala Leu
 210 215 220

Lys Leu Ser Gln Ala Pro Val Ile Phe Ser His Ser Ser Ala Tyr Ser
 225 230 235 240

Leu Cys Pro His Arg Arg Asn Val Pro Asp Asp Val Leu Gln Leu Val
 245 250 255

Lys Glu Thr Gly Ser Leu Val Met Val Asn Phe Tyr Asn Asp Tyr Val
 260 265 270

Ser Cys Ser Ala Lys Ala Asn Leu Ser Gln Val Ala Asp His Leu Asp
 275 280 285

His Ile Lys Lys Val Ala Gly Ala Ala Ala Val Gly Phe Gly Gly Asp
 290 295 300

Tyr Asp Gly Val Ser Arg Val Pro Ser Gly Leu Glu Asp Val Ser Lys
 305 310 315 320

Tyr Pro Asp Leu Val Ala Glu Leu Leu Arg Arg Gln Trp Thr Glu Ala
 325 330 335

Glu Val Arg Gly Ala Leu Ala Asp Asn Leu Leu Arg Val Phe Glu Ala
 340 345 350

Val Glu Gln Ala Ser Asn His Ala Gln Val Pro Gly Glu Glu Pro Ile
 355 360 365

Pro Leu Gly Gln Leu Glu Ala Ser Cys Arg Thr Asn Tyr Gly Tyr Ser
 370 375 380

Ala Ala Pro Ser Leu His Leu Pro Pro Gly Ser Leu Leu Ala Ser Leu
 385 390 395 400

Val Pro Leu Leu Leu Leu Ser Leu Pro
 405

<210> 450

<211> 410

<212> PRT

<213> Rattus sp.

<400> 450

Met Leu Ile Ile Trp Trp Phe Trp Ser Leu Leu Ala Ile Cys Ala Ser
 1 5 10 15

Asp Ser Phe Arg Asn Gln Ala Glu Asn Ile Met Arg Thr Thr Pro Val
 20 25 30

Ile Asp Gly His Asn Asp Leu Pro Trp Gln Met Leu Thr Leu Phe Asn
 35 40 45

Asn Gln Leu Arg Lys Ser Glu Ala Asn Leu Ser Ala Leu Ala Glu Thr
 50 55 60

His Thr Asn Ile Pro Lys Leu Arg Ala Gly Phe Val Gly Gly Gln Phe
 65 70 75 80

Trp Ser Ala Tyr Met Pro Cys Asp Thr Gln Asn Lys Asp Ala Val Lys
 85 90 95

Arg Ile Leu Glu Gln Ile Asp Val Ile His Arg Met Cys Gln Leu Tyr
 100 105 110

Pro Glu Thr Phe Glu Cys Val Thr Asn Ser Ser Asp Ile Leu Gln Ala
 115 120 125

Phe Arg Arg Gly Lys Val Ala Ser Leu Ile Gly Val Glu Gly Gly His

130	135	140
Leu Ile Asp Ser Ser Leu Gly Val Leu Arg Thr Leu Tyr His Leu Gly		
145	150	155 160
Met Arg Tyr Leu Thr Leu Thr His Asn Cys Asn Thr Pro Trp Ala Asp		
165	170	175
Asn Trp Leu Val Asp Lys Gly Asp Asp Glu Ala Glu Ser Gln Gly Leu		
180	185	190
Ser Pro Phe Gly Lys Leu Val Leu Asn Glu Met Asn Arg Leu Gly Val		
195	200	205
Met Ile Asp Leu Ser His Val Ser Val Ala Thr Met Lys Asp Ala Leu		
210	215	220
Gln Leu Ser Lys Ala Pro Val Ile Phe Ser His Ser Ser Ala Tyr Ser		
225	230	235 240
Val Cys Pro His Arg Arg Asn Val Pro Asp Asp Val Leu Gln Leu Val		
245	250	255
Lys Ser Thr Asn Ser Leu Val Met Val Asn Phe Tyr Asn Gln Phe Val		
260	265	270
Ser Cys Ser Asp Ser Ala Thr Leu Ser Gln Val Ala Asp His Leu Asp		
275	280	285
His Ile Lys Lys Val Ala Gly Ala Gly Ala Val Gly Leu Gly Gly Asp		
290	295	300
Tyr Asp Gly Val Thr Asn Leu Pro Val Gly Leu Glu Asp Val Ser Lys		
305	310	315 320
Tyr Pro Asp Leu Ile Ala Glu Leu Leu Arg Arg Asn Trp Thr Glu Thr		
325	330	335
Glu Val Arg Gly Leu Leu Ala Glu Asn Leu Leu Arg Val Phe Ser Ala		
340	345	350
Val Glu Leu Val Ser Asn Ile Met Gln Val Pro Glu Glu Glu Thr Ile		
355	360	365
Pro Val Glu Lys Leu Asp Gly Ser Cys Arg Thr Phe Tyr Gly His Ser		
370	375	380
Arg Ala Pro Ser Ile His Leu Gln Ile Gly Ala Leu Leu Ala Ser Leu		

385

390

395

400

Ala Ser Leu Val Phe Ser Leu His Pro Leu
 405 410

<210> 451

<211> 410

<212> PRT

<213> Mus musculus

<400> 451

Met Val Ile Ile Trp Trp Phe Trp Ser Leu Leu Ala Ile Cys Ala Ser
 1 5 10 15

Asp Ser Phe Arg Asp Gln Ala Val Ala Ile Met Arg Thr Thr Pro Val
 20 25 30

Ile Asp Gly His Asn Asp Leu Pro Trp Gln Leu Leu Asn Leu Phe Asn
 35 40 45

Asn Gln Leu Leu Arg Pro Asp Ala Asp Leu Asn Lys Leu Ala Gln Thr
 50 55 60

His Thr Asn Ile Pro Lys Leu Lys Ala Gly Phe Val Gly Gly Gln Phe
 65 70 75 80

Trp Ser Ala Tyr Met Pro Cys Asp Thr Gln Asn Lys Asp Ala Val Lys
 85 90 95

Arg Thr Leu Glu Gln Met Asp Val Ile His Arg Met Cys Gln Leu Tyr
 100 105 110

Pro Glu Thr Phe Met Cys Val Thr Asn Ser Ser Asp Ile Leu Gln Ala
 115 120 125

Phe Arg Arg Gly Lys Val Ala Ser Leu Ile Gly Val Glu Gly Gly His
 130 135 140

Leu Ile Asp Ser Ser Leu Gly Val Leu Arg Thr Leu Tyr His Leu Gly
 145 150 155 160

Met Arg Tyr Leu Thr Leu Thr His Asn Cys Asn Thr Pro Trp Ala Asp
 165 170 175

Asn Trp Leu Val Asp Arg Gly Asp Asp Glu Ala Glu Ser His Gly Leu
 180 185 190

Ser Pro Phe Gly Lys Arg Leu Leu Asn Glu Met Thr Arg Leu Gly Val
 195 200 205

Met Ile Asp Leu Ser His Val Ser Val Ala Thr Met Lys Asp Ala Leu
 210 215 220

Gln Ile Ser Arg Ala Pro Val Ile Phe Ser His Ser Ser Ala Tyr Ser
 225 230 235 240

Leu Cys Pro His Arg Arg Asn Val Pro Asp Asp Val Leu Gln Leu Val
 245 250 255

Lys Asn Thr Ser Ser Leu Val Met Val Asn Phe Phe Ser Asn Phe Val
 260 265 270

Ser Cys Ser Asp Ser Ala Thr Leu Pro Gln Val Ala Asp His Leu Asp
 275 280 285

His Ile Lys Lys Val Ala Gly Ala Gly Ala Val Gly Leu Gly Gly Asp
 290 295 300

Tyr Asp Gly Val Thr Met Leu Pro Val Gly Leu Glu Asp Val Ser Lys
 305 310 315 320

Tyr Pro Asp Leu Ile Ala Glu Leu Leu Arg Arg Asn Trp Thr Glu Thr
 325 330 335

Glu Val Arg Gly Leu Leu Ala Asp Asn Leu Ile Arg Val Phe Ser Glu
 340 345 350

Val Glu Leu Val Ser Ser Asn Met Gln Ser Pro Glu Glu Val Pro Ile
 355 360 365

Thr Leu Lys Glu Leu Asp Gly Ser Cys Arg Thr Tyr Tyr Gly Tyr Ser
 370 375 380

Gln Ala His Ser Ile His Leu Gln Thr Gly Ala Leu Val Ala Ser Leu
 385 390 395 400

Ala Ser Leu Leu Phe Arg Leu His Leu Leu
 405 410

<210> 452

<211> 410

<212> PRT

<213> *Oryctolagus cuniculus*

<400> 452

Met Trp Thr Ser Trp Trp Leu Trp Pro Leu Val Ala Val Cys Thr Ala
1 5 10 15

Asp Ser Phe Leu Asp Gln Ala Val Gln Ile Leu Arg Val Thr Pro Val
20 25 30

Ile Asp Gly His Asn Asp Leu Pro Trp Gln Leu Leu Asn Lys Phe Asn
35 40 45

Asn Arg Leu Gln Asp Ser Arg Ala Asn Leu Thr Val Leu Ala Asp Thr
50 55 60

His Thr Asn Ile Pro Lys Leu Arg Ala Gly Phe Val Gly Gly Gln Phe
65 70 75 80

Trp Ser Ala Tyr Thr Pro Cys Asp Thr Gln Asn Lys Asp Thr Val Arg
85 90 95

Arg Thr Leu Glu Gln Met Asp Val Val His Arg Met Cys Gln Leu Tyr
100 105 110

Pro Glu Thr Phe Leu Cys Val Thr Asp Ser Ala Gly Ile Gln Gln Ala
115 120 125

Phe Arg Glu Gly Lys Val Ala Ser Leu Ile Gly Val Glu Gly Gly His
130 135 140

Ser Ile Asp Ser Ser Leu Gly Val Leu Arg Ala Leu Tyr Arg Leu Gly
145 150 155 160

Met Arg Tyr Leu Thr Leu Thr His Asn Cys Asn Thr Pro Trp Ala Asp
165 170 175

Asn Trp Leu Val Asp Arg Gly Asp Asp Glu Ala Gln Ser Gly Gly Leu
180 185 190

Ser Val Phe Gly Gln Arg Val Val Arg Glu Met Asn Arg Leu Gly Val
195 200 205

Met Ile Asp Leu Ala His Val Ser Val Ala Thr Met Lys Ala Ala Leu
210 215 220

Gln Leu Ser Thr Ala Pro Val Ile Phe Ser His Ser Ser Ala Phe Thr
225 230 235 240

Val Cys Ala His Lys Arg Asn Val Pro Asp Asp Val Leu Gln Leu Val
245 250 255

[illegible][illegible][illegible][illegible][illegible]

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

[illegible][illegible][illegible][illegible]